

# PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS

## CROSS-REFERENCE INFORMATION

5 This application claims priority under 35 U.S.C. 119(e)  
to U.S. Provisional Applications Serial Nos. 60/182,710, filed  
February 15, 2000, 60/216,422 filed on July 6, 2000 and Serial  
No. 60/243,532, filed October 27, 2000, the disclosures of  
which are incorporated by reference herein in their entirety.

## BACKGROUND OF THE INVENTION

### Field of Invention

10 The present invention relates to certain 3-pyrrole  
substituted 2-indolinone compounds which modulate the activity  
of protein kinases ("PKs"). The compounds of this invention  
are therefore useful in treating disorders related to abnormal  
PK activity. Pharmaceutical compositions comprising these  
compounds, methods of treating diseases utilizing  
pharmaceutical compositions comprising these compounds and  
methods of preparing them are also disclosed.

### State of the Art

15 The following is offered as background information only  
and is not admitted to be prior art to the present invention.

20 PKs are enzymes that catalyze the phosphorylation of  
hydroxy groups on tyrosine, serine and threonine residues of  
proteins. The consequences of this seemingly simple activity  
are staggering; cell growth, differentiation and  
proliferation, i.e., virtually all aspects of cell life in one  
way or another depend on PK activity. Furthermore, abnormal  
PK activity has been related to a host of disorders, ranging  
from relatively non-life threatening diseases such as  
psoriasis to extremely virulent diseases such as glioblastoma  
(brain cancer).

35 The PKs can be conveniently broken down into two classes,

the protein tyrosine kinases (PTKs) and the serine-threonine kinases (STKs).

One of the prime aspects of PTK activity is their involvement with growth factor receptors. Growth factor  
5 receptors are cell-surface proteins. When bound by a growth factor ligand, growth factor receptors are converted to an active form which interacts with proteins on the inner surface of a cell membrane. This leads to phosphorylation on tyrosine residues of the receptor and other proteins and to the  
10 formation inside the cell of complexes with a variety of cytoplasmic signaling molecules that, in turn, effect numerous cellular responses such as cell division (proliferation), cell differentiation, cell growth, expression of metabolic effects to the extracellular microenvironment, etc. For a more  
5 complete discussion, see Schlessinger and Ullrich, Neuron, 9:303-391 (1992) which is incorporated by reference, including any drawings, as if fully set forth herein.

Growth factor receptors with PTK activity are known as receptor tyrosine kinases ("RTKs"). They comprise a large  
20 family of transmembrane receptors with diverse biological activity. At present, at least nineteen (19) distinct subfamilies of RTKs have been identified. An example of these is the subfamily designated the "HER" RTKs, which include EGFR (epithelial growth factor receptor), HER2, HER3 and HER4.  
25 These RTKs consist of an extracellular glycosylated ligand binding domain, a transmembrane domain and an intracellular cytoplasmic catalytic domain that can phosphorylate tyrosine residues on proteins.

Another RTK subfamily consists of insulin receptor (IR),  
30 insulin-like growth factor I receptor (IGF-1R) and insulin receptor related receptor (IRR). IR and IGF-1R interact with insulin, IGF-I and IGF-II to form a heterotetramer of two entirely extracellular glycosylated  $\alpha$  subunits and two  $\beta$  subunits which cross the cell membrane and which contain the  
35 tyrosine kinase domain.

A third RTK subfamily is referred to as the platelet derived growth factor receptor ("PDGFR") group, which includes PDGFR $\alpha$ , PDGFR $\beta$ , CSFIR, c-kit and c-fms. These receptors consist of glycosylated extracellular domains composed of variable numbers of immunoglobulin-like loops and an intracellular domain wherein the tyrosine kinase domain is interrupted by unrelated amino acid sequences.

Another group which, because of its similarity to the PDGFR subfamily, is sometimes subsumed into the later group is the fetus liver kinase ("flk") receptor subfamily. This group is believed to be made up of kinase insert domain-receptor fetal liver kinase-1 (KDR/FLK-1, VEGF-R2), flk-1R, flk-4 and fms-like tyrosine kinase 1 (flt-1).

A further member of the tyrosine kinase growth factor receptor family is the fibroblast growth factor ("FGF") receptor subgroup. This group consists of four receptors, FGFR1-4, and seven ligands, FGF1-7. While not yet well defined, it appears that the receptors consist of a glycosylated extracellular domain containing a variable number of immunoglobulin-like loops and an intracellular domain in which the tyrosine kinase sequence is interrupted by regions of unrelated amino acid sequences.

Still another member of the tyrosine kinase growth factor receptor family is the vascular endothelial growth factor (VEGF") receptor subgroup. VEGF is a dimeric glycoprotein similar to PDGF but has different biological functions and target cell specificity *in vivo*. In particular, VEGF is presently thought to play an essential role in vasculogenesis and angiogenesis.

A more complete listing of the known RTK subfamilies is described in Plowman et al., DN&P, 7(6):334-339 (1994) which is incorporated by reference, including any drawings, as if fully set forth herein.

In addition to the RTKs, there also exists a family of entirely intracellular PTKs called "non-receptor tyrosine kinases" or "cellular tyrosine kinases." This latter

designation, abbreviated "CTK," will be used herein. CTKs do not contain extracellular and transmembrane domains. At present, over 24 CTKs in 11 subfamilies (Src, Frk, Btk, Csk, Abl, Zap70, Fes, Fps, Fak, Jak and Ack) have been identified.

5 The Src subfamily appear so far to be the largest group of CTKs and includes Src, Yes, Fyn, Lyn, Lck, Blk, Hck, Fgr and Yrk. For a more detailed discussion of CTKs, see Bolen, Oncogene, 8:2025-2031 (1993), which is incorporated by reference, including any drawings, as if fully set forth  
10 herein.

The serine/threonine kinases, STKs, like the CTKs, are predominantly intracellular although there are a few receptor kinases of the STK type. STKs are the most common of the cytosolic kinases; i.e., kinases that perform their function  
15 in that part of the cytoplasm other than the cytoplasmic organelles and cytoskelton. The cytosol is the region within the cell where much of the cell's intermediary metabolic and biosynthetic activity occurs; e.g., it is in the cytosol that proteins are synthesized on ribosomes.

20 RTKs, CTKs and STKs have all been implicated in a host of pathogenic conditions including, significantly, cancer. Other pathogenic conditions which have been associated with PTKs include, without limitation, psoriasis, hepatic cirrhosis, diabetes, angiogenesis, restenosis, ocular diseases,  
25 rheumatoid arthritis and other inflammatory disorders, immunological disorders such as autoimmune disease, cardiovascular disease such as atherosclerosis and a variety of renal disorders.

With regard to cancer, two of the major hypotheses  
30 advanced to explain the excessive cellular proliferation that drives tumor development relate to functions known to be PK regulated. That is, it has been suggested that malignant cell growth results from a breakdown in the mechanisms that control cell division and/or differentiation. It has been shown that  
35 the protein products of a number of proto-oncogenes are involved in the signal transduction pathways that regulate

cell growth and differentiation. These protein products of proto-oncogenes include the extracellular growth factors, transmembrane growth factor PTK receptors (RTKs), cytoplasmic PTKs (CTKs) and cytosolic STKs, discussed above.


5 In view of the apparent link between PK-related cellular activities and wide variety of human disorders, it is no surprise that a great deal of effort is being expended in an attempt to identify ways to modulate PK activity. Some of this effort has involved biomimetic approaches using large  
10 molecules patterned on those involved in the actual cellular processes (e.g., mutant ligands (U.S. App. No. 4,966,849); soluble receptors and antibodies (App. No. WO 94/10202, Kendall and Thomas, Proc. Nat'l Acad. Sci., 90:10705-09 (1994), Kim, et al., Nature, 362:841-844 (1993)); RNA ligands (Jelinek, et al., Biochemistry, 33:10450-56); Takano, et al., Mol. Bio. Cell 4:358A (1993); Kinsella, et al., Exp. Cell Res. 199:56-62 (1992); Wright, et al., J. Cellular Phys., 152:448-57) and tyrosine kinase inhibitors (WO 94/03427; WO 92/21660; WO 91/15495; WO 94/14808; U.S. Pat. No. 5,330,992; Mariani, et al., Proc. Am. Assoc. Cancer Res., 35:2268 (1994)).

15 In addition to the above, attempts have been made to identify small molecules which act as PK inhibitors. For example, bis- monocyclic, bicyclic and heterocyclic aryl compounds (PCT WO 92/20642), vinyleneazaindole derivatives  
25 (PCT WO 94/14808) and 1-cyclopropyl-4-pyridylquinolones (U.S. Pat. No. 5,330,992) have been described as tyrosine kinase inhibitors. Styryl compounds (U.S. Pat. No. 5,217,999), styryl-substituted pyridyl compounds (U.S. Pat. No. 5,302,606), quinazoline derivatives (EP App. No.0 566 266 A1),  
30 selenaindoles and selenides (PCT WO 94/03427), tricyclic polyhydroxylic compounds (PCT WO 92/21660) and benzylphosphonic acid compounds (PCT WO 91/15495) have all been described as PTK inhibitors useful in the treatment of cancer.

## SUMMARY OF THE INVENTION

The present invention is directed to certain 3-pyrrole substituted 2-indolinone compounds which exhibit PK modulating ability and are therefore useful in treating disorders related to abnormal PK activity.

Accordingly, in one aspect, the present invention relates to 3-pyrrole substituted 2-indolinones of Formula (I):



(I)

wherein:

R<sup>1</sup> is selected from the group consisting of hydrogen, halo, alkyl, cycloalkyl, aryl, heteroaryl, heteroalicyclic, hydroxy, alkoxy,  $-(CO)R^{15}$ ,  $-NR^{13}R^{14}$ ,  $-(CH_2)_rR^{16}$  and  $-C(O)NR^8R^9$ ;

R<sup>2</sup> is selected from the group consisting of hydrogen, halo, alkyl, trihalomethyl, hydroxy, alkoxy, cyano,  $-NR^{13}R^{14}$ ,  $-NR^{13}C(O)R^{14}$ ,  $-C(O)R^{15}$ , aryl, heteroaryl,  $-S(O)_2NR^{13}R^{14}$  and  $-SO_2R^{20}$  (wherein R<sup>20</sup> is alkyl, aryl, aralkyl, heteroaryl and heteroaralkyl);

R<sup>3</sup> is selected from the group consisting of hydrogen, halogen, alkyl, trihalomethyl, hydroxy, alkoxy,  $-(CO)R^{15}$ ,  $-NR^{13}R^{14}$ , aryl, heteroaryl,  $-NR^{13}S(O)_2R^{14}$ ,  $-S(O)_2NR^{13}R^{14}$ ,  $-NR^{13}C(O)R^{14}$ ,

$-NR^{13}C(O)OR^{14}$  and  $-SO_2R^{20}$  (wherein R<sup>20</sup> is alkyl, aryl, aralkyl, heteroaryl and heteroaralkyl);

R<sup>4</sup> is selected from the group consisting of hydrogen, halogen, alkyl, hydroxy, alkoxy and  $-NR^{13}R^{14}$ ;

R<sup>5</sup> is selected from the group consisting of hydrogen, alkyl and  $-C(O)R^{10}$ ;

R<sup>6</sup> is selected from the group consisting of hydrogen, alkyl and -C(O)R<sup>10</sup>;

R<sup>7</sup> is selected from the group consisting of hydrogen, alkyl, aryl, heteroaryl, -C(O)R<sup>17</sup> and -C(O)R<sup>10</sup>; or

5 R<sup>6</sup> and R<sup>7</sup> may combine to form a group selected from the group consisting of -(CH<sub>2</sub>)<sub>4</sub>-, -(CH<sub>2</sub>)<sub>5</sub>- and -(CH<sub>2</sub>)<sub>6</sub>-; with the proviso that at least one of R<sup>5</sup>, R<sup>6</sup> or R<sup>7</sup> must be -C(O)R<sup>10</sup>;

10 R<sup>8</sup> and R<sup>9</sup> are independently selected from the group consisting of hydrogen, alkyl and aryl;

R<sup>10</sup> is selected from the group consisting of hydroxy, alkoxy, aryloxy, -N(R<sup>11</sup>)(CH<sub>2</sub>)<sub>n</sub>R<sup>12</sup>, and -NR<sup>13</sup>R<sup>14</sup>;

R<sup>11</sup> is selected from the group consisting of hydrogen and alkyl;

15 R<sup>12</sup> is selected from the group consisting of -NR<sup>13</sup>R<sup>14</sup>, hydroxy, -C(O)R<sup>15</sup>, aryl, heteroaryl, -N<sup>+</sup>(O<sup>-</sup>)R<sup>13</sup>R<sup>14</sup>, -N(OH)R<sup>13</sup>, and -NHC(O)R<sup>a</sup> (wherein R<sup>a</sup> is unsubstituted alkyl, haloalkyl, or aralkyl);

20 R<sup>13</sup> and R<sup>14</sup> are independently selected from the group consisting of hydrogen, alkyl, cyanoalkyl, cycloalkyl, aryl and heteroaryl; or

R<sup>13</sup> and R<sup>14</sup> may combine to form a heterocyclo group;

R<sup>15</sup> is selected from the group consisting of hydrogen, hydroxy, alkoxy and aryloxy;

25 R<sup>16</sup> is selected from the group consisting of hydroxy, -C(O)R<sup>15</sup>, -NR<sup>13</sup>R<sup>14</sup> and -C(O)NR<sup>13</sup>R<sup>14</sup>;

R<sup>17</sup> is selected from the group consisting of alkyl, cycloalkyl, aryl and heteroaryl;

R<sup>20</sup> is alkyl, aryl, aralkyl or heteroaryl; and

30 n and r are independently 1, 2, 3, or 4;

or a pharmaceutically acceptable salt thereof.

Preferably, R<sup>1</sup> is selected from the group consisting of hydrogen, halo, alkyl, cycloalkyl, aryl, heteroaryl, heteroalicyclic, hydroxy, alkoxy, -C(O)R<sup>15</sup>, -NR<sup>13</sup>R<sup>14</sup>, -(CH<sub>2</sub>)<sub>r</sub>R<sup>16</sup>  
35 and -C(O)NR<sup>8</sup>R<sup>9</sup>;

R<sup>2</sup> is selected from the group consisting of hydrogen,

halo, alkyl, trihalomethyl, hydroxy, alkoxy,  $-NR^{13}R^{14}$ ,  $-NR^{13}C(O)R^{14}$ ,  $-C(O)R^{15}$ , aryl, heteroaryl, and  $-S(O)_2NR^{13}R^{14}$ ;

$R^3$  is selected from the group consisting of hydrogen, halogen, alkyl, trihalomethyl, hydroxy, alkoxy,  $-(CO)R^{15}$ ,  $-NR^{13}R^{14}$ , aryl, heteroaryl,  $-NR^{13}S(O)_2R^{14}$ ,  $-S(O)_2NR^{13}R^{14}$ ,  $-NR^{13}C(O)R^{14}$ , and  $-NR^{13}C(O)OR^{14}$ ;

$R^4$  is selected from the group consisting of hydrogen, halogen, alkyl, hydroxy, alkoxy and  $-NR^{13}R^{14}$ ;

$R^5$  is selected from the group consisting of hydrogen, alkyl and  $-C(O)R^{10}$ ;

$R^6$  is selected from the group consisting of hydrogen, alkyl and  $-C(O)R^{10}$ ;

$R^7$  is selected from the group consisting of hydrogen, alkyl, aryl, heteroaryl,  $-C(O)R^{17}$  and  $-C(O)R^{10}$ ;

$R^6$  and  $R^7$  may combine to form a group selected from the group consisting of  $-(CH_2)_4-$ ,  $-(CH_2)_5-$  and  $-(CH_2)_6-$ ; with the proviso that at least one of  $R^5$ ,  $R^6$  or  $R^7$  must be  $-C(O)R^{10}$ ;

$R^8$  and  $R^9$  are independently selected from the group consisting of hydrogen, alkyl and aryl;

$R^{10}$  is selected from the group consisting of hydroxy, alkoxy, aryloxy,  $-N(R^{11})(CH_2)_nR^{12}$  and  $-NR^{13}R^{14}$ ;

$R^{11}$  is selected from the group consisting of hydrogen and alkyl;

$R^{12}$  is selected from the group consisting of  $-NR^{13}R^{14}$ , hydroxy,  $-C(O)R^{15}$ , aryl and heteroaryl;

$R^{13}$  and  $R^{14}$  are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl and heteroaryl;

$R^{13}$  and  $R^{14}$  may combine to form a group selected from the group consisting of  $-(CH_2)_4-$ ,  $-(CH_2)_5-$ ,  $-(CH_2)_2O(CH_2)_2-$ , and  $-(CH_2)_2N(CH_3)(CH_2)_2-$ ;

$R^{15}$  is selected from the group consisting of hydrogen, hydroxy, alkoxy and aryloxy;

$R^{16}$  is selected from the group consisting of hydroxy,  $-C(O)R^{15}$ ,  $-NR^{13}R^{14}$  and  $-C(O)NR^{13}R^{14}$ ;



R<sup>17</sup> is selected from the group consisting of alkyl, cycloalkyl, aryl and heteroaryl; and

n and r are independently 1, 2, 3, or 4;  
or a pharmaceutically acceptable salt thereof.

5 In a second aspect this invention is directed to a pharmaceutical composition comprising one or more compound(s) of Formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.


10 In a third aspect, this invention is directed to a method of treating diseases mediated by abnormal protein kinase activity, in particular, receptor tyrosine kinases (RTKs), non-receptor protein tyrosine kinases (CTKs) and serine/threonine protein kinases (STKs), in an organism, in particular humans, which method comprises administering to  
15 said organism a pharmaceutical composition comprising a compound of Formula (I). Such diseases include by way of example and not limitation, cancer, diabetes, hepatic cirrhosis, cardiovascular disease such as atherosclerosis, angiogenesis, immunological disease such as autoimmune disease  
20 and renal disease.

25 In a fourth aspect, this invention is directed to a method of modulating of the catalytic activity of PKs, in particular, receptor tyrosine kinases (RTKs), non-receptor protein tyrosine kinases (CTKs) and serine/threonine protein  
30 kinases (STKs), using a compound of this invention which may be carried out *in vitro* or *in vivo*. In particular, the receptor protein kinase whose catalytic activity is modulated by a compound of this invention is selected from the group consisting of EGF, HER2, HER3, HER4, IR, IGF-1R, IRR, PDGFR $\alpha$ ,  
35 PDGFR $\beta$ , CSF1R, C-Kit, C-fms, Flk-1R, Flk4, KDR/Flk-1, Flt-1, FGFR-1R, FGFR-2R, FGFR-3R and FGFR-4R. The cellular tyrosine kinase whose catalytic activity is modulated by a compound of this invention is selected from the group consisting of Src, Frk, Btk, Csk, Abl, ZAP70, Fes/Fps, Fak, Jak, Ack, Yes, Fyn,  
Lyn, Lck, Blk, Hck, Fgr and Yrk. The serine-threonine protein kinase whose catalytic activity is modulated by a compound of

this invention is selected from the group consisting of CDK2 and Raf.

In a fifth aspect, this invention is directed to the use of a compound of Formula (I) in the preparation of a medicament which is useful in the treatment of a disease mediated by abnormal PK activity.

In a sixth aspect, this invention is directed to an intermediate of Formula (II):



wherein:

$R^5$  is selected from the group consisting of hydrogen, alkyl and  $-C(O)R^{10}$ ;

$R^6$  is selected from the group consisting of hydrogen, alkyl and  $-C(O)R^{10}$ ;

$R^7$  is selected from the group consisting of hydrogen, alkyl, aryl, heteroaryl,  $-C(O)R^{17}$  and  $-C(O)R^{10}$ ;

$R^6$  and  $R^7$  may combine to form a group selected from the group consisting of  $-(CH_2)_4-$ ,  $-(CH_2)_5-$  and  $-(CH_2)_6-$ ;

with the proviso that at least one of  $R^5$ ,  $R^6$  or  $R^7$  must be  $-C(O)R^{10}$ ;

$R^{10}$  is selected from the group consisting of hydroxy, alkoxy, aryloxy,  $-N(R^{11})(CH_2)_nR^{12}$  and  $-NR^{13}R^{14}$ ;

$R^{11}$  is selected from the group consisting of hydrogen and alkyl;

$R^{12}$  is selected from the group consisting of  $-NR^{13}R^{14}$ , hydroxy,  $-C(O)R^{15}$ , aryl and heteroaryl;

$R^{13}$  and  $R^{14}$  are independently selected from the group consisting of hydrogen, alkyl, cyanoalkyl, cycloalkyl, aryl and heteroaryl; or

$R^{13}$  and  $R^{14}$  may combine to form a heterocyclo group;

$R^{15}$  is selected from the group consisting of hydrogen, hydroxy, alkoxy and aryloxy;

$R^{17}$  is selected from the group consisting of alkyl, cycloalkyl, aryl and heteroaryl; and

$n$  is 1, 2, 3, or 4.

Preferably,  $R^5$  or  $R^6$ , in the compound of formula II, is  $-C(O)R^{10}$ ;

$R^6$  is selected from the group consisting of hydrogen, and alkyl, more preferably hydrogen or methyl;

$R^5$  is selected from the group consisting of hydrogen, and alkyl, more preferably hydrogen or methyl when  $R^6$  is  $-COR^{10}$ ;

$R^6$  is selected from the group consisting of hydrogen, and alkyl, more preferably hydrogen or methyl when  $R^5$  is  $-COR^{10}$ ;

$R^7$  is selected from the group consisting of hydrogen, alkyl, and aryl, more preferably hydrogen, methyl or phenyl;

$R^{10}$  is selected from the group consisting of hydroxy, alkoxy,  $-N(R^{11})(CH_2)_nR^{12}$  and  $-NR^{13}R^{14}$ ;

$R^{11}$  is selected from the group consisting of hydrogen and alkyl, more preferably hydrogen or methyl;

$R^{12}$  is selected from the group consisting of  $-NR^{13}R^{14}$ ;

$R^{13}$  and  $R^{14}$  are independently selected from the group consisting of hydrogen, or alkyl; or

$R^{13}$  and  $R^{14}$  may combine to form a heterocyclo group; and

$n$  is 1, 2 or 3.

Within the above preferred groups, more preferred groups of intermediate compounds are those wherein  $R^5$ ,  $R^6$ ,  $R^{11}$ ,  $R^{12}$ ,  $R^{13}$  or  $R^{14}$  are independently groups described in the section titled "preferred embodiments" herein below.

In a seventh aspect, this invention is directed to methods of preparing compounds of Formula (I).

Lastly, this invention is also directed to identifying a chemical compound that modulates the catalytic activity of a protein kinase by contacting cells expressing said protein kinase with a compound or a salt of the present invention and then monitoring said cells for an effect.

## DETAILED DESCRIPTION OF THE INVENTION

### Definitions

Unless otherwise stated the following terms used in the specification and claims have the meanings discussed below:

"Alkyl" refers to a saturated aliphatic hydrocarbon radical including straight chain and branched chain groups of 1 to 20 carbon atoms (whenever a numerical range; e.g. "1-20", is stated herein, it means that the group, in this case the alkyl group, may contain 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc. up to and including 20 carbon atoms). Alkyl groups containing from 1 to 4 carbon atoms are referred to as lower alkyl groups. When said lower alkyl groups lack substituents, they are referred to as unsubstituted lower alkyl groups. More preferably, an alkyl group is a medium size alkyl having 1 to 10 carbon atoms e.g., methyl, ethyl, propyl, 2-propyl, *n*-butyl, *iso*-butyl, *tert*-butyl, pentyl, and the like. Most preferably, it is a lower alkyl having 1 to 4 carbon atoms e.g., methyl, ethyl, propyl, 2-propyl, *n*-butyl, *iso*-butyl, or *tert*-butyl, and the like. The alkyl group may be substituted or unsubstituted. When substituted, the substituent group(s) is preferably one or more, more preferably one to three, even more preferably one or two substituent(s) independently selected from the group consisting of halo, hydroxy, unsubstituted lower alkoxy, aryl optionally substituted with one or more groups, preferably one, two or three groups which are independently of each other halo, hydroxy, unsubstituted lower alkyl or unsubstituted lower alkoxy groups, aryloxy optionally substituted with one or more groups, preferably one, two or three groups which are independently of each other halo, hydroxy, unsubstituted lower alkyl or unsubstituted lower alkoxy groups, 6-member heteroaryl having from 1 to 3 nitrogen atoms in the ring, the carbons in the ring being optionally substituted with one or more groups, preferably one, two or three groups which are independently of each other halo, hydroxy, unsubstituted lower alkyl or unsubstituted lower alkoxy groups, 5-member heteroaryl having from 1 to 3 heteroatoms selected from the

group consisting of nitrogen, oxygen and sulfur, the carbon and the nitrogen atoms in the group being optionally substituted with one or more groups, preferably one, two or three groups which are independently of each other halo, hydroxy, unsubstituted lower alkyl or unsubstituted lower alkoxy groups, 5- or 6-member heteroalicyclic group having from 1 to 3 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, the carbon and nitrogen (if present) atoms in the group being optionally substituted with one or more groups, preferably one, two or three groups which are independently of each other halo, hydroxy, unsubstituted lower alkyl or unsubstituted lower alkoxy groups, mercapto, (unsubstituted lower alkyl)thio, arylthio optionally substituted with one or more groups, preferably one, two or three groups which are independently of each other halo, hydroxy, unsubstituted lower alkyl or unsubstituted lower alkoxy groups, cyano, acyl, thioacyl, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, nitro, N-sulfonamido, S-sulfonamido,  $R^{18}S(O)-$ ,  $R^{18}S(O)_2-$ ,  $-C(O)OR^{18}$ ,  $R^{18}C(O)O-$ , and  $-NR^{18}R^{19}$ , wherein  $R^{18}$  and  $R^{19}$  are independently selected from the group consisting of hydrogen, unsubstituted lower alkyl, trihalomethyl, unsubstituted  $(C_3-C_6)$ cycloalkyl, unsubstituted lower alkenyl, unsubstituted lower alkynyl and aryl optionally substituted with one or more, groups, preferably one, two or three groups which are independently of each other halo, hydroxy, unsubstituted lower alkyl or unsubstituted lower alkoxy groups.

Preferably, the alkyl group is substituted with one or two substituents independently selected from the group consisting of hydroxy, 5- or 6-member heteroalicyclic group having from 1 to 3 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, the carbon and nitrogen (if present) atoms in the group being optionally substituted with one or more groups, preferably one, two or three groups which are independently of each other halo, hydroxy, unsubstituted lower alkyl or unsubstituted lower alkoxy groups, 5-member heteroaryl having from 1 to 3 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, the carbon and the nitrogen atoms in the

group being optionally substituted with one or more groups,  
preferably one, two or three groups which are independently of  
each other halo, hydroxy, unsubstituted lower alkyl or  
unsubstituted lower alkoxy groups, 6-member heteroaryl having  
5 from 1 to 3 nitrogen atoms in the ring, the carbons in the  
ring being optionally substituted with one or more groups,  
preferably one, two or three groups which are independently of  
each other halo, hydroxy, unsubstituted lower alkyl or  
unsubstituted lower alkoxy groups, or  $-NR^{18}R^{19}$ , wherein  $R^{18}$  and  
10  $R^{19}$  are independently selected from the group consisting of  
hydrogen, unsubstituted lower alkyl. Even more preferably the  
alkyl group is substituted with one or two substituents which  
are independently of each other hydroxy, dimethylamino,  
ethylamino, diethylamino, dipropylamino, pyrrolidino,  
15 piperidino, morpholino, piperazino, 4-lower alkylpiperazino,  
phenyl, imidazolyl, pyridinyl, pyridazinyl, pyrimidinyl,  
oxazolyl, triazinyl, and the like.

"Cycloalkyl" refers to a 3 to 8 member all-carbon  
monocyclic ring, an all-carbon 5-member/6-member or 6-  
member/6-member fused bicyclic ring or a multicyclic fused  
ring (a "fused" ring system means that each ring in the system  
shares an adjacent pair of carbon atoms with each other ring  
in the system) group wherein one or more of the rings may  
contain one or more double bonds but none of the rings has a  
25 completely conjugated pi-electron system.

Examples, without limitation, of cycloalkyl groups are  
cyclopropane, cyclobutane, cyclopentane, cyclopentene,  
cyclohexane, cyclohexadiene, adamantane, cycloheptane,  
cycloheptatriene, and the like. A cycloalkyl group may be  
30 substituted or unsubstituted. When substituted, the  
substituent group(s) is preferably one or more, more  
preferably one or two substituents, independently selected  
from the group consisting of unsubstituted lower alkyl,  
trihaloalkyl, halo, hydroxy, unsubstituted lower alkoxy, aryl  
35 optionally substituted with one or more, preferably one or two  
groups independently of each other halo, hydroxy,  
unsubstituted lower alkyl or unsubstituted lower alkoxy  
groups, aryloxy optionally substituted with one or more,

preferably one or two groups independently of each other halo, hydroxy, unsubstituted lower alkyl or unsubstituted lower alkoxy groups, 6-member heteroaryl having from 1 to 3 nitrogen atoms in the ring, the carbons in the ring being optionally substituted with one or more, preferably one or two groups independently of each other halo, hydroxy, unsubstituted lower alkyl or unsubstituted lower alkoxy groups, 5-member heteroaryl having from 1 to 3 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, the carbon and nitrogen atoms of the group being optionally substituted with one or more, preferably one or two groups independently of each other halo, hydroxy, unsubstituted lower alkyl or unsubstituted lower alkoxy groups, 5- or 6-member heteroalicyclic group having from 1 to 3 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, the carbon and nitrogen (if present) atoms in the group being optionally substituted with one or more, preferably one or two groups independently of each other halo, hydroxy, unsubstituted lower alkyl or unsubstituted lower alkoxy groups, mercapto, (unsubstituted lower alkyl)thio, arylthio optionally substituted with one or more, preferably one or two groups independently of each other halo, hydroxy, unsubstituted lower alkyl or unsubstituted lower alkoxy groups, cyano, acyl, thioacyl, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, nitro, N-sulfonamido, S-sulfonamido,  $R^{18}S(O)-$ ,  $R^{18}S(O)_2-$ ,  $-C(O)OR^{18}$ ,  $R^{18}C(O)O-$ , and  $-NR^{18}R^{19}$  are as defined above.

"Alkenyl" refers to a lower alkyl group, as defined herein, consisting of at least two carbon atoms and at least one carbon-carbon double bond. Representative examples include, but are not limited to, ethenyl, 1-propenyl, 2-propenyl, 1-, 2-, or 3-butenyl, and the like.

"Alkynyl" refers to a lower alkyl group, as defined herein, consisting of at least two carbon atoms and at least one carbon-carbon triple bond. Representative examples include, but are not limited to, ethynyl, 1-propynyl, 2-

propynyl, 1-, 2-, or 3-butynyl, and the like.

"Aryl" refers to an all-carbon monocyclic or fused-ring polycyclic (i.e., rings which share adjacent pairs of carbon atoms) groups of 1 to 12 carbon atoms having a completely conjugated pi-electron system. Examples, without limitation, of aryl groups are phenyl, naphthalenyl and anthracenyl. The aryl group may be substituted or unsubstituted. When substituted, the substituted group(s) is preferably one or more, more preferably one, two or three, even more preferably one or two, independently selected from the group consisting of unsubstituted lower alkyl, trihaloalkyl, halo, hydroxy, unsubstituted lower alkoxy, mercapto, (unsubstituted lower alkyl)thio, cyano, acyl, thioacyl, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, nitro, N-sulfonamido, S-sulfonamido,  $R^{18}S(O)-$ ,  $R^{18}S(O)_2-$ ,  $-C(O)OR^{18}$ ,  $R^{18}C(O)O-$ , and  $-NR^{18}R^{19}$ , with  $R^{18}$  and  $R^{19}$  as defined above. Preferably, the aryl group is optionally substituted with one or two substituents independently selected from halo, unsubstituted lower alkyl, trihaloalkyl, hydroxy, mercapto, cyano, N-amido, mono or dialkylamino, carboxy, or N-sulfonamido.

"Heteroaryl" refers to a monocyclic or fused ring (i.e., rings which share an adjacent pair of atoms) group of 5 to 12 ring atoms containing one, two, or three ring heteroatoms selected from N, O, or S, the remaining ring atoms being C, and, in addition, having a completely conjugated pi-electron system. Examples, without limitation, of unsubstituted heteroaryl groups are pyrrole, furan, thiophene, imidazole, oxazole, thiazole, pyrazole, pyridine, pyrimidine, quinoline, isoquinoline, purine and carbazole. The heteroaryl group may be substituted or unsubstituted. When substituted, the substituted group(s) is preferably one or more, more preferably one, two, or three, even more preferably one or two, independently selected from the group consisting of unsubstituted lower alkyl, trihaloalkyl, halo, hydroxy, unsubstituted lower alkoxy, mercapto, (unsubstituted lower alkyl)thio, cyano, acyl, thioacyl, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, nitro, N-sulfonamido, S-sulfonamido,  $R^{18}S(O)-$ ,  $R^{18}O)_2-$ ,  $-C(O)OR^{18}$ ,



$R^{18}C(O)O-$ , and  $-NR^{18}R^{19}$ , with  $R^{18}$  and  $R^{19}$  as defined above.

Preferably, the heteroaryl group is optionally substituted with one or two substituents independently selected from halo, unsubstituted lower alkyl, trihaloalkyl, hydroxy, mercapto, cyano, N-amido, mono or dialkylamino, carboxy, or N-sulfonamido.

"Heteroalicyclic" refers to a monocyclic or fused ring group having in the ring(s) of 5 to 9 ring atoms in which one or two ring atoms are heteroatoms selected from N, O, or  $S(O)_n$  (where n is an integer from 0 to 2), the remaining ring atoms being C. The rings may also have one or more double bonds. However, the rings do not have a completely conjugated pi-electron system. Examples, without limitation, of unsubstituted heteroalicyclic groups are pyrrolidino, piperidino, piperazino, morpholino, thiomorpholino, homopiperazino, and the like. The heteroalicyclic ring may be substituted or unsubstituted. When substituted, the substituted group(s) is preferably one or more, more preferably one, two or three, even more preferably one or two, independently selected from the group consisting of unsubstituted lower alkyl, trihaloalkyl, halo, hydroxy, unsubstituted lower alkoxy, mercapto, (unsubstituted lower alkyl)thio, cyano, acyl, thioacyl, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, nitro, N-sulfonamido, S-sulfonamido,  $R^{18}S(O)-$ ,  $R^{18}S(O)_2-$ ,  $-C(O)OR^{18}$ ,  $R^{18}C(O)O-$ , and  $-NR^{18}R^{19}$ , with  $R^{18}$  and  $R^{19}$  as defined above. Preferably, the heteroalicyclic group is optionally substituted with one or two substituents independently selected from halo, unsubstituted lower alkyl, trihaloalkyl, hydroxy, mercapto, cyano, N-amido, mono or dialkylamino, carboxy, or N-sulfonamido.

Preferably, the heteroalicyclic group is optionally substituted with one or two substituents independently selected from halo, unsubstituted lower alkyl, trihaloalkyl, hydroxy, mercapto, cyano, N-amido, mono or dialkylamino, carboxy, or N-sulfonamido.

"Heterocycle" means a saturated cyclic radical of 3 to 8 ring atoms in which one or two ring atoms are heteroatoms selected from N, O, or  $S(O)_n$  (where n is an integer from 0 to

2), the remaining ring atoms being C, where one or two C atoms may optionally be replaced by a carbonyl group. The heterocyclyl ring may be optionally substituted independently with one, two, or three substituents selected from optionally substituted lower alkyl (substituted with 1 or 2 substituents independently selected from carboxy or ester), haloalkyl, cyanoalkyl, halo, nitro, cyano, hydroxy, alkoxy, amino, monoalkylamino, dialkylamino, aralkyl, heteroaralkyl, -COR (where R is alkyl) or  $\text{COOR}$  where R is (hydrogen or alkyl).

More specifically the term heterocyclyl includes, but is not limited to, tetrahydropyranyl, 2,2-dimethyl-1,3-dioxolane, piperidino, N-methylpiperidin-3-yl, piperazino, N-methylpyrrolidin-3-yl, 3-pyrrolidino, morpholino, thiomorpholino, thiomorpholino-1-oxide, thiomorpholino-1,1-dioxide, 4-ethyloxycarbonylpiperazino, 3-oxopiperazino, 2-imidazolidone, 2-pyrrolidinone, 2-oxohomopiperazino, tetrahydropyrimidin-2-one, and the derivatives thereof. Preferably, the heterocycle group is optionally substituted with one or two substituents independently selected from halo, unsubstituted lower alkyl, lower alkyl substituted with carboxy, ester hydroxy, mono or dialkylamino.

"Hydroxy" refers to an -OH group.

"Alkoxy" refers to both an -O-(unsubstituted alkyl) and an -O-(unsubstituted cycloalkyl) group. Representative examples include, but are not limited to, e.g., methoxy, ethoxy, propoxy, butoxy, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, and the like.

"Aryloxy" refers to both an -O-aryl and an -O-heteroaryl group, as defined herein. Representative examples include, but are not limited to, phenoxy, pyridinyloxy, furanyloxy, thienyloxy, pyrimidinyloxy, pyrazinyloxy, and the like, and derivatives thereof.

"Mercapto" refers to an -SH group.

"Alkylthio" refers to both an -S-(unsubstituted alkyl) and an -S-(unsubstituted cycloalkyl) group. Representative examples include, but are not limited to, e.g., methylthio,

ethylthio, propylthio, butylthio, cyclopropylthio, cyclobutylthio, cyclopentylthio, cyclohexylthio, and the like.

"Arylthio" refers to both an -S-aryl and an -S-heteroaryl group, as defined herein. Representative examples include, but are not limited to, phenylthio, pyridinylthio, furanylthio, thientylthio, pyrimidinylthio, and the like and derivatives thereof.

"Acyl" refers to a -C(O)-R" group, where R" is selected from the group consisting of hydrogen, unsubstituted lower alkyl, trihalomethyl, unsubstituted cycloalkyl, aryl optionally substituted with one or more, preferably one, two, or three substituents selected from the group consisting of unsubstituted lower alkyl, trihalomethyl, unsubstituted lower alkoxy, halo and -NR<sup>18</sup>R<sup>19</sup> groups, heteroaryl (bonded through a ring carbon) optionally substituted with one or more, preferably one, two, or three substituents selected from the group consisting of unsubstituted lower alkyl, trihaloalkyl, unsubstituted lower alkoxy, halo and -NR<sup>18</sup>R<sup>19</sup> groups and heteroalicyclic (bonded through a ring carbon) optionally substituted with one or more, preferably one, two, or three substituents selected from the group consisting of unsubstituted lower alkyl, trihaloalkyl, unsubstituted lower alkoxy, halo and -NR<sup>18</sup>R<sup>19</sup> groups. Representative acyl groups include, but are not limited to, acetyl, trifluoroacetyl, benzoyl, and the like

"Aldehyde" refers to an acyl group in which R" is hydrogen.

"Thioacyl" refers to a -C(S)-R" group, with R" as defined herein.

"Ester" refers to a -C(O)O-R" group with R" as defined herein except that R" cannot be hydrogen.

"Acetyl" group refers to a -C(O)CH<sub>3</sub> group.

"Halo" group refers to fluorine, chlorine, bromine or iodine, preferably fluorine or chlorine.

"Trihalomethyl" group refers to a -CX<sub>3</sub> group wherein X is a halo group as defined herein.

"Trihalomethanesulfonyl" group refers to a  $X_3CS(=O)_2-$  groups with X as defined above.

"Cyano" refers to a  $-C\equiv N$  group.

5 "Methylenedioxy" refers to a  $-OCH_2O-$  group where the two oxygen atoms are bonded to adjacent carbon atoms.

"Ethylenedioxy" group refers to a  $-OCH_2CH_2O-$  where the two oxygen atoms are bonded to adjacent carbon atoms.

"S-sulfonamido" refers to a  $-S(O)_2NR^{18}R^{19}$  group, with  $R^{18}$  and  $R^{19}$  as defined herein.

10 "N-sulfonamido" refers to a  $-NR^{18}S(O)_2R^{19}$  group, with  $R^{18}$  and  $R^{19}$  as defined herein.

"O-carbamyl" group refers to a  $-OC(O)NR^{18}R^{19}$  group with  $R^{18}$  and  $R^{19}$  as defined herein.

15 "N-carbamyl" refers to an  $R^{18}OC(O)NR^{19}-$  group, with  $R^{18}$  and  $R^{19}$  as defined herein.

"O-thiocarbamyl" refers to a  $-OC(S)NR^{18}R^{19}$  group with  $R^{18}$  and  $R^{19}$  as defined herein.

"N-thiocarbamyl" refers to a  $R^{18}OC(S)NR^{19}-$  group, with  $R^{18}$  and  $R^{19}$  as defined herein.

20 "Amino" refers to an  $-NR^{18}R^{19}$  group, wherein  $R^{18}$  and  $R^{19}$  are both hydrogen.

"C-amido" refers to a  $-C(O)NR^{18}R^{19}$  group with  $R^{18}$  and  $R^{19}$  as defined herein.

25 "N-amido" refers to a  $R^{18}C(O)NR^{19}-$  group, with  $R^{18}$  and  $R^{19}$  as defined herein.

"Nitro" refers to a  $-NO_2$  group.

30 "Haloalkyl" means an unsubstituted alkyl, preferably unsubstituted lower alkyl as defined above that is substituted with one or more same or different halo atoms, e.g.,  $-CH_2Cl$ ,  $-CF_3$ ,  $-CH_2CF_3$ ,  $-CH_2CCl_3$ , and the like.

"Aralkyl" means unsubstituted alkyl, preferably unsubstituted lower alkyl as defined above which is substituted with an aryl group as defined above, e.g.,  $-CH_2phenyl$ ,  $-(CH_2)_2phenyl$ ,  $-(CH_2)_3phenyl$ ,  $CH_3CH(CH_3)CH_2phenyl$ , and 35 the like and derivatives thereof.

"Heteroaralkyl" group means unsubstituted alkyl,

preferably unsubstituted lower alkyl as defined above which is substituted with a heteroaryl group, e.g., -CH<sub>2</sub>pyridinyl, -(CH<sub>2</sub>)<sub>2</sub>pyrimidinyl, -(CH<sub>2</sub>)<sub>3</sub>imidazolyl, and the like, and derivatives thereof.

5 "Monoalkylamino" means a radical -NHR where R is an unsubstituted alkyl or unsubstituted cycloalkyl group as defined above, e.g., methylamino, (1-methylethyl)amino, cyclohexylamino, and the like.


10 "Dialkylamino" means a radical -NRR where each R is independently an unsubstituted alkyl or unsubstituted cycloalkyl group as defined above, e.g., dimethylamino, diethylamino, (1-methylethyl)-ethylamino, cyclohexylmethylamino, cyclopentylmethylamino, and the like.

15 "Cyanoalkyl" means unsubstituted alkyl, preferably unsubstituted lower alkyl as defined above, which is substituted with 1 or 2 cyano groups.


20 "Optional" or "optionally" means that the subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs and instances in which it does not. For example, "heterocycle group optionally substituted with an alkyl group" means that the alkyl may but need not be present, and the description includes situations where the heterocycle group is substituted with an alkyl group and  
25 situations where the heterocycle group is not substituted with the alkyl group.

The terms "2-indolinone", "indolin-2-one" and "2-oxindole" are used interchangeably herein to refer to a molecule having the chemical structure:

30



The term "pyrrole" refers to a molecule having the chemical structure:



5        The term "pyrrole substituted 2-indolinone" and "3-pyrrolidenyl-2-indolinone" are used interchangeably herein to refer to a chemical compound having the general structure shown in Formula (I).

Compounds that have the same molecular formula but differ in the nature or sequence of bonding of their atoms or the arrangement of their atoms in space are termed "isomers". Isomers that differ in the arrangement of their atoms in space are termed "stereoisomers". Stereoisomers that are not mirror images of one another are termed "diastereomers" and those that are non-superimposable mirror images of each other are termed "enantiomers". When a compound has an asymmetric center, for example, it is bonded to four different groups, a pair of enantiomers is possible. An enantiomer can be characterized by the absolute configuration of its asymmetric center and is described by the R- and S-sequencing rules of Cahn and Prelog, or by the manner in which the molecule rotates the plane of polarized light and designated as dextrorotatory or levorotatory (i.e., as (+) or (-)-isomers respectively). A chiral compound can exist as either individual enantiomer or as a mixture thereof. A mixture containing equal proportions of the enantiomers is called a "racemic mixture".

The compounds of this invention may possess one or more asymmetric centers; such compounds can therefore be produced as individual (R)- or (S)- stereoisomers or as mixtures thereof. For example, if the R<sup>6</sup> substituent in a compound of formula (I) is 2-hydroxyethyl, then the carbon to which the

hydroxy group is attached is an asymmetric center and therefore the compound of Formula (I) can exist as an (R)- or (S)-stereoisomer. Unless indicated otherwise, the description or naming of a particular compound in the specification and claims is intended to include both individual enantiomers and mixtures, racemic or otherwise, thereof. The methods for the determination of stereochemistry and the separation of stereoisomers are well-known in the art (see discussion in Chapter 4 of "Advanced Organic Chemistry", 4th edition J. March, John Wiley and Sons, New York, 1992).

The compounds of Formula (I) may exhibit the phenomena of tautomerism and structural isomerism. For example, the compounds described herein may adopt an E or a Z configuration about the double bond connecting the 2-indolinone moiety to the pyrrole moiety or they may be a mixture of E and Z. This invention encompasses any tautomeric or structural isomeric form and mixtures thereof which possess the ability to modulate RTK, CTK and/or STK activity and is not limited to any one tautomeric or structural isomeric form.

A "pharmaceutical composition" refers to a mixture of one or more of the compounds described herein, or physiologically/pharmacaceutically acceptable salts or prodrugs thereof, with other chemical components, such as physiologically/pharmacaceutically acceptable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration of a compound to an organism.

The compound of Formula (I) may also act as a prodrug. A "prodrug" refers to an agent which is converted into the parent drug *in vivo*. Prodrugs are often useful because, in some situations, they may be easier to administer than the parent drug. They may, for instance, be bioavailable by oral administration whereas the parent drug is not. The prodrug may also have improved solubility in pharmaceutical compositions over the parent drug. An example, without limitation, of a prodrug would be a compound of the present invention which is administered as an ester (the "prodrug") to facilitate

transmittal across a cell membrane where water solubility is detrimental to mobility but then is metabolically hydrolyzed to the carboxylic acid, the active entity, once inside the cell where water solubility is beneficial.

5 A further example of a prodrug might be a short polypeptide, for example, without limitation, a 2 - 10 amino acid polypeptide, bonded through a terminal amino group to a carboxy group of a compound of this invention wherein the polypeptide is hydrolyzed or metabolized *in vivo* to release  
10 the active molecule. The prodrugs of a compound of Formula (I) are within the scope of this invention.

Additionally, it is contemplated that a compound of Formula (I) would be metabolized by enzymes in the body of the organism such as human being to generate a metabolite that can modulate the activity of the protein kinases. Such  
15 metabolites are within the scope of the present invention.

As used herein, a "physiologically/pharmacologically acceptable carrier" refers to a carrier or diluent that does not cause significant irritation to an organism and does not abrogate the biological activity and properties of the  
20 administered compound.

An "pharmacologically acceptable excipient" refers to an inert substance added to a pharmaceutical composition to further facilitate administration of a compound. Examples,  
25 without limitation, of excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils and polyethylene glycols.

As used herein, the term "pharmacologically acceptable salt" refers to those salts which retain the biological effectiveness and properties of the parent compound. Such salts include:

(i) acid addition salt which is obtained by reaction of the free base of the parent compound with inorganic acids such  
35 as hydrochloric acid, hydrobromic acid, nitric acid, phosphoric acid, sulfuric acid, and perchloric acid and the



like, or with organic acids such as acetic acid, oxalic acid, (D) or (L) malic acid, maleic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, tartaric acid, citric acid, succinic acid or malonic acid and the like, preferably hydrochloric acid or (L)-malic acid such as the L-malate salt of 5-(5-fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid(2-diethylaminoethyl)amide; or

(2) salts formed when an acidic proton present in the parent compound either is replaced by a metal ion, e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic base such as ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, and the like.

"PK" refers to receptor protein tyrosine kinase (RTKs), non-receptor or "cellular" tyrosine kinase (CTKs) and serine-threonine kinases (STKs).

"Method" refers to manners, means, techniques and procedures for accomplishing a given task including, but not limited to, those manners, means, techniques and procedures either known to, or readily developed from known manners, means, techniques and procedures by, practitioners of the chemical, pharmaceutical, biological, biochemical and medical arts.

"Modulation" or "modulating" refers to the alteration of the catalytic activity of RTKs, CTKs and STKs. In particular, modulating refers to the activation of the catalytic activity of RTKs, CTKs and STKs, preferably the activation or inhibition of the catalytic activity of RTKs, CTKs and STKs, depending on the concentration of the compound or salt to which the RTK, CTK or STK is exposed or, more preferably, the inhibition of the catalytic activity of RTKs, CTKs and STKs.

"Catalytic activity" refers to the rate of phosphorylation of tyrosine under the influence, direct or indirect, of RTKs and/or CTKs or the phosphorylation of serine and threonine under the influence, direct or indirect, of STKs.

"Contacting" refers to bringing a compound of this invention

and a target PK together in such a manner that the compound can affect the catalytic activity of the PK, either directly, i.e., by interacting with the kinase itself, or indirectly, i.e., by interacting with another molecule on which the catalytic activity of the kinase is dependent. Such "contacting" can be accomplished "in vitro," i.e., in a test tube, a petri dish or the like. In a test tube, contacting may involve only a compound and a PK of interest or it may involve whole cells. Cells may also be maintained or grown in cell culture dishes and contacted with a compound in that environment. In this context, the ability of a particular compound to affect a PK related disorder, i.e., the IC<sub>50</sub> of the compound, defined below, can be determined before use of the compounds *in vivo* with more complex living organisms is attempted. For cells outside the organism, multiple methods exist, and are well-known to those skilled in the art, to get the PKs in contact with the compounds including, but not limited to, direct cell microinjection and numerous transmembrane carrier techniques.

"*In vitro*" refers to procedures performed in an artificial environment such as, e.g., without limitation, in a test tube or culture medium.

"*In vivo*" refers to procedures performed within a living organism such as, without limitation, a mouse, rat or rabbit.

"PK related disorder," "PK driven disorder," and "abnormal PK activity" all refer to a condition characterized by inappropriate, i.e., under or, more commonly, over, PK catalytic activity, where the particular PK can be an RTK, a CTK or an STK. Inappropriate catalytic activity can arise as the result of either: (1) PK expression in cells which normally do not express PKs, (2) increased PK expression leading to unwanted cell proliferation, differentiation and/or growth, or, (3) decreased PK expression leading to unwanted reductions in cell proliferation, differentiation and/or growth. Over-activity of a PK refers to either amplification of the gene encoding a particular PK or production of a level of PK activity which can correlate with a cell proliferation,

differentiation and/or growth disorder (that is, as the level of the PK increases, the severity of one or more of the symptoms of the cellular disorder increases). Under-activity is, of course, the converse, wherein the severity of one or more symptoms of a cellular disorder increase as the level of the PK activity decreases.

"Treat", "treating" and "treatment" refer to a method of alleviating or abrogating a PK mediated cellular disorder and/or its attendant symptoms. With regard particularly to cancer, these terms simply mean that the life expectancy of an individual affected with a cancer will be increased or that one or more of the symptoms of the disease will be reduced.

"Organism" refers to any living entity comprised of at least one cell. A living organism can be as simple as, for example, a single eukariotic cell or as complex as a mammal, including a human being.

"Therapeutically effective amount" refers to that amount of the compound being administered which will relieve to some extent one or more of the symptoms of the disorder being treated. In reference to the treatment of cancer, a therapeutically effective amount refers to that amount which has the effect of:

- (1) reducing the size of the tumor;
- (2) inhibiting (that is, slowing to some extent, preferably stopping) tumor metastasis;
- (3) inhibiting to some extent (that is, slowing to some extent, preferably stopping) tumor growth, and/or,
- (4) relieving to some extent (or, preferably, eliminating) one or more symptoms associated with the cancer.

"Monitoring" means observing or detecting the effect of contacting a compound with a cell expressing a particular PK. The observed or detected effect can be a change in cell phenotype, in the catalytic activity of a PK or a change in the interaction of a PK with a natural binding partner. Techniques for observing or detecting such effects are well-

known in the art.

The above-referenced effect is selected from a change or an absence of change in a cell phenotype, a change or absence of change in the catalytic activity of said protein kinase or  
5 a change or absence of change in the interaction of said protein kinase with a natural binding partner in a final aspect of this invention.










"Cell phenotype" refers to the outward appearance of a cell or tissue or the biological function of the cell or  
10 tissue. Examples, without limitation, of a cell phenotype are cell size, cell growth, cell proliferation, cell differentiation, cell survival, apoptosis, and nutrient uptake and use. Such phenotypic characteristics are measurable by techniques well-known in the art.









"Natural binding partner" refers to a polypeptide that binds to a particular PK in a cell. Natural binding partners can play a role in propagating a signal in a PK-mediated  
15 signal transduction process. A change in the interaction of the natural binding partner with the PK can manifest itself as an increased or decreased concentration of the PK/natural  
20 binding partner complex and, as a result, in an observable change in the ability of the PK to mediate signal transduction.

25 Representative compounds of the present invention are shown in Table I below.

TABLE 1









Example	Structure	Name
1		4-Methyl-5-(2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-2-carboxylic acid
2		4-Methyl-5-(1-methyl-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-2-carboxylic acid
3		4-Methyl-5-(2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-2-carboxylic acid methyl ester
4		5-(5-Chloro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-4-methyl-1H-pyrrole-2-carboxylic acid ethyl ester
5		5-(5-Chloro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-4-methyl-1H-pyrrole-2-carboxylic acid
6		5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-4-methyl-1H-pyrrole-2-carboxylic acid (3-pyrrolidin-1-ylpropyl)amide
7		5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-4-methyl-1H-pyrrole-2-carboxylic acid (3-diethylaminopropyl)amide
8		5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-2-carboxylic acid (2-diethylaminoethyl)amide
9		5-(2-Oxo-6-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-2-carboxylic acid (2-diethylaminoethyl)amide

10		5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-2-carboxylic acid (2-diethylaminoethyl)methylamide
11		5-(2-Oxo-6-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-2-carboxylic acid (2-diethylaminoethyl)methylamide
12		3-Methyl-5-(2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-2-carboxylic acid (3-diethylaminopropyl)amide
13		5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-3-methyl-1H-pyrrole-2-carboxylic acid (3-diethylaminopropyl)amide
14		3-Methyl-5-(2-oxo-6-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-2-carboxylic acid (3-diethylaminopropyl)amide
15		5-(5-Methoxy-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-3-methyl-1H-pyrrole-2-carboxylic acid (3-diethylaminopropyl)amide
16		5-(6-Methoxy-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-3-methyl-1H-pyrrole-2-carboxylic acid (3-diethylaminopropyl)amide
17		3-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-4,5,6,7-tetrahydro-2H-isoindole-1-carboxylic acid (2-diethylaminoethyl)amide
18		3-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-4,5,6,7-tetrahydro-2H-isoindole-1-carboxylic acid (3-diethylaminopropyl)amide

19		3-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-4,5,6,7-tetrahydro-2H-isindole-1-carboxylic acid (3-pyrrolidin-1-ylpropyl)amide
20		3-(2-Oxo-6-pyridin-3-yl-1,2-dihydroindol-3-ylidenemethyl)-4,5,6,7-tetrahydro-2H-isindole-1-carboxylic acid (2-diethylaminoethyl)amide
21		4-Benzoyl-5-(5-bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-3-methyl-1H-pyrrole-2-carboxylic acid (3-diethylaminopropyl)amide
22		4-Benzoyl-5-(5-bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-3-methyl-1H-pyrrole-2-carboxylic acid (3-morpholin-4-ylpropyl)amide
23		4-Benzoyl-3-methyl-5-(2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-2-carboxylic acid (3-pyrrolidin-1-ylpropyl)amide
24		4-Benzoyl-5-(5-bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-3-methyl-1H-pyrrole-2-carboxylic acid (3-pyrrolidin-1-ylpropyl)amide
25		4-Benzoyl-3-methyl-5-(2-oxo-6-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-2-carboxylic acid (3-pyrrolidin-1-ylpropyl)amide
26		4-Benzoyl-5-(6-methoxy-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-3-methyl-1H-pyrrole-2-carboxylic acid (3-pyrrolidin-1-ylpropyl)amide

27		4-Benzoyl-5-(5-methoxy-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-3-methyl-1H-pyrrole-2-carboxylic acid (3-pyrrolidin-1-ylpropyl)amide
28		4-Benzoyl-5-(5-fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-3-methyl-1H-pyrrole-2-carboxylic acid (3-pyrrolidin-1-ylpropyl)amide
29		4-Acetyl-5-(5-bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-3-methyl-1H-pyrrole-2-carboxylic acid (3-diethylaminopropyl)amide
30		4-Acetyl-5-(5-bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-3-methyl-1H-pyrrole-2-carboxylic acid (3-pyrrolidin-1-ylpropyl)amide
31		4-Acetyl-5-(5-bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-3-methyl-1H-pyrrole-2-carboxylic acid (3-morpholin-4-ylpropyl)amide
32		4-Acetyl-5-(5-bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-3-methyl-1H-pyrrole-2-carboxylic acid (3-hydroxy-propyl)amide
33		4-Acetyl-5-(5-bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-3-methyl-1H-pyrrole-2-carboxylic acid (2-hydroxy-ethyl)amide
34		4-Acetyl-5-(5-bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-3-methyl-1H-pyrrole-2-carboxylic acid (2-morpholin-4-yl-ethyl)amide
35		4-Acetyl-5-(5-bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-3-methyl-1H-pyrrole-2-carboxylic acid (2-pyrrolidin-1-yl-ethyl)amide



36		4-Acetyl-5-(5-bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-3-methyl-1H-pyrrole-2-carboxylic acid (2-(4-hydroxy-phenyl)-ethyl)amide
37		5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid (3-diethylaminopropyl)amide
38		5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid (3-pyrrolidin-1-ylpropyl)amide
39		5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide
40		5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid [3-(4-methyl-piperazin-1-yl)-propyl]amide
41		5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid
42		5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2-methyl-4-phenyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)amide
43		5-[6-(2-Methoxy-phenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2-methyl-4-phenyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)amide

44		5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2-methyl-4-phenyl-1H-pyrrole-3-carboxylic acid (2-dimethylamino-ethyl)amide
45		5-[6-(2-Methoxy-phenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2-methyl-4-phenyl-1H-pyrrole-3-carboxylic acid (2-dimethylamino-ethyl)amide
46		5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2-methyl-4-phenyl-1H-pyrrole-3-carboxylic acid ethyl ester
47		5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2-methyl-4-phenyl-1H-pyrrole-3-carboxylic acid (3-diethylaminopropyl)amide
48		5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-dimethylamino-ethyl)amide
49		2,4-Dimethyl-5-(2-oxo-6-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (2-dimethylamino-ethyl)amide
50		5-(5-Chloro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-dimethylamino-ethyl)amide
51		5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide

52		5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)amide
53		5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (3-imidazol-1-ylpropyl)amide
54		5-[6-(2-Methoxy-phenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-dimethylamino-ethyl)amide
55		5-[6-(3-Methoxy-phenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-dimethylamino-ethyl)amide
56		2,4-Dimethyl-5-(2-oxo-5-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide
57		2,4-Dimethyl-5-(2-oxo-5-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)amide
58		2,4-Dimethyl-5-(2-oxo-5-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (3-imidazol-1-ylpropyl)amide
59		2,4-Dimethyl-5-(2-oxo-6-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide
60		2,4-Dimethyl-5-(2-oxo-6-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)amide

61		2,4-Dimethyl-5-(2-oxo-6-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (3-imidazol-1-ylpropyl)amide
62		5-[6-(3,5-Dichloro-phenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide
63		2,4-Dimethyl-5-(2-oxo-6-pyridin-3-yl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide
64		2,4-Dimethyl-5-(2-oxo-6-pyridin-3-yl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)amide
65		2,4-Dimethyl-5-(2-oxo-6-pyridin-3-yl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (3-dimethylamino-propyl)amide
66		2,4-Dimethyl-5-(2-oxo-5-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (3-dimethylamino-propyl)amide
67		2,4-Dimethyl-5-(2-oxo-5-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (3-diethylaminopropyl)amide
68		2,4-Dimethyl-5-(2-oxo-6-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (3-diethylaminopropyl)amide

69		3-[4-(3-Diethylamino-propylcarbamoyl)-3,5-dimethyl-1H-pyrrol-2-yl(methylene)-2-oxo-2,3-dihydro-1H-indole-4-carboxylic acid (3-chloro-4-methoxy-phenyl)amide
70		5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (3-diethylaminopropyl)amide
71		5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-diisopropyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide
72		5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-diisopropyl-1H-pyrrole-3-carboxylic acid (3-diethylaminopropyl)amide
73		5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-diisopropyl-1H-pyrrole-3-carboxylic acid (3-pyrrolidin-1-ylpropyl)amide
74		5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (pyridin-4-ylmethyl)amide
75		5-[6-(4-Butyl-phenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)amide
76		5-[6-(5-Isopropyl-2-methoxy-phenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)amide

77		5-[6-(4-Ethyl-phenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)amide
78		5-[6-(2,4-Dimethoxy-phenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)amide
79		5-[6-(3-Isopropyl-phenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)amide
80		5-(5-Fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide
81		3-[4-(2-diethylaminoethylcarbamoyl)-3,5-dimethyl-1H-pyrrol-2-ylmethylene]-2-oxo-2,3-dihydro-1H-indole-6-carboxylic acid
82		5-(5-Dimethylsulfamoyl-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)amide
83		5-[5-(3-Chloro-phenylsulfamoyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)amide









84		2,4-Dimethyl-5-{2-oxo-5-(pyridin-3-ylsulfamoyl)-1,2-dihydroindol-3-ylidenemethyl}-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)amide
85		3-{3,5-Dimethyl-4-(4-methyl-piperazine-1-carbonyl)-1H-pyrrol-2-ylmethylene}-4-(2-hydroxy-ethyl)-1,3-dihydroindol-2-one
86		3-{3,5-Dimethyl-4-(4-methyl-piperazine-1-carbonyl)-1H-pyrrol-2-ylmethylene}-2-oxo-2,3-dihydro-1H-indole-5-sulfonic acid phenylamide
87		5-(5-Dimethylsulfamoyl-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide
88		5-[5-(3-Chloro-phenylsulfamoyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide
89		3-(5-Bromo-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-4,5,6,7-tetrahydro-2H-isoindole-1-carboxylic acid (2-dimethylamino-ethyl)-amide
90		3-(2-Oxo-1,2-dihydro-indol-3-ylidenemethyl)-4,5,6,7-tetrahydro-2H-isoindole-1-carboxylic acid ethyl ester
91		3-(4-Methyl-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-4,5,6,7-tetrahydro-2H-isoindole-1-carboxylic acid ethyl ester

92		3-(5-Bromo-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-4,5,6,7-tetrahydro-2H-isoindole-1-carboxylic acid ethyl ester
93		3-(3-Ethoxycarbonyl-4,5,6,7-tetrahydro-2H-isoindol-1-ylmethylene)-2-oxo-2,3-dihydro-1H-indole-5-carboxylic acid
94		3-(5-Methoxy-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-4,5,6,7-tetrahydro-2H-isoindole-1-carboxylic acid ethyl ester
95		3-(2-Oxo-5-phenyl-1,2-dihydro-indol-3-ylidenemethyl)-4,5,6,7-tetrahydro-2H-isoindole-1-carboxylic acid ethyl ester
96		3-(2-Oxo-5-sulfamoyl-1,2-dihydro-indol-3-ylidenemethyl)-4,5,6,7-tetrahydro-2H-isoindole-1-carboxylic acid ethyl ester
97		3-(5-Methylsulfamoyl-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-4,5,6,7-tetrahydro-2H-isoindole-1-carboxylic acid ethyl ester
98		3-(5-Dimethylsulfamoyl-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-4,5,6,7-tetrahydro-2H-isoindole-1-carboxylic acid ethyl ester
99		3-(2-Oxo-5-phenylsulfamoyl-1,2-dihydro-indol-3-ylidenemethyl)-4,5,6,7-tetrahydro-2H-isoindole-1-carboxylic acid ethyl ester
100		3-(6-Bromo-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-4,5,6,7-tetrahydro-2H-isoindole-1-carboxylic acid ethyl ester










101		3-(2-Oxo-6-phenyl-1,2-dihydro-indol-3-ylidenemethyl)-4,5,6,7-tetrahydro-2H-isoindole-1-carboxylic acid ethyl ester
102		3-(3-Ethoxycarbonyl-4,5,6,7-tetrahydro-2H-isoindol-1-ylmethylene)-2-oxo-2,3-dihydro-1H-indole-6-carboxylic acid
103		3-(6-Methoxy-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-4,5,6,7-tetrahydro-2H-isoindole-1-carboxylic acid ethyl ester
104		3-(5-Isopropylsulfamoyl-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-4,5,6,7-tetrahydro-2H-isoindole-1-carboxylic acid ethyl ester
105		3-(3-Methylcarbamoyl-4,5,6,7-tetrahydro-2H-isoindol-1-ylmethylene)-2-oxo-2,3-dihydro-1H-indole-5-carboxylic acid
106		3-(3-Dimethylcarbamoyl-4,5,6,7-tetrahydro-2H-isoindol-1-ylmethylene)-2-oxo-2,3-dihydro-1H-indole-5-carboxylic acid
107		2-Oxo-3-[3-(pyrrolidine-1-carbonyl)-4,5,6,7-tetrahydro-2H-isoindol-1-ylmethylene]-2,3-dihydro-1H-indole-5-carboxylic acid
108		3-[3-(Morpholine-4-carbonyl)-4,5,6,7-tetrahydro-2H-isoindol-1-ylmethylene]-2-oxo-2,3-dihydro-1H-indole-5-carboxylic acid
109		3-[3-(Morpholine-4-carbonyl)-4,5,6,7-tetrahydro-2H-isoindol-1-ylmethylene]-2-oxo-2,3-dihydro-1H-indole-6-carboxylic acid

110		3-(5-Bromo-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-4,5,6,7-tetrahydro-2H-isoindole-1-carboxylic acid methylamide
111		3-(5-Bromo-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-4,5,6,7-tetrahydro-2H-isoindole-1-carboxylic acid dimethylamide
112		5-Bromo-3-[3-(pyrrolidine-1-carbonyl)-4,5,6,7-tetrahydro-2H-isoindol-1-ylmethylene]-1,3-dihydro-indol-2-one
113		5-Bromo-3-[3-(morpholine-4-carbonyl)-4,5,6,7-tetrahydro-2H-isoindol-1-ylmethylene]-1,3-dihydro-indol-2-one
114		3-(3-Dimethylcarbamoyl-4,5,6,7-tetrahydro-2H-isoindol-1-ylmethylene)-2-oxo-2,3-dihydro-1H-indole-6-carboxylic acid
115		4-Methyl-5-(5-methylsulfamoyl-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid
116		[[4-Methyl-5-(4-methyl-5-methylsulfamoyl-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-1H-pyrrole-3-carbonyl]-amino]-acetic acid ethyl ester
117		[[4-Methyl-5-(5-methylsulfamoyl-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-1H-pyrrole-3-carbonyl]-amino]-acetic acid ethyl ester


118		{[4-Methyl-5-(5-methylsulfamoyl-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-1H-pyrrole-3-carbonyl]-amino}-acetic acid
119		3-[3-Methyl-4-(piperidine-1-carbonyl)-1H-pyrrol-2-ylmethylene]-2-oxo-2,3-dihydro-1H-indole-5-sulfonic acid methylamide
120		5-Methyl-2-(2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid
121		5-Methyl-2-(2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid ethyl ester
122		2-(5-Bromo-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-5-methyl-1H-pyrrole-3-carboxylic acid ethyl ester
123		2-(5-Bromo-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-5-methyl-1H-pyrrole-3-carboxylic acid
124		2-(5-Bromo-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-5-methyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide
125		2-(5-Bromo-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-5-methyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide

133		5-[5-Chloro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-acetylamino-ethyl)-amide	399 [M-1]
134		5-[5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-acetylamino-ethyl)-amide	383 [M-1]
135		2,4-Dimethyl-5-[2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-1H-pyrrole-3-carboxylic acid (2-acetylamino-ethyl)-amide	365 [M-1]
136		5-[5-Bromo-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [3-(2-oxo-tetrahydro-pyrimidin-1-yl)-propyl]-amide	500 [M+1] 502 [M+1]
137		5-[5-Chloro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [3-(2-oxo-tetrahydro-pyrimidin-1-yl)-propyl]-amide	454 [M-1]
138		5-[5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [3-(2-oxo-tetrahydro-pyrimidin-1-yl)-propyl]-amide	438 [M-1]
139		2,4-Dimethyl-5-[2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-1H-pyrrole-3-carboxylic acid [3-(2-oxo-tetrahydro-pyrimidin-1-yl)-propyl]-amide	422 [M+1]
140		5-[5-Cyano-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [3-(2-oxo-tetrahydro-pyrimidin-1-yl)-propyl]-amide	447 [M+1]
141		Trifluoro-acetate 4-[2-({5-[5-bromo-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carbonyl}-amino)-ethyl]-2-oxo-piperazin-1-ium;	486 [M+1] 488 [M+1]

126		2,4-Dimethyl-5-[2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)-amide	381 [M+1]
127		5-[5-Chloro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)-amide	415 [M+1]
128		2,4-Dimethyl-5-[2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-ylethyl)-amide	379 [M+1]
129		5-[5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-ylethyl)-amide	397 [M+1]
130		5-[5-Chloro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-ylethyl)-amide	413 [M+1]
131		2,4-Dimethyl-5-[2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-dimethylaminoethyl)-amide	353 [M+1]
132		5-[5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-dimethylaminoethyl)-amide	371 [M+1]

142		5-[5-Cyano-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [3-(2-oxo-pyrrolidin-1-yl)-propyl]-amide	430 [M-1]
143		5-[5-Bromo-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(2-oxo-imidazolidin-1-yl)-ethyl]-amide	470 [M-1] 472 [M-1]
144		5-[5-Chloro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(2-oxo-imidazolidin-1-yl)-ethyl]-amide	428 [M+1]
145		5-[5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(2-oxo-imidazolidin-1-yl)-ethyl]-amide	412 [M+1]
146		2,4-Dimethyl-5-[2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-1H-pyrrole-3-carboxylic acid [2-(2-oxo-imidazolidin-1-yl)-ethyl]-amide	392 [M-1]
147		5-[5-Cyano-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(2-oxo-imidazolidin-1-yl)-ethyl]-amide	419 [M+1]
148		{4-[2-({5-[5-Bromo-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carbonyl}amino)-ethyl]-piperazin-1-yl}-acetic acid ethyl ester	558 [M+1] 560 [M+1]
149		{4-[2-({5-[5-Chloro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carbonyl}amino)-ethyl]-piperazin-1-yl}-acetic acid ethyl ester	514 [M+1]
150		{4-[2-({5-[5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carbonyl}amino)-ethyl]-piperazin-1-yl}-acetic acid ethyl ester	498 [M+1]


153



2,4-Dimethyl-5-[2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-1H-pyrrole-3-carboxylic acid [2-(cyanomethyl-amino)-ethyl]-amide

362 [M-1]

154




5-[5-Bromo-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [3-(2-oxo-azepan-1-yl)-propyl]-amide

511 [M-1]

513 [M-1]


155



5-[5-Chloro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [3-(2-oxo-azepan-1-yl)-propyl]-amide

469 [M+1]


156



5-[5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [3-(2-oxo-azepan-1-yl)-propyl]-amide

453 [M+1]


157



2,4-Dimethyl-5-[2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-1H-pyrrole-3-carboxylic acid [3-(2-oxo-azepan-1-yl)-propyl]-amide

435 [M+1]


158



5-[5-Cyano-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [3-(2-oxo-azepan-1-yl)-propyl]-amide

460 [M+1]










159



5-[5-Bromo-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-acetyl-amino-ethyl)-amide

443 [M-1]

445 [M-1]

160		Trifluoro-acetate 4-[2-({5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carbonyl}-amino)-ethyl]-2-oxo-piperazin-1-ium;	426 [M+1]
161		Trifluoro-acetate 4-[2-({2,4-dimethyl-5-[2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-1H-pyrrole-3-carbonyl}-amino)-ethyl]-2-oxo-piperazin-1-ium;	408 [M+1]
162		Trifluoro-acetate 4-[2-({5-[5-cyano-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carbonyl}-amino)-ethyl]-2-oxo-piperazin-1-ium;	433 [M+1]
163		5-[5-Bromo-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(2-cyanoethylamino)-ethyl]-amide	454 [M-1] 456 [M-1]
164		5-[5-Chloro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(2-cyanoethylamino)-ethyl]-amide	410 [M-1]
165		5-[5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(2-cyanoethylamino)-ethyl]-amide	394 [M-1]
166		2,4-Dimethyl-5-[2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-1H-pyrrole-3-carboxylic acid [2-(2-cyanoethylamino)-ethyl]-amide	376 [M-1]
167		5-[5-Cyano-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(2-cyanoethylamino)-ethyl]-amide	401 [M-1]
168		Trifluoro-acetate 4-[2-({5-[5-chloro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carbonyl}-amino)-ethyl]-2-oxo-piperazin-1-ium;	440 [M-1]



168		5-[5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(4-methyl-piperazin-1-yl)-ethyl]-amide	424 [M-1]
169		5-[5-Chloro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(4-methyl-piperazin-1-yl)-ethyl]-amide	440 [M-1]
170		5-[5-Bromo-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(4-methyl-piperazin-1-yl)-ethyl]-amide	484 [M-1] 486 [M-1]
171		2,4-Dimethyl-5-[2-oxo-1,2-dihydro-indol-(3Z)ylidenemethyl]-1H-pyrrole-3-carboxylic acid [2-(4-methyl-piperazin-1-yl)-ethyl]-amide	406 [M-1]
172		2,4-Dimethyl-5-[2-oxo-1,2-dihydro-indol-(3Z)ylidenemethyl]-1H-pyrrole-3-carboxylic acid [2-(3,5-dimethyl-piperazin-1-yl)-ethyl]-amide	422 [M+1]
173		5-[5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(3,5-dimethyl-piperazin-1-yl)-ethyl]-amide	438 [M-1]
174		5-[5-Chloro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(3,5-dimethyl-piperazin-1-yl)-ethyl]-amide	456 [M+1]
175		5-[5-Bromo-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(3,5-dimethyl-piperazin-1-yl)-ethyl]-amide	498 [M-1] 500 [M-1]

176		2,4-Dimethyl-5-[2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-1H-pyrrole-3-carboxylic acid [3-(4-methyl-piperazin-1-yl)-propyl]-amide	422 [M+1]
177		5-[5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [3-(4-methyl-piperazin-1-yl)-propyl]-amide	438 [M-1]
178		5-[5-Chloro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [3-(4-methyl-piperazin-1-yl)-propyl]-amide	454 [M-1]
179		5-[5-Bromo-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [3-(4-methyl-piperazin-1-yl)-propyl]-amide	498 [M-1] 500 [M-1]
180		2,4-Dimethyl-5-[2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-1H-pyrrole-3-carboxylic acid [2-(4-benzyl-piperazin-1-yl)-ethyl]-amide	482 [M-1]
181		5-[5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(4-benzyl-piperazin-1-yl)-ethyl]-amide	500 [M-1]
182		5-[5-Chloro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(4-benzyl-piperazin-1-yl)-ethyl]-amide	517 [M-1]
183		5-[5-Bromo-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(4-benzyl-piperazin-1-yl)-ethyl]-amide	560 [M-1] 562 [M-1]

184		5-[5-Chloro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (3-pyrrolidin-1yl-2-one)-amide	480 [M+1]
185		Trifluoroacetate 4-[2-({5-[5-Chloro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carbonyl}amino)-ethyl] 2-oxo-piperazin-1-ium	440 [M-1]
186		5-[5-Chloro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (3-pyrrolidin-1yl-2-one)-amide	
187		5-[5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (3-pyrrolidin-1yl-2-one)-amide	
188		5-[2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (3-pyrrolidin-1yl-2-one)-amide	
189		5-[5-Chloro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyridin-2-ylethyl)-amide	
190		5-[5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyridin-2-ylethyl)-amide trifluoroacetate salt	
191		5-[2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyridin-2-ylethyl)-amide hydrochloride salt	
192		5-[5-Bromo-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyridin-2-ylethyl)-amide trifluoroacetate salt	

193		5-[5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-ethylaminoethyl)-amide
194		5-[5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-aminoethyl)-amide
195		5-[5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethyl-N-oxoaminoethyl)-amide
196		5-[5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-ethyl-N-hydroxy-aminoethyl)-amide
197		5-[5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-1H-pyrrole-3-carboxylic acid (2-diethylamino-2-hydroxyethyl)-amide
198		5-[5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-ethyl-2-(2-hydroxyethyl)aminoethyl]-amide
199		5-[5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-ethyl-2-(1-hydroxyethyl)aminoethyl]-amide
200		5-[5-Cyano-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-N-acetylaminoethyl)-amide
201		5-[5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (carboxymethyl)-amide

202		5-[5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-1H-pyrrole-3-carboxylic acid [2-(2-hydroxethylamino)ethyl]-amide
203		5-[5-Cyano-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-1H-pyrrole-3-carboxylic acid (2-pyridin-2-ylethyl)-amide trifluoroacetate
204		5-[5-Bromo-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-1H-pyrrole-3-carboxylic acid (3-pyrrolidin-1-yl-2-onepropyl)-amide trifluoroacetate

The compound numbers correspond to the Example numbers in the Examples section. That is, the synthesis of Compound 1 in Table 1 is described in Example 1. The compounds presented in Table 1 are exemplary only and are not to be construed as limiting the scope of this invention in any manner.

#### PREFERRED EMBODIMENTS

While the broadest definition is set forth in the Summary of the Invention, certain compounds of Formula (I) set forth below are preferred.

- (1) A preferred group of compounds of Formula (I) is that wherein  $R^1$ ,  $R^3$ , and  $R^4$  are hydrogen.
- (2) Another preferred group of compounds of Formula (I) is that wherein  $R^1$ ,  $R^2$ , and  $R^4$  are hydrogen.
- (3) Another preferred group of compounds of Formula (I) is that wherein  $R^1$ ,  $R^2$ , and  $R^3$  are hydrogen.
- (4) Another preferred group of compounds of Formula (I) is that wherein  $R^2$ ,  $R^3$ , and  $R^4$  are hydrogen.
- (5) Another preferred group of compounds of Formula (I) is that wherein  $R^1$ ,  $R^2$ ,  $R^3$  and  $R^4$  are hydrogen.
- (6) Yet another preferred group of compounds of Formula (I) is that wherein  $R^5$ ,  $R^6$  or  $R^7$ , preferably  $R^5$  or  $R^6$ , more preferably  $R^6$  is  $-\text{COR}^{10}$  wherein  $R^{10}$  is  $-\text{NR}^{11}(\text{CH}_2)_n\text{R}^{12}$  wherein:

$R^{11}$  is hydrogen or lower unsubstituted alkyl,

preferably hydrogen or methyl;

n is 2, 3 or 4, preferably 2 or 3; and

$R^{12}$  is  $-NR^{13}R^{14}$  wherein  $R^{13}$  and  $R^{14}$  are independently alkyl, more preferably lower unsubstituted lower alkyl or  $R^{13}$  and  $R^{14}$  combine to form a group selected from  $-(CH_2)_4-$ ,  $-(CH_2)_5-$ ,  $-(CH_2)_2-O-(CH_2)_2-$  or  $-(CH_2)_2N(CH_3)(CH_2)_2-$ , preferably  $R^{13}$  and  $R^{14}$  are independently hydrogen, methyl, ethyl, or combine to form morpholin-4-yl, pyrrolidin-1-yl, piperazin-1-yl, or 4-methylpiperazin-1-yl.

More preferably,  $R^5$  or  $R^6$  in (6) above is N-(2-dimethylaminoethyl)-aminocarbonyl, N-(2-ethylaminoethyl)-N-methylaminocarbonyl, N-(3-dimethylaminopropyl)-aminocarbonyl, N-(2-diethylaminoethyl)aminocarbonyl, N-(3-ethylaminopropyl)aminocarbonyl, N-(3-diethylaminopropyl)aminocarbonyl, 3-pyrrolidin-1-yl-propylaminocarbonyl, 3-morpholin-4-ylpropylaminocarbonyl, 2-pyrrolidin-1-ylethylaminocarbonyl, 2-morpholin-4-ylethylaminocarbonyl, 2-(4-methylpiperazin-1-yl)ethylaminocarbonyl, 2-(4-methylpiperazin-1-yl)propylaminocarbonyl, 2-(3,5-dimethylpiperazin-1-yl)ethylaminocarbonyl or 2-(3,5-dimethylpiperazin-1-yl)propylaminocarbonyl, even more preferably N-(2-diethylaminoethyl)aminocarbonyl or N-(2-ethylaminoethyl)aminocarbonyl.

- (7) Yet another preferred group of compounds of Formula (I) is that wherein  $R^5$ ,  $R^6$  or  $R^7$ , preferably  $R^5$  or  $R^6$ , more preferably  $R^6$  is  $-COR^{10}$  wherein  $R^{10}$  is  $-NR^{13}R^{14}$  wherein  $R^{13}$  is hydrogen and  $R^{14}$  is alkyl, preferably lower alkyl substituted with hydroxy, aryl, heteroaryl, heteroalicyclic, or carboxy, more preferably methyl, ethyl, propyl or butyl substituted with hydroxy, aryl, heteroalicyclic such as piperidine, piperazine, morpholine and the like, heteroaryl, or carboxy. Even more preferably within this group (7),  $R^5$  or  $R^6$  is 2-ethoxycarbonylmethyl-aminocarbonyl, carboxymethylaminocarbonyl, 3-hydroxypropyl-aminocarbonyl, 2-

hydroxyethylaminocarbonyl, 3-triazin-1-ylpropylamino-  
carbonyl, triazin-1-ylethylaminocarbonyl, 4-hydroxy-  
phenylethylaminocarbonyl, 3-imidazol-1-ylpropyl-  
aminocarbonyl, pyridin-4-ylmethylethylaminocarbonyl, 2-  
pyridin-2-ylethylaminocarbonyl or 2-imidazol-1-  
ylethylaminocarbonyl.

- (8) Yet another preferred group of compounds of Formula (I)  
is that wherein  $R^5$ ,  $R^6$  or  $R^7$ , preferably  $R^5$  or  $R^6$ , more  
preferably  $R^6$  is  $-COR^{10}$  wherein  $R^{10}$  is  $-NR^{11}(CH_2)_nR^{12}$   
wherein:

$R^{11}$  is hydrogen or alkyl, preferably hydrogen or  
methyl;

$n$  is 2, 3 or 4, preferably 2 or 3; and

$R^{12}$  is  $-NR^{13}R^{14}$  wherein  $R^{13}$  and  $R^{14}$  together combine to  
form a heterocycle, preferably a 5, 6 or 7 membered  
heterocycle containing a carbonyl group and 1 or 2  
nitrogen atoms. Preferably,  $R^5$  or  $R^6$  is 2-(3-  
ethoxycarbonylmethylpiperazin-1-yl)ethylaminocarbonyl, 2-  
(3-oxopiperazin-1-yl)ethylaminocarbonyl, 2-(imidazolidin-  
1-yl-2-one)ethylaminocarbonyl, 2-(tetrahydropyrimidin-1-  
yl-2-one)ethylaminocarbonyl, 2-(2-oxopyrrolidin-1-yl)-  
ethylaminocarbonyl, 3-(4-methylpiperazin-1-yl)-  
propylaminocarbonyl, 3-(3-ethoxycarbonylmethylpiperazin-  
1-yl)-propylaminocarbonyl, 3-(3-oxopiperazin-1-yl)propyl-  
aminocarbonyl, 3-(imidazolidin-1-yl-2-one)propyl-  
aminocarbonyl, 3-(tetrahydropyrimidin-1-yl-2-one)-  
propylaminocarbonyl, 3-(2-oxopyrrolidin-1-yl)propyl-  
aminocarbonyl, 2-(2-oxohomopiperidin-1-yl)ethylamino-  
carbonyl or 3-(2-oxohomopiperidin-1-  
yl)propylaminocarbonyl.

- (9) Yet another preferred group of compounds of Formula (I)  
is that wherein  $R^5$ ,  $R^6$  or  $R^7$ , preferably  $R^5$  or  $R^6$ , more  
preferably  $R^6$  is  $-COR^{10}$  wherein:

(a)  $R^{10}$  is  $-NR^{11}(CH_2)_nR^{12}$  wherein:

$R^{11}$  is hydrogen or alkyl, preferably hydrogen or  
methyl;

n is 2, 3 or 4, preferably 2 or 3; and  
R<sup>12</sup> is -NR<sup>13</sup>R<sup>14</sup> wherein R<sup>13</sup> is hydrogen and R<sup>14</sup> is  
cyanoalkyl or -NHCOR<sup>a</sup> where R<sup>a</sup> is alkyl; or

(b) R<sup>10</sup> is -NR<sup>13</sup>R<sup>14</sup> wherein R<sup>13</sup> and R<sup>14</sup> together combine  
to form a heterocycle not containing a carbonyl group  
within the ring. Preferably, R<sup>5</sup> or R<sup>6</sup> is 2-(2-  
cyanoethylamino)ethylaminocarbonyl, 2-(acetylamino)-  
ethylaminocarbonyl, morpholinocarbonyl, piperidin-1-yl-  
carbonyl, 2-cyanomethylaminoethylaminocarbonyl or  
piperidin-1-ylcarbonyl.

(10) Another preferred group of compounds of Formula (I) is  
that wherein R<sup>5</sup> is -COR<sup>10</sup> wherein R<sup>10</sup> is -NR<sup>13</sup>R<sup>14</sup> wherein R<sup>13</sup>  
is hydrogen and R<sup>14</sup> is lower alkyl substituted with  
hydroxy, lower alkyl substituted with hydroxyalkylamino,  
carboxy, or -NR<sup>18</sup>R<sup>19</sup> wherein R<sup>18</sup> and R<sup>19</sup> are independently  
hydrogen or lower unsubstituted alkyl, more preferably R<sup>5</sup>  
is 2-[(diethylamino)-2-hydroxyethyl]aminocarbonyl, 2-(N-  
ethyl-N-2-hydroxyethylamino)ethylaminocarbonyl,  
carboxymethylamino-carbonyl, or 2-(2-  
hydroxyethylamino)ethylamino-carbonyl.

(11) Yet another preferred group of compounds of Formula (I)  
is that wherein R<sup>6</sup> is -COR<sup>10</sup> wherein R<sup>10</sup> is -NR<sup>13</sup>R<sup>14</sup> wherein  
R<sup>13</sup> is hydrogen and R<sup>14</sup> is lower alkyl substituted with  
hydroxy, lower alkyl substituted with hydroxyalkylamino,  
carboxy, or -NR<sup>18</sup>R<sup>19</sup> wherein R<sup>18</sup> and R<sup>19</sup> are independently  
hydrogen or lower unsubstituted alkyl; more preferably R<sup>6</sup>  
is [2-(diethylamino)-2-hydroxy]ethylaminocarbonyl, 2-(N-  
ethyl-N-2-hydroxyethyl-amino)ethylaminocarbonyl,  
carboxymethylaminocarbonyl, or 2-(2-  
hydroxyethylamino)ethylamino-carbonyl.

(12) Yet another preferred group of compounds of Formula  
(I) is that wherein R<sup>5</sup> is -COR<sup>10</sup> wherein R<sup>10</sup> is -  
NR<sup>11</sup>(CH<sub>2</sub>)<sub>n</sub>R<sup>12</sup> wherein R<sup>12</sup> is -N<sup>+</sup>(O<sup>-</sup>)NR<sup>13</sup>R<sup>14</sup> or -N(OH)R<sup>13</sup>  
wherein R<sup>13</sup> and R<sup>14</sup> are independently selected from the  
group consisting of hydrogen and unsubstituted lower  
alkyl, preferably R<sup>5</sup> is 2-(N-hydroxy-N-ethylamino)-



ethylaminocarbonyl or 2-[N<sup>+</sup>(O<sup>-</sup>)(C<sub>2</sub>H<sub>5</sub>)<sub>2</sub>]ethyl-aminocarbonyl  
(13) Yet another preferred group of compounds of Formula  
(I) is that wherein R<sup>6</sup> is -COR<sup>10</sup> wherein R<sup>10</sup> is -  
NR<sup>11</sup>(CH<sub>2</sub>)<sub>n</sub>R<sup>12</sup> wherein R<sup>12</sup> is -N<sup>+</sup>(O<sup>-</sup>)NR<sup>13</sup>R<sup>14</sup> or -N(OH)R<sup>13</sup>  
wherein R<sup>13</sup> and R<sup>14</sup> are independently selected from the  
group consisting of hydrogen and unsubstituted lower  
alkyl, preferably R<sup>6</sup> is 2-(N-hydroxy-N-  
ethylamino)ethylaminocarbonyl or 2-[N<sup>+</sup>(O<sup>-</sup>)(C<sub>2</sub>H<sub>5</sub>)<sub>2</sub>]ethyl-  
aminocarbonyl.

(14) In the above preferred groups (6)-(13) when R<sup>5</sup> is -COR<sup>10</sup>,  
then a more preferred group of compounds is that wherein:

R<sup>6</sup> is selected from the group consisting of hydrogen  
and alkyl, preferably hydrogen, methyl, ethyl, isopropyl,  
tert-butyl, isobutyl, or n-butyl, more preferably  
hydrogen or methyl; and

R<sup>7</sup> is selected from the group consisting of hydrogen,  
alkyl, aryl, heteroaryl, and -C(O)R<sup>17</sup> wherein R<sup>17</sup> is  
hydroxy, alkyl or aryl, more preferably hydrogen, methyl,  
ethyl, isopropyl, n-, iso or tert-butyl, phenyl, benzoyl,  
acetyl or carboxy, even more preferably methyl, hydrogen  
or phenyl.

(15) In the above preferred groups (6)-(13) when R<sup>5</sup> is -COR<sup>10</sup>,  
then another more preferred group of compounds is that  
wherein R<sup>6</sup> and R<sup>7</sup> combine to form -(CH<sub>2</sub>)<sub>4</sub>-.

(16) In the above preferred groups (6)-(13) when R<sup>6</sup> is -COR<sup>10</sup>,  
then a more preferred group of compounds is that wherein:

R<sup>5</sup> is selected from the group consisting of hydrogen  
and alkyl, preferably hydrogen, methyl, ethyl, isopropyl,  
tert-butyl, isobutyl, or n-butyl, more preferably hydrogen  
or methyl; and

R<sup>7</sup> is selected from the group consisting of hydrogen,  
alkyl, aryl, heteroaryl, and -C(O)R<sup>17</sup>, wherein R<sup>17</sup> is  
hydroxy, alkyl or aryl, more preferably hydrogen, methyl,  
ethyl, isopropyl, n-, iso or tert-butyl, phenyl, benzoyl,  
acetyl or carboxy, even more preferably methyl, hydrogen  
or phenyl.

(17) Within the above preferred and more preferred groups (6)-(16), an even more preferred group of compounds is that wherein:

$R^1$  is hydrogen, alkyl,  $-C(O)NR^8R^9$ , unsubstituted cycloalkyl or aryl, preferably hydrogen, phenyl, 3,4-dimethoxyphenylaminocarbonyl, 4-methoxy-3-chlorophenylaminocarbonyl, even more preferably hydrogen or methyl, most preferably hydrogen;

$R^2$  is cyano, hydrogen, halo, lower alkoxy, aryl or  $-S(O)_2NR^{13}R^{14}$  wherein  $R^{13}$  is hydrogen and  $R^{14}$  is hydrogen, aryl or alkyl, preferably  $R^2$  is hydrogen, chloro, bromo, fluoro, methoxy, ethoxy, phenyl, dimethylaminosulfonyl, 3-chlorophenyl-aminosulfonyl, carboxy, methoxy, aminosulfonyl, methylaminosulfonyl, phenylaminosulfonyl, pyridin-3-yl-aminosulfonyl, dimethylaminosulfonyl, isopropylamino-sulfonyl, more preferably hydrogen, fluoro, or bromo;

$R^3$  is selected from the group consisting of hydrogen, lower alkoxy,  $-C(O)R^{15}$ ,  $-NR^{13}C(O)R^{14}$ , aryl preferably aryl optionally substituted with one or two substituents selected from the group consisting of lower alkyl, halo, or lower alkoxy, and heteroaryl, preferably heteroaryl optionally substituted with one or two substituents selected from the group consisting of lower alkyl, halo, or lower alkoxy,; preferably hydrogen, methoxy, carboxy, phenyl, pyridin-3-yl, 3,4-dichlorophenyl, 2-methoxy-5-isopropylphenyl, 4-n-butylphenyl, 3-isopropylphenyl, more preferably hydrogen or phenyl; and

$R^4$  is hydrogen.

(18) Another more preferred group of compounds of Formula (I) is that wherein:

$R^1$  is hydrogen, alkyl,  $-C(O)NR^8R^9$ , unsubstituted cycloalkyl or aryl, preferably hydrogen, 3,4-dimethoxyphenylaminocarbonyl, 4-methoxy-3-chlorophenylaminocarbonyl, even more preferably hydrogen or methyl, particularly hydrogen;

$R^2$  is cyano, hydrogen, halo, lower alkoxy, aryl or  $-S(O)_2NR^{13}R^{14}$  wherein  $R^{13}$  is hydrogen and  $R^{14}$  is hydrogen, aryl or alkyl, preferably  $R^2$  is hydrogen, chloro, bromo, fluoro, methoxy, ethoxy, phenyl, dimethylaminosulfonyl, 3-chlorophenyl-aminosulfonyl, carboxy, methoxy, aminosulfonyl, methylaminosulfonyl, phenylaminosulfonyl, pyridin-3-yl-aminosulfonyl, dimethylaminosulfonyl, isopropylamino-sulfonyl, more preferably hydrogen, fluoro, or bromo;

$R^3$  is selected from the group consisting of hydrogen, lower alkoxy,  $-C(O)R^{15}$ ,  $-NR^{13}C(O)R^{14}$ , aryl preferably aryl optionally substituted with one or two substituents selected from the group consisting of lower alkyl, halo, or lower alkoxy, and heteroaryl, preferably heteroaryl optionally substituted with one or two substituents selected from the group consisting of lower alkyl, halo, or lower alkoxy,; preferably hydrogen, methoxy, carboxy, phenyl, pyridin-3-yl, 3,4-dichlorophenyl, 2-methoxy-5-isopropylphenyl, 4-n-butylphenyl, 3-isopropylphenyl, more preferably hydrogen or phenyl; and

$R^4$  is hydrogen.

Within the above preferred group (18) a more preferred group of compounds is wherein:

$R^5$  is  $-COR^{10}$  where  $R^{10}$  is as defined in the Summary of the Invention, preferably  $-NR^{11}(CH_2)_nR^{12}$  or  $-NR^{13}R^{14}$  as defined in the Summary of the Invention.

$R^6$  is selected from the group consisting of hydrogen and alkyl, preferably hydrogen, methyl, ethyl, isopropyl, tert-butyl, isobutyl, or n-butyl, more preferably hydrogen or methyl; and

$R^7$  is selected from the group consisting of hydrogen, alkyl, aryl, heteroaryl, and  $-C(O)R^{17}$  wherein  $R^{17}$  is hydroxy, alkyl or aryl, more preferably hydrogen, methyl, ethyl, isopropyl, n-, iso or tert-butyl, phenyl, benzoyl, acetyl or carboxy, even more preferably methyl, hydrogen or phenyl.

In the above preferred group (18) another more preferred group of compounds is that wherein:

$R^6$  is  $-COR^{10}$  where  $R^{10}$  is as defined in the Summary of the Invention, preferably  $-NR^{11}(CH_2)_nR^{12}$  or  $-NR^{13}R^{14}$  as defined in the Summary of the Invention.

$R^5$  is selected from the group consisting of hydrogen and alkyl, preferably hydrogen, methyl, ethyl, isopropyl, tert-butyl, isobutyl, or n-butyl, more preferably hydrogen or methyl; and

$R^7$  is selected from the group consisting of hydrogen, alkyl, aryl, heteroaryl, and  $-C(O)R^{17}$  wherein  $R^{17}$  is hydroxy, alkyl or aryl, more preferably hydrogen, methyl, ethyl, isopropyl, n-, iso or tert-butyl, phenyl, benzoyl, acetyl or carboxy, even more preferably methyl, hydrogen or phenyl.

(19) Another more preferred group of compounds of Formula (I) is that wherein:

$R^1$  and  $R^4$  are hydrogen;

$R^2$  is selected from the group consisting of hydrogen, halo, lower alkoxy,  $-C(O)R^{15}$  and  $-S(O)_2NR^{13}R^{14}$ ;

$R^3$  is selected from the group consisting of hydrogen, lower alkoxy,  $-C(O)R^{15}$ ,  $-S(O)_2NR^{13}R^{14}$ , aryl and heteroaryl;

$R^5$  is  $-C(O)R^{10}$ ;

$R^6$  is selected from the group consisting of hydrogen and lower alkyl; and

$R^7$  is selected from the group consisting of hydrogen, lower alkyl and  $-C(O)R^{17}$ .

It is another presently preferred embodiment of this invention that, in a compound having a structure as described in (15):

$R^{10}$  is selected from the group consisting of hydroxy, lower alkoxy and  $-NR^{11}(CH_2)_nR^{12}$ , wherein

n is 2 or 3;

$R^{11}$  is selected from the group consisting of hydrogen and lower alkyl; and,

$R^{12}$  is selected from the group consisting of aryl and

-NR<sup>13</sup>R<sup>14</sup>.

It is a further presently preferred embodiment of this invention that, in a compound having a structure as described in the previous two paragraphs, R<sup>13</sup> and R<sup>14</sup> are independently selected from the group consisting of hydrogen, lower alkyl, and, combined, -(CH<sub>2</sub>)<sub>4</sub>-, -(CH<sub>2</sub>)<sub>5</sub>-, -(CH<sub>2</sub>)<sub>2</sub>O(CH<sub>2</sub>)<sub>2</sub>- or -(CH<sub>2</sub>)<sub>2</sub>N(CH<sub>3</sub>)(CH<sub>2</sub>)<sub>2</sub>-.

(20) Another presently preferred embodiment of this invention is a compound in which:

R<sup>1</sup> is selected from the group consisting of hydrogen, lower alkyl, -(CH<sub>2</sub>)<sub>r</sub>R<sup>16</sup> and -C(O)NR<sup>8</sup>R<sup>9</sup>;

R<sup>2</sup> is selected from the group consisting of hydrogen, halogen, aryl and -S(O)<sub>2</sub>NR<sup>13</sup>R<sup>14</sup>;

R<sup>3</sup> is selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, aryl, heteroaryl and -C(O)R<sup>15</sup>;

R<sup>4</sup> is hydrogen;

R<sup>5</sup> is selected from the group consisting of hydrogen and lower alkyl;

R<sup>6</sup> is -C(O)R<sup>10</sup>;

R<sup>7</sup> is selected from the group consisting of hydrogen, lower alkyl and aryl;

R<sup>16</sup> is selected from the group consisting of hydroxy and -C(O)R<sup>15</sup>; and,

r is 2 or 3.

A presently preferred embodiment of this invention is a compound having as structure described in the paragraph just above in which R<sup>3</sup> is aryl optionally substituted with one or more groups selected from the group consisting of lower alkyl, lower alkoxy and halo.

(21) Likewise, it is a presently preferred embodiment of this invention that, in a compound in which:

R<sup>1</sup> is selected from the group consisting of hydrogen, lower alkyl, -(CH<sub>2</sub>)<sub>r</sub>R<sup>16</sup> and -C(O)NR<sup>8</sup>R<sup>9</sup>;

R<sup>2</sup> is selected from the group consisting of hydrogen, halogen, aryl and -S(O)<sub>2</sub>NR<sup>13</sup>R<sup>14</sup>;

R<sup>3</sup> is selected from the group consisting of hydrogen,

lower alkyl, lower alkoxy, aryl, heteroaryl and  $-C(O)R^{15}$ ;

$R^4$  is hydrogen;

$R^5$  is selected from the group consisting of hydrogen and lower alkyl;

5  $R^6$  is  $-C(O)R^{10}$ ;

$R^7$  is selected from the group consisting of hydrogen, lower alkyl and aryl;

$R^{16}$  is selected from the group consisting of hydroxy and  $-C(O)R^{15}$ ; and,

10  $r$  is 2 or 3,

$R^{10}$  is selected from the group consisting of hydroxy, lower alkoxy,  $-NR^{13}R^{14}$  and  $-NR^{11}(CH_2)_nR^{12}$ , wherein  $n$  is 1, 2 or 3,  $R^{11}$  is hydrogen and  $R^{12}$  is selected from the group consisting of hydroxy, lower alkoxy,  $-C(O)R^{15}$ , heteroaryl and  $-NR^{13}R^{14}$ .

(22) A further presently preferred embodiment of this invention is a compound having a structure as described in the paragraph immediately above in which  $R^{13}$  and  $R^{14}$  are independently selected from the group consisting of hydrogen, lower alkyl, heteroaryl and, combined,  $-(CH_2)_4-$ ,  $-(CH_2)_5-$ ,  $-(CH_2)_2O(CH_2)_2-$ , or  $-(CH_2)_2N(CH_3)(CH_2)_2-$ .

(23) Another presently preferred embodiment of this invention is a compound in which:

25  $R^1$  is  $-C(O)NR^8R^9$ , wherein  $R^8$  is hydrogen and  $R^9$  is aryl optionally substituted with one or more groups selected from the group consisting of halo, hydroxy and lower alkoxy;

$R^2$  is selected from the group consisting of hydrogen, halogen, aryl and  $-S(O)_2NR^{13}R^{14}$ ;

30  $R^3$  is selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, aryl, heteroaryl and  $-C(O)R^{15}$ ;

$R^4$  is hydrogen;

$R^5$  is selected from the group consisting of hydrogen and lower alkyl;

35  $R^6$  is  $-C(O)R^{10}$ ;

$R^7$  is selected from the group consisting of hydrogen,

lower alkyl and aryl;

$R^{16}$  is selected from the group consisting of hydroxy and  $-C(O)R^{15}$ ; and,

$r$  is 2 or 3,

- 5 (24) A still further presently preferred embodiment of this invention is a compound in which:

$R^1$  is selected from the group consisting of hydrogen and lower alkyl;

10  $R^2$  is selected from the group consisting of hydrogen, halo, lower alkoxy, aryl,  $-C(O)R^{15}$  and  $-S(O)_2NR^{13}R^{14}$ ;

$R^3$  is selected from the group consisting of hydrogen, halo, aryl, heteroaryl and  $-C(O)R^{15}$ ;

$R^4$  is hydrogen;

$R^5$  is  $-C(O)R^{10}$ ; and,

15  $R^6$  and  $R^7$  combine to form a  $-(CH_2)_4-$  group.

In a compound having a structure as described in the paragraph immediately above, it is a presently preferred embodiment that  $R^{10}$  is selected from the group consisting of hydroxy, alkoxy,  $-NR^{13}R^{14}$  and  $-NH(CH_2)_nNR^{13}R^{14}$  wherein  $n$  is 2 or 3.

20 It is a presently preferred embodiment of this invention that, in a compound having a structure as described in the two paragraphs immediately above,  $R^{13}$  and  $R^{14}$  are independently selected from the group consisting of hydrogen, lower alkyl, and, combined,  $-(CH_2)_4-$ ,  $-(CH_2)_5-$ ,  $-(CH_2)_2O(CH_2)_2-$  or  $-(CH_2)_2N(CH_3)(CH_2)_2-$ .

### Utility

25 The PKs whose catalytic activity is modulated by the compounds of this invention include protein tyrosine kinases of which there are two types, receptor tyrosine kinases (RTKs) and cellular tyrosine kinases (CTKs), and serine-threonine kinases (STKs). RTK mediated signal transduction is initiated by extracellular interaction with a specific growth factor (ligand), followed by receptor dimerization, transient stimulation of the intrinsic protein tyrosine kinase activity

and phosphorylation. Binding sites are thereby created for intracellular signal transduction molecules and lead to the formation of complexes with a spectrum of cytoplasmic signaling molecules that facilitate the appropriate cellular response (e.g., cell division, metabolic effects on the extracellular microenvironment, etc.). See, Schlessinger and Ullrich, 1992, Neuron 9:303-391.

It has been shown that tyrosine phosphorylation sites on growth factor receptors function as high-affinity binding sites for SH2 (src homology) domains of signaling molecules. Fantl *et al.*, 1992, Cell 69:413-423, Songyang *et al.*, 1994, Mol. Cell. Biol. 14:2777-2785), Songyang *et al.*, 1993, Cell 72:767-778, and Koch *et al.*, 1991, Science 252:668-678.

Several intracellular substrate proteins that associate with RTKs have been identified. They may be divided into two principal groups: (1) substrates that have a catalytic domain, and (2) substrates which lack such domain but which serve as adapters and associate with catalytically active molecules. Songyang *et al.*, 1993, Cell 72:767-778. The specificity of the interactions between receptors and SH2 domains of their substrates is determined by the amino acid residues immediately surrounding the phosphorylated tyrosine residue. Differences in the binding affinities between SH2 domains and the amino acid sequences surrounding the phosphotyrosine residues on particular receptors are consistent with the observed differences in their substrate phosphorylation profiles. Songyang *et al.*, 1993, Cell 72:767-778. These observations suggest that the function of each RTK is determined not only by its pattern of expression and ligand availability but also by the array of downstream signal transduction pathways that are activated by a particular receptor. Thus, phosphorylation provides an important regulatory step which determines the selectivity of signaling pathways recruited by specific growth factor receptors, as well as differentiation factor receptors.



STKs, being primarily cytosolic, affect the internal  
biochemistry of the cell, often as a down-line response to a  
PTK event. STKs have been implicated in the signaling process  
which initiates DNA synthesis and subsequent mitosis leading  
5 to cell proliferation.

Thus, PK signal transduction results in, among other  
responses, cell proliferation, differentiation, growth and  
metabolism. Abnormal cell proliferation may result in a wide  
array of disorders and diseases, including the development of  
10 neoplasia such as carcinoma, sarcoma, glioblastoma and  
hemangioma, disorders such as leukemia, psoriasis,  
arteriosclerosis, arthritis and diabetic retinopathy and other  
disorders related to uncontrolled angiogenesis and/or  
vasculogenesis.

A precise understanding of the mechanism by which the  
compounds of this invention inhibit PKs is not required in  
order to practice the present invention. However, while not  
hereby being bound to any particular mechanism or theory, it  
is believed that the compounds interact with the amino acids  
10 in the catalytic region of PKs. PKs typically possess a bi-  
lobate structure wherein ATP appears to bind in the cleft  
between the two lobes in a region where the amino acids are  
conserved among PKs. Inhibitors of PKs are believed to bind  
by non-covalent interactions such as hydrogen bonding, van der  
25 Waals forces and ionic interactions in the same general region  
where the aforesaid ATP binds to the PKs. More specifically,  
it is thought that the 2-indolinone component of the compounds  
of this invention binds in the general space normally occupied  
by the adenine ring of ATP. Specificity of a particular  
30 molecule for a particular PK may then arise as the result of  
additional interactions between the various substituents on  
the 2-indolinone core and the amino acid domains specific to  
particular PKs. Thus, different indolinone substituents may  
contribute to preferential binding to particular PKs. The  
35 ability to select compounds active at different ATP (or other  
nucleotide) binding sites makes the compounds of this

invention useful for targeting any protein with such a site. The compounds disclosed herein thus have utility in *in vitro* assays for such proteins as well as exhibiting *in vivo* therapeutic effects through interaction with such proteins.

5        Additionally, the compounds of the present invention provide a therapeutic approach to the treatment of many kinds of solid tumors, including but not limited to carcinomas, sarcomas including Kaposi's sarcoma, erythroblastoma, glioblastoma, meningioma, astrocytoma, melanoma and  
10       myoblastoma. Treatment or prevention of non-solid tumor cancers such as leukemia are also contemplated by this invention. Indications may include, but are not limited to brain cancers, bladder cancers, ovarian cancers, gastric cancers, pancreas cancers, colon cancers, blood cancers, lung  
15       cancers and bone cancers.

20       Further examples, without limitation, of the types of disorders related to inappropriate PK activity that the compounds described herein may be useful in preventing, treating and studying, are cell proliferative disorders, fibrotic disorders and metabolic disorders.

25       Cell proliferative disorders, which may be prevented, treated or further studied by the present invention include cancer, blood vessel proliferative disorders and mesangial cell proliferative disorders.

30       Blood vessel proliferative disorders refer to disorders related to abnormal vasculogenesis (blood vessel formation) and angiogenesis (spreading of blood vessels). While vasculogenesis and angiogenesis play important roles in a variety of normal physiological processes such as embryonic  
35       development, corpus luteum formation, wound healing and organ regeneration, they also play a pivotal role in cancer development where they result in the formation of new capillaries needed to keep a tumor alive. Other examples of blood vessel proliferation disorders include arthritis, where  
40       new capillary blood vessels invade the joint and destroy cartilage, and ocular diseases, like diabetic retinopathy,

where new capillaries in the retina invade the vitreous, bleed and cause blindness.

Two structurally related RTKs have been identified to bind VEGF with high affinity: the fms-like tyrosine 1 (fit-1) receptor (Shibuya *et al.*, 1990, Oncogene, 5:519-524; De Vries *et al.*, 1992, Science, 255:989-991) and the KDR/FLK-1 receptor, also known as VEGF-R2. Vascular endothelial growth factor (VEGF) has been reported to be an endothelial cell specific mitogen with *in vitro* endothelial cell growth promoting activity. Ferrara & Henzel, 1989, Biochein. Biophys. Res. Comm., 161:851-858; Vaisman *et al.*, 1990, J. Biol. Chem., 265:19461-19566. Information set forth in U.S. application Ser. Nos. 08/193,829, 08/038,596 and 07/975,750, strongly suggest that VEGF is not only responsible for endothelial cell proliferation, but also is the prime regulator of normal and pathological angiogenesis. See generally, Klagsburn & Soker, 1993, Current Biology, 3(10):699-702; Houck, *et al.*, 1992, J. Biol. Chem., 267:26031-26037.

Normal vasculogenesis and angiogenesis play important roles in a variety of physiological processes such as embryonic development, wound healing, organ regeneration and female reproductive processes such as follicle development in the corpus luteum during ovulation and placental growth after pregnancy. Folkman & Shing, 1992, J. Biological Chem., 267(16):10931-34. Uncontrolled vasculogenesis and/or angiogenesis has been associated with diseases such as diabetes as well as with malignant solid tumors that rely on vascularization for growth. Klagsburn & Soker, 1993, Current Biology, 3(10):699-702; Folkham, 1991, J. Natl. Cancer Inst., 82:4-6; Weidner, *et al.*, 1991, New Engl. J. Med., 324:1-5.

The surmised role of VEGF in endothelial cell proliferation and migration during angiogenesis and vasculogenesis indicates an important role for the KDR/FLK-1 receptor in these processes. Diseases such as diabetes mellitus (Folkman, 198, in XIth Congress of Thrombosis and Haemostasis (Verstraeta, *et al.*, eds.), pp. 583-596, Leuven

University Press, Leuven) and arthritis, as well as malignant tumor growth may result from uncontrolled angiogenesis. See e.g., Folkman, 1971, N. Engl. J. Med., 285:1182-1186. The receptors to which VEGF specifically binds are an important and powerful therapeutic target for the regulation and modulation of vasculogenesis and/or angiogenesis and a variety of severe diseases which involve abnormal cellular growth caused by such processes. Plowman, et al., 1994, DN&P, 7(6):334-339. More particularly, the KDR/FLK-1 receptor's highly specific role in neovascularization make it a choice target for therapeutic approaches to the treatment of cancer and other diseases which involve the uncontrolled formation of blood vessels.

Thus, the present invention provides compounds capable of regulating and/or modulating tyrosine kinase signal transduction including KDR/FLK-1 receptor signal transduction in order to inhibit or promote angiogenesis and/or vasculogenesis, that is, compounds that inhibit, prevent, or interfere with the signal transduced by KDR/FLK-1 when activated by ligands such as VEGF. Although it is believed that the compounds of the present invention act on a receptor or other component along the tyrosine kinase signal transduction pathway, they may also act directly on the tumor cells that result from uncontrolled angiogenesis.

Although the nomenclature of the human and murine counterparts of the generic "flk-I" receptor differ, they are, in many respects, interchangeable. The murine receptor, Flk-1, and its human counterpart, KDR, share a sequence homology of 93.4% within the intracellular domain. Likewise, murine FLK-I binds human VEGF with the same affinity as mouse VEGF, and accordingly, is activated by the ligand derived from either species. Millauer et al., 1993, Cell, 72:835-846; Quinn et al., 1993, Proc. Natl. Acad. Sci. USA, 90:7533-7537. FLK-1 also associates with and subsequently tyrosine phosphorylates human RTK substrates (e.g., PLC- $\gamma$  or p85) when co-expressed in 293 cells (human embryonal kidney fibroblasts).

Models which rely upon the FLK-1 receptor therefore are directly applicable to understanding the KDR receptor. For example, use of the murine FLK-1 receptor in methods which identify compounds that regulate the murine signal transduction pathway are directly applicable to the identification of compounds which may be used to regulate the human signal transduction pathway, that is, which regulate activity related to the KDR receptor. Thus, chemical compounds identified as inhibitors of KDR/FLK-1 *in vitro*, can be confirmed in suitable *in vivo* models. Both *in vivo* mouse and rat animal models have been demonstrated to be of excellent value for the examination of the clinical potential of agents acting on the KDR/FLK-1 induced signal transduction pathway.

Thus, the present invention provides compounds that regulate, modulate and/or inhibit vasculogenesis and/or angiogenesis by affecting the enzymatic activity of the KDR/FLK-1 receptor and interfering with the signal transduced by KDR/FLK-1. Thus the present invention provides a therapeutic approach to the treatment of many kinds of solid tumors including, but not limited to, glioblastoma, melanoma and Kaposi's sarcoma, and ovarian, lung, mammary, prostate, pancreatic, colon and epidermoid carcinoma. In addition, data suggests the administration of compounds which inhibit the KDR/Flk-1 mediated signal transduction pathway may also be used in the treatment of hemangioma, restenosis and diabetic retinopathy.

Furthermore, this invention relates to the inhibition of vasculogenesis and angiogenesis by other receptor-mediated pathways, including the pathway comprising the flt-1 receptor.

Receptor tyrosine kinase mediated signal transduction is initiated by extracellular interaction with a specific growth factor (ligand), followed by receptor dimerization, transient stimulation of the intrinsic protein tyrosine kinase activity and autophosphorylation. Binding sites are thereby created for intracellular signal transduction molecules which leads to the formation of complexes with a spectrum of cytoplasmic

signalling molecules that facilitate the appropriate cellular response, e.g., cell division and metabolic effects to the extracellular microenvironment. See, Schlessinger and Ullrich, 1992, Neuron, 9:1-20.

5       The close homology of the intracellular regions of KDR/FLK-1 with that of the PDGF- $\beta$  receptor (50.3% homology) and/or the related flt-1 receptor indicates the induction of overlapping signal transduction pathways. For example, for the PDGF- $\beta$  receptor, members of the src family (Twamley et al., 1993, Proc. Natl. Acad. Sci. USA, 90:7696-7700), phosphatidylinositol-3'-kinase (Hu et al., 1992, Mol. Cell. Biol., 12:981-990), phospholipase  $\gamma$  (Kashishian & Cooper, 1993, Mol. Cell. Biol., 4:49-51), ras-GTPase-activating protein, (Kashishian et al., 1992, EMBO J., 11:1373-1382), PTP-ID/syp (Kazlauskas et al., 1993, Proc. Natl. Acad. Sci. USA, 10 90:6939-6943), Grb2 (Arvidsson et al., 1994, Mol. Cell. Biol., 14:6715-6726), and the adapter molecules Shc and Nck (Nishimura et al., 1993, Mol. Cell. Biol., 13:6889-6896), have been shown to bind to regions involving different autophosphorylation sites. See generally, Claesson-Welsh, 1994, Prog. Growth Factor Res., 5:37-54. Thus, it is likely that signal transduction pathways activated by KDR/FLK-1 include the ras pathway (Rozakis et al., 1992, Nature, 360:689-692), the PI-3'-kinase, the src-mediated and the plcy-mediated pathways. Each of these pathways may play a critical role in the angiogenic and/or vasculogenic effect of KDR/FLK-1 in endothelial cells. Consequently, a still further aspect of this invention relates to the use of the organic compounds described herein to modulate angiogenesis and vasculogenesis as such processes are controlled by these pathways.

Conversely, disorders related to the shrinkage, contraction or closing of blood vessels, such as restenosis, are also implicated and may be treated or prevented by the methods of this invention.

35       Fibrotic disorders refer to the abnormal formation of extracellular matrices. Examples of fibrotic disorders

include hepatic cirrhosis and mesangial cell proliferative disorders. Hepatic cirrhosis is characterized by the increase in extracellular matrix constituents resulting in the formation of a hepatic scar. An increased extracellular matrix  
5 resulting in a hepatic scar can also be caused by a viral infection such as hepatitis. Lipocytes appear to play a major role in hepatic cirrhosis. Other fibrotic disorders implicated include atherosclerosis.

Mesangial cell proliferative disorders refer to disorders  
10 brought about by abnormal proliferation of mesangial cells. Mesangial proliferative disorders include various human renal diseases such as glomerulonephritis, diabetic nephropathy and malignant nephrosclerosis as well as such disorders as thrombotic microangiopathy syndromes, transplant rejection, and glomerulopathies. The RTK PDGFR has been implicated in the maintenance of mesangial cell proliferation. Floege *et al.*, 1993, Kidney International 43:47S-54S.

Many cancers are cell proliferative disorders and, as noted previously, PKs have been associated with cell  
20 proliferative disorders. Thus, it is not surprising that PKs such as, for example, members of the RTK family have been associated with the development of cancer. Some of these receptors, like EGFR (Tuzi *et al.*, 1991, Br. J. Cancer 63:227-233, Torp *et al.*, 1992, APMIS 100:713-719) HER2/neu (Slamon *et al.*, 1989, Science 244:707-712) and PDGF-R (Kumabe *et al.*, 1992, Oncogene, 7:627-633) are over-expressed in many tumors and/or persistently activated by autocrine loops. In fact, in the most common and severe cancers these receptor over-expressions (Akbasak and Suner-Akbasak *et al.*, 1992, J. Neurol. Sci., 111:119-133, Dickson *et al.*, 1992, Cancer Treatment Res. 61:249-273, Korc *et al.*, 1992, J. Clin. Invest. 90:1352-1360) and autocrine loops (Lee and Donoghue, 1992, J. Cell. Biol., 118:1057-1070, Korc *et al.*, supra, Akbasak and Suner-Akbasak *et al.*, supra) have been demonstrated. For  
35 example, EGFR has been associated with squamous cell carcinoma, astrocytoma, glioblastoma, head and neck cancer,

lung cancer and bladder cancer. HER2 has been associated with breast, ovarian, gastric, lung, pancreas and bladder cancer. PDGFR has been associated with glioblastoma and melanoma as well as lung, ovarian and prostate cancer. The RTK c-met has also been associated with malignant tumor formation. For example, c-met has been associated with, among other cancers, colorectal, thyroid, pancreatic, gastric and hepatocellular carcinomas and lymphomas. Additionally c-met has been linked to leukemia. Over-expression of the c-met gene has also been detected in patients with Hodgkins disease and Burkitts disease.

IGF-IR, in addition to being implicated in nutritional support and in type-II diabetes, has also been associated with several types of cancers. For example, IGF-I has been implicated as an autocrine growth stimulator for several tumor types, e.g. human breast cancer carcinoma cells (Arteaga *et al.*, 1989, J. Clin. Invest. 84:1418-1423) and small lung tumor cells (Macauley *et al.*, 1990, Cancer Res., 50:2511-2517). In addition, IGF-I, while integrally involved in the normal growth and differentiation of the nervous system, also appears to be an autocrine stimulator of human gliomas. Sandberg-Nordqvist *et al.*, 1993, Cancer Res. 53:2475-2478. The importance of IGF-IR and its ligands in cell proliferation is further supported by the fact that many cell types in culture (fibroblasts, epithelial cells, smooth muscle cells, T-lymphocytes, myeloid cells, chondrocytes and osteoblasts (the stem cells of the bone marrow)) are stimulated to grow by IGF-I. Goldring and Goldring, 1991, Eukaryotic Gene Expression, 1:301-326. Baserga and Coppola suggest that IGF-IR plays a central role in the mechanism of transformation and, as such, could be a preferred target for therapeutic interventions for a broad spectrum of human malignancies. Baserga, 1995, Cancer Res., 55:249-252, Baserga, 1994, Cell 79:927-930, Coppola *et al.*, 1994, Mol. Cell. Biol., 14:4588-4595.

STKs have been implicated in many types of cancer including, notably, breast cancer (Cance, *et al.*, Int. J.



Cancer, 54:571-77 (1993)).

The association between abnormal PK activity and disease is not restricted to cancer. For example, RTKs have been associated with diseases such as psoriasis, diabetes mellitus, endometriosis, angiogenesis, atheromatous plaque development, Alzheimer's disease, restenosis, von Hippel-Lindau disease, epidermal hyperproliferation, neurodegenerative diseases, age-related macular degeneration and hemangiomas. For example, EGFR has been indicated in corneal and dermal wound healing.

Defects in Insulin-R and IGF-1R are indicated in type-II diabetes mellitus. A more complete correlation between specific RTKs and their therapeutic indications is set forth in Plowman et al., 1994, DN&P 7:334-339.

As noted previously, not only RTKs but CTKs including, but not limited to, src, abl, fps, yes, fyn, lyn, lck, blk, hck, fgr and yrk (reviewed by Bolen et al., 1992, FASEB J., 6:3403-3409) are involved in the proliferative and metabolic signal transduction pathway and thus could be expected, and have been shown, to be involved in many PTK-mediated disorders to which the present invention is directed. For example, mutated src (v-src) has been shown to be an oncoprotein (pp60<sup>v-src</sup>) in chicken. Moreover, its cellular homolog, the proto-oncogene pp60<sup>c-src</sup> transmits oncogenic signals of many receptors. Over-expression of EGFR or HER2/neu in tumors leads to the constitutive activation of pp60<sup>c-src</sup>, which is characteristic of malignant cells but absent in normal cells. On the other hand, mice deficient in the expression of c-src exhibit an osteopetrotic phenotype, indicating a key participation of c-src in osteoclast function and a possible involvement in related disorders.

Similarly, Zap70 has been implicated in T-cell signaling which may relate to autoimmune disorders.

STKs have been associated with inflammation, autoimmune disease, immunoresponses, and hyperproliferation disorders such as restenosis, fibrosis, psoriasis, osteoarthritis and rheumatoid arthritis.

PKs have also been implicated in embryo implantation. Thus, the compounds of this invention may provide an effective method of preventing such embryo implantation and thereby be useful as birth control agents. Additional disorders which may be treated or prevented using the compounds of this invention are immunological disorders such as autoimmune disease, AIDS and cardiovascular disorders such as atherosclerosis.

Finally, both RTKs and CTKs are currently suspected as being involved in hyperimmune disorders.

Examples of the effect of a number of exemplary compounds of this invention on several PTKs are shown in Table 2 below. The compounds and data presented are not to be construed as limiting the scope of this invention in any manner whatsoever.

#### **Administration and Pharmaceutical Composition**

A compound of the present invention or a pharmaceutically acceptable salt thereof, can be administered as such to a human patient or can be administered in pharmaceutical compositions in which the foregoing materials are mixed with suitable carriers or excipient(s). Techniques for formulation and administration of drugs may be found in "Remington's Pharmacological Sciences," Mack Publishing Co., Easton, PA., latest edition.

As used herein, "administer" or "administration" refers to the delivery of a compound of Formula (I) or a pharmaceutically acceptable salt thereof or of a pharmaceutical composition containing a compound of Formula (I) or a pharmaceutically acceptable salt thereof of this invention to an organism for the purpose of prevention or treatment of a PK-related disorder.

Suitable routes of administration may include, without limitation, oral, rectal, transmucosal or intestinal administration or intramuscular, subcutaneous, intramedullary, intrathecal, direct intraventricular, intravenous, intravitreal, intraperitoneal, intranasal, or intraocular

injections. The preferred routes of administration are oral and parenteral.

Alternatively, one may administer the compound in a local rather than systemic manner, for example, via injection of the compound directly into a solid tumor, often in a depot or sustained release formulation.

Furthermore, one may administer the drug in a targeted drug delivery system, for example, in a liposome coated with tumor-specific antibody. The liposomes will be targeted to and taken up selectively by the tumor.

Pharmaceutical compositions of the present invention may be manufactured by processes well known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.

Pharmaceutical compositions for use in accordance with the present invention may be formulated in conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.

For injection, the compounds of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiological saline buffer. For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

For oral administration, the compounds can be formulated by combining the active compounds with pharmaceutically acceptable carriers well known in the art. Such carriers enable the compounds of the invention to be formulated as tablets, pills, lozenges, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient. Pharmaceutical preparations for oral use can be

made using a solid excipient, optionally grinding the resulting mixture, and processing the mixture of granules, after adding other suitable auxiliaries if desired, to obtain tablets or dragee cores. Useful excipients are, in

5 particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol, cellulose preparations such as, for example, maize starch, wheat starch, rice starch and potato starch and other materials such as gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, 10 sodium carboxymethylcellulose, and/or polyvinyl-pyrrolidone (PVP). If desired, disintegrating agents may be added, such as cross-linked polyvinyl pyrrolidone, agar, or alginic acid. A salt such as sodium alginate may also be used.

15 Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be 20 added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.

Pharmaceutical compositions which can be used orally include push-fit capsules made of gelatin, as well as soft, 25 sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with a filler such as lactose, a binder such as starch, and/or a lubricant such as talc or magnesium stearate and, optionally, stabilizers. In soft 30 capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. Stabilizers may be added in these formulations, also.

Pharmaceutical compositions which may also be used 35 include hard gelatin capsules. As a non-limiting example, the active compound capsule oral drug product formulation may be

as 50 and 200 mg dose strengths (formulation codes J-011248-AA-00 and J-011248-AA-01, respectively). The two dose strengths are made from the same granules by filling into different size hard gelatin capsules, size 3 for the 50 mg capsule and size 0 for the 200 mg capsule. The composition of the formulation may be, for example, as indicated in Table 2.

**TABLE 2**

Ingredient Name/Grade	Concentration in Granulation (% w/w)	Amount in 50 mg Capsule (mg)	Amount in 200 mg Capsule (mg)
Formulation Code	J-011248-AA	J-011248-AA-00	J-011248-AA-01
Active Compound NF	65.0	50.0	200.0
Mannitol NF	23.5	18.1	72.4
Croscarmellose sodium NF	6.0	4.6	18.4
Povidone K 30 NF	5.0	3.8	15.2
Magnesium stearate NF	0.5	0.38	1.52
Capsule, Swedish yellow NF		Size 3	Size 0

The capsules may be packaged into brown glass or plastic bottles to protect the active compound from light. The containers containing the active compound capsule formulation must be stored at controlled room temperature (15-30°C).

For administration by inhalation, the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray using a pressurized pack or a nebulizer and a suitable propellant, e.g., without limitation, dichlorodifluoromethane, trichlorofluoromethane, dichlorotetra- fluoroethane or carbon dioxide. In the case of a pressurized aerosol, the dosage unit may be controlled by providing a valve to deliver a metered amount. Capsules and cartridges of, for example, gelatin for use in an inhaler or

insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

The compounds may also be formulated for parenteral administration, e.g., by bolus injection or continuous  
5 infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulating materials such  
10 as suspending, stabilizing and/or dispersing agents.

Pharmaceutical compositions for parenteral administration include aqueous solutions of a water soluble form, such as, without limitation, a salt, of the active compound.  
Additionally, suspensions of the active compounds may be  
5 prepared in a lipophilic vehicle. Suitable lipophilic vehicles include fatty oils such as sesame oil, synthetic fatty acid esters such as ethyl oleate and triglycerides, or materials such as liposomes. Aqueous injection suspensions may contain substances which increase the viscosity of the  
20 suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers and/or agents that increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

25 Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile, pyrogen-free water, before use.

The compounds may also be formulated in rectal compositions such as suppositories or retention enemas, using,  
30 e.g., conventional suppository bases such as cocoa butter or other glycerides.

In addition to the formulations described previously, the compounds may also be formulated as depot preparations. Such long acting formulations may be administered by implantation  
35 (for example, subcutaneously or intramuscularly) or by intramuscular injection. A compound of this invention may be

formulated for this route of administration with suitable polymeric or hydrophobic materials (for instance, in an emulsion with a pharmcologically acceptable oil), with ion exchange resins, or as a sparingly soluble derivative such as, without limitation, a sparingly soluble salt.

A non-limiting example of a pharmaceutical carrier for the hydrophobic compounds of the invention is a cosolvent system comprising benzyl alcohol, a nonpolar surfactant, a water-miscible organic polymer and an aqueous phase such as the VPD co-solvent system. VPD is a solution of 3% w/v benzyl alcohol, 8% w/v of the nonpolar surfactant Polysorbate 80, and 65% w/v polyethylene glycol 300, made up to volume in absolute ethanol. The VPD co-solvent system (VPD:D5W) consists of VPD diluted 1:1 with a 5% dextrose in water solution. This co-solvent system dissolves hydrophobic compounds well, and itself produces low toxicity upon systemic administration. Naturally, the proportions of such a co-solvent system may be varied considerably without destroying its solubility and toxicity characteristics. Furthermore, the identity of the co-solvent components may be varied: for example, other low-toxicity nonpolar surfactants may be used instead of Polysorbate 80, the fraction size of polyethylene glycol may be varied, other biocompatible polymers may replace polyethylene glycol, e.g., polyvinyl pyrrolidone, and other sugars or polysaccharides may substitute for dextrose.

Alternatively, other delivery systems for hydrophobic pharmaceutical compounds may be employed. Liposomes and emulsions are well known examples of delivery vehicles or carriers for hydrophobic drugs. In addition, certain organic solvents such as dimethylsulfoxide also may be employed, although often at the cost of greater toxicity.

Additionally, the compounds may be delivered using a sustained-release system, such as semipermeable matrices of solid hydrophobic polymers containing the therapeutic agent. Various sustained-release materials have been established and are well known by those skilled in the art. Sustained-release

capsules may, depending on their chemical nature, release the compounds for a few weeks up to over 100 days. Depending on the chemical nature and the biological stability of the therapeutic reagent, additional strategies for protein stabilization may be employed.

The pharmaceutical compositions herein also may comprise suitable solid or gel phase carriers or excipients. Examples of such carriers or excipients include, but are not limited to, calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols.

Many of the PK modulating compounds of the invention may be provided as physiologically acceptable salts wherein the claimed compound may form the negatively or the positively charged species. Examples of salts in which the compound forms the positively charged moiety include, without limitation, quaternary ammonium (defined elsewhere herein), salts such as the hydrochloride, sulfate, carbonate, lactate, tartrate, malate, maleate, succinate wherein the nitrogen atom of the quaternary ammonium group is a nitrogen of the selected compound of this invention which has reacted with the appropriate acid. Salts in which a compound of this invention forms the negatively charged species include, without limitation, the sodium, potassium, calcium and magnesium salts formed by the reaction of a carboxylic acid group in the compound with an appropriate base (e.g. sodium hydroxide (NaOH), potassium hydroxide (KOH), Calcium hydroxide (Ca(OH)<sub>2</sub>), etc.).

Pharmaceutical compositions suitable for use in the present invention include compositions wherein the active ingredients are contained in an amount sufficient to achieve the intended purpose, e.g., the modulation of PK activity or the treatment or prevention of a PK-related disorder.

More specifically, a therapeutically effective amount means an amount of compound effective to prevent, alleviate or



ameliorate symptoms of disease or prolong the survival of the subject being treated.

Determination of a therapeutically effective amount is well within the capability of those skilled in the art,  
5 especially in light of the detailed disclosure provided herein.

For any compound used in the methods of the invention, the therapeutically effective amount or dose can be estimated initially from cell culture assays. Then, the dosage can be  
10 formulated for use in animal models so as to achieve a circulating concentration range that includes the  $IC_{50}$  as determined in cell culture (i.e., the concentration of the test compound which achieves a half-maximal inhibition of the PK activity). Such information can then be used to more  
15 accurately determine useful doses in humans.

Toxicity and therapeutic efficacy of the compounds described herein can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., by determining the  $IC_{50}$  and the  $LD_{50}$  (both of which are discussed  
20 elsewhere herein) for a subject compound. The data obtained from these cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage may vary depending upon the dosage form employed and the route of administration utilized. The exact formulation, route of  
25 administration and dosage can be chosen by the individual physician in view of the patient's condition. (See e.g., Fingl, et al., 1975, in "The Pharmacological Basis of Therapeutics", Ch. 1 p.1).

Dosage amount and interval may be adjusted individually  
30 to provide plasma levels of the active species which are sufficient to maintain the kinase modulating effects. These plasma levels are referred to as minimal effective concentrations (MECs). The MEC will vary for each compound but can be estimated from *in vitro* data, e.g., the  
35 concentration necessary to achieve 50-90% inhibition of a kinase may be ascertained using the assays described herein.

Dosages necessary to achieve the MEC will depend on individual characteristics and route of administration. HPLC assays or bioassays can be used to determine plasma concentrations.

Dosage intervals can also be determined using MEC value.

5 Compounds should be administered using a regimen that maintains plasma levels above the MEC for 10-90% of the time, preferably between 30-90% and most preferably between 50-90%.

At present, the therapeutically effective amounts of compounds of Formula (I) may range from approximately 25 mg/m<sup>2</sup> to 1500 mg/m<sup>2</sup> per day; preferably about 3 mg/m<sup>2</sup>/day. Even more preferably 50mg/qm qd till 400 mg/qd.

In cases of local administration or selective uptake, the effective local concentration of the drug may not be related to plasma concentration and other procedures known in the art may be employed to determine the correct dosage amount and interval.

The amount of a composition administered will, of course, be dependent on the subject being treated, the severity of the affliction, the manner of administration, the judgment of the prescribing physician, etc.

The compositions may, if desired, be presented in a pack or dispenser device, such as an FDA approved kit, which may contain one or more unit dosage forms containing the active ingredient. The pack may for example comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration.

The pack or dispenser may also be accompanied by a notice associated with the container in a form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals, which notice is reflective of approval by the agency of the form of the compositions or of human or veterinary administration. Such notice, for example, may be of the labeling approved by the U.S. Food and Drug Administration for prescription drugs or of an approved product insert. Compositions comprising a compound of the invention formulated in a compatible pharmaceutical carrier

may also be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition. Suitable conditions indicated on the label may include treatment of a tumor, inhibition of angiogenesis, treatment of fibrosis, diabetes, and the like.

It is also an aspect of this invention that a compound described herein, or its salt or prodrug, might be combined with other chemotherapeutic agents for the treatment of the diseases and disorders discussed above. For instance, a compound, salt or prodrug of this invention might be combined with alkylating agents such as fluorouracil (5-FU) alone or in further combination with leukovorin; or other alkylating agents such as, without limitation, other pyrimidine analogs such as UFT, capecitabine, gemcitabine and cytarabine, the alkyl sulfonates, e.g., busulfan (used in the treatment of chronic granulocytic leukemia), improsulfan and piposulfan; aziridines, e.g., benzodepa, carboquone, meturedopa and uredepa; ethyleneimines and methylmelamines, e.g., altretamine, triethylenemelamine, triethylenephosphoramidate, triethylenethiophosphoramidate and trimethylolmelamine; and the nitrogen mustards, e.g., chlorambucil (used in the treatment of chronic lymphocytic leukemia, primary macroglobulinemia and non-Hodgkin's lymphoma), cyclophosphamide (used in the treatment of Hodgkin's disease, multiple myeloma, neuroblastoma, breast cancer, ovarian cancer, lung cancer, Wilm's tumor and rhabdomyosarcoma), estramustine, ifosfamide, novembrichin, prednimustine and uracil mustard (used in the treatment of primary thrombocytosis, non-Hodgkin's lymphoma, Hodgkin's disease and ovarian cancer); and triazines, e.g., dacarbazine (used in the treatment of soft tissue sarcoma).

A compound, salt or prodrug of this invention can also be used in combination with other antimetabolite chemotherapeutic agents such as, without limitation, folic acid analogs, e.g. methotrexate (used in the treatment of acute lymphocytic leukemia, choriocarcinoma, mycosis fungoides breast cancer, head and neck cancer and osteogenic sarcoma) and pteropterin;

and the purine analogs such as mercaptopurine and thioguanine which find use in the treatment of acute granulocytic, acute lymphocytic and chronic granulocytic leukemias.

It is contemplated that a compound, salt or prodrug of this invention can also be used in combination with natural product based chemotherapeutic agents such as, without limitation, the vinca alkaloids, e.g., vinblastin (used in the treatment of breast and testicular cancer), vincristine and vindesine; the epipodophylotoxins, e.g., etoposide and teniposide, both of which are useful in the treatment of testicular cancer and Kaposi's sarcoma; the antibiotic chemotherapeutic agents, e.g., daunorubicin, doxorubicin, epirubicin, mitomycin (used to treat stomach, cervix, colon, breast, bladder and pancreatic cancer), dactinomycin, temozolomide, plicamycin, bleomycin (used in the treatment of skin, esophagus and genitourinary tract cancer); and the enzymatic chemotherapeutic agents such as L-asparaginase.

In addition to the above, a compound, salt or prodrug of this invention could also be used in combination with the platinum coordination complexes (cisplatin, etc.); substituted ureas such as hydroxyurea; methylhydrazine derivatives, e.g., procarbazine; adrenocortical suppressants, e.g., mitotane, aminogluthethimide; and hormone and hormone antagonists such as the adrenocorticosteroids (e.g., prednisone), progestins (e.g., hydroxyprogesterone caproate); estrogens (e.g., diethylstilbesterol); antiestrogens such as tamoxifen; androgens, e.g., testosterone propionate; and aromatase inhibitors such as anastrozole.

Finally, it is also contemplated that the combination of a compound of this invention will be effective in combination with mitoxantrone or paclitaxel for the treatment of solid tumor cancers or leukemias such as, without limitation, acute myelogenous (non-lymphocytic) leukemia.

### General Synthetic Procedure.

The following general methodology may be employed to prepare the compounds of this invention:

5       The appropriately substituted 2-oxindole (1 equiv.), the appropriately substituted aldehyde (1.2 equiv.) and a base (0.1 equiv.) are mixed in a solvent (1-2 ml/mmol 2-oxindole) and the mixture is then heated for from about 2 to about 12 hours. After cooling, the precipitate that forms is filtered,  
10 washed with cold ethanol or ether and vacuum dried to give the solid product. If no precipitate forms, the reaction mixture is concentrated and the residue is triturated with dichloromethane/ether, the resulting solid is collected by filtration and then dried. The product may optionally be further purified by chromatography.

15       The base may be an organic or an inorganic base. If an organic base is used, preferably it is a nitrogen base. Examples of organic nitrogen bases include, but are not limited to, diisopropylamine, trimethylamine, triethylamine, aniline, pyridine, 1,8-diazabicyclo[5.4.1]undec-7-ene,  
20 pyrrolidine and piperidine.

25       Examples of inorganic bases are, without limitation, ammonia, alkali metal or alkaline earth hydroxides, phosphates, carbonates, bicarbonates, bisulfates and amides. The alkali metals include, lithium, sodium and potassium while the alkaline earths include calcium, magnesium and barium.

30       In a presently preferred embodiment of this invention, when the solvent is a protic solvent, such as water or alcohol, the base is an alkali metal or an alkaline earth inorganic base, preferably, a alkali metal or an alkaline earth hydroxide.

      It will be clear to those skilled in the art, based both on known general principles of organic synthesis and on the disclosures herein which base would be most appropriate for the reaction contemplated.

35       The solvent in which the reaction is carried out may be a protic or an aprotic solvent, preferably it is a protic solvent. A "protic solvent" is a solvent which has hydrogen atom(s)

covalently bonded to oxygen or nitrogen atoms which renders the hydrogen atoms appreciably acidic and thus capable of being "shared" with a solute through hydrogen bonding. Examples of protic solvents include, without limitation, water and alcohols.

5 An "aprotic solvent" may be polar or non-polar but, in either case, does not contain acidic hydrogens and therefore is not capable of hydrogen bonding with solutes. Examples, without limitation, of non-polar aprotic solvents, are pentane, hexane, benzene, toluene, methylene chloride and carbon tetrachloride.

10 Examples of polar aprotic solvents are chloroform, tetrahydrofuran, dimethylsulfoxide and dimethylformamide.

In a presently preferred embodiment of this invention, the solvent is a protic solvent, preferably water or an alcohol such as ethanol.

15 The reaction is carried out at temperatures greater than room temperature. The temperature is generally from about 30° C to about 150° C, preferably about 80°C to about 100° C, most preferable about 75° C to about 85° C, which is about the boiling point of ethanol. By "about" is meant that the temperature range is preferably within 10 degrees Celcius of the indicated temperature, more preferably within 5 degrees Celcius of the indicated temperature and, most preferably, within 2 degrees Celcius of the indicated temperature. Thus, for example, by  
20 "about 75° C" is meant 75° C ± 10° C, preferably 75° C ± 5° C and  
25 most preferably, 75° C ± 2° C.

2-Oxindoles and aldehydes, may be readily synthesized using techniques well known in the chemical arts. It will be appreciated by those skilled in the art that other synthetic pathways for forming the compounds of the invention are  
30 available and that the following is offered by way of example and not limitation.

#### EXAMPLES

The following preparations and examples are given to  
35 enable those skilled in the art to more clearly understand and to practice the present invention. They should not be

considered as limiting the scope of the invention, but merely as being illustrative and representative thereof.

### Synthetic Examples

#### 5 **Method A: Formylation of pyrroles**

POCl<sub>3</sub> (1.1 equiv.) is added dropwise to dimethylformamide (3 equiv.) at -10° C followed by addition of the appropriate pyrrole dissolved in dimethylformamide. After stirring for two hours, the reaction mixture is diluted with H<sub>2</sub>O and basified to  
10 pH 11 with 10 N KOH. The precipitate which forms is collected by filtration, washed with H<sub>2</sub>O and dried in a vacuum oven to give the desired aldehyde.

#### **Method B: Saponification of pyrrolicarboxylic acid esters**

A mixture of a pyrrolicarboxylic acid ester and KOH (2 -  
5 4 equiv.) in EtOH is refluxed until reaction completion is indicated by thin layer chromatography (TLC). The cooled reaction mixture is acidified to pH 3 with 1 N HCl. The precipitate which forms is collected by filtration, washed with H<sub>2</sub>O and dried in a vacuum oven to give the desired  
20 pyrrolicarboxylic acid.

#### **Method C: Amidation**

To a stirred solution of a pyrrolicarboxylic acid dissolved in dimethylformamide (0.3M) is added 1-ethyl-3-(3-dimethylamino-propyl)carbodiimide (1.2 equiv.), 1-  
25 hydroxybenzotriazole (1.2 equiv.), and triethylamine (2 equiv.). The appropriate amine is added (1 equiv.) and the reaction stirred until completion is indicated by TLC. Ethyl acetate is then added to the reaction mixture and the solution washed with saturated NaHCO<sub>3</sub> and brine (with extra salt), dried  
30 over anhydrous MgSO<sub>4</sub> and concentrated to afford the desired amide.

#### **Method D: Condensation of aldehydes and oxindoles containing carboxylic acid substituents**

A mixture of the oxindole (1 equivalent), 1 equivalent of  
35 the aldehyde and 1 - 3 equivalents of piperidine (or pyrrolidine) in ethanol (0.4 M) is stirred at 90-100° C until

reaction completion is indicated by TLC. The mixture is then concentrated and the residue acidified with 2N HCl. The precipitate that forms is washed with H<sub>2</sub>O and EtOH and then dried in a vacuum oven to give the product.

5 **Method E: Condensation of aldehydes and oxindoles not containing carboxylic acid substituents**

10 A mixture of the oxindole (1 equivalent), 1 equivalent of the aldehyde and 1 - 3 equivalents of piperidine (or pyrrolidine) in ethanol (0.4 M) is stirred at 90-100°C until reaction completion is indicated by TLC. The mixture is cooled to room temperature and the solid which forms is collected by vacuum filtration, washed with ethanol and dried to give the product. If a precipitate does not form upon cooling of the reaction mixture, the mixture is concentrated and purified by column chromatography.

15 **C. Examples of oxindole syntheses**

20 The following examples of the synthesis of representative oxindoles is not to be construed as limiting the scope of this invention in any manner whatsoever. Alternate routes to the oxindoles shown as well as other oxindoles to be used to make the compounds of this invention will become apparent to those skilled in the art based on the following disclosures. Such syntheses and oxindoles are within the scope and spirit of this invention.

25 **5-Amino-2-oxindole**

5-Nitro-2-oxindole (6.3 g) was hydrogenated in methanol over 10% palladium on carbon to give 3.0 g (60% yield) of the title compound as a white solid.

**5-Bromo-2-oxindole**

30 2-Oxindole (1.3 g) in 20 mL acetonitrile was cooled to -10 °C and 2.0 g N-bromosuccinimide was slowly added with stirring. The reaction was stirred for 1 hour at -10 °C and 2 hours at 0 °C. The precipitate was collected, washed with water and dried to give 1.9 g (90 % yield) of the title compound.

35 **4-Methyl-2-oxindole**

Diethyl oxalate (30 mL) in 20 mL of dry ether was added



with stirring to 19 g of potassium ethoxide suspended in 50 mL of dry ether. The mixture was cooled in an ice bath and 20 mL of 3-nitro-o-xylene in 20 mL of dry ether was slowly added. The thick dark red mixture was heated to reflux for 0.5 hr, concentrated to a dark red solid, and treated with 10% sodium hydroxide until almost all of the solid dissolved. The dark red mixture was treated with 30% hydrogen peroxide until the red color changed to yellow. The mixture was treated alternately with 10% sodium hydroxide and 30% hydrogen peroxide until the dark red color was no longer present. The solid was filtered off and the filtrate acidified with 6N hydrochloric acid. The resulting precipitate was collected by vacuum filtration, washed with water, and dried under vacuum to give 9.8 g (45% yield) of 2-methyl-6-nitrophenylacetic acid as an off-white solid. The solid was hydrogenated in methanol over 10 % palladium on carbon to give 9.04 g of the title compound as a white solid.

#### **7-Bromo-5-chloro-2-oxindole**

5-Chloro-2-oxindole (16.8 g) and 19.6 g of N-bromosuccinimide were suspended in 140 mL of acetonitrile and refluxed for 3 hours. Thin layer chromatography (silica, ethyl acetate) at 2 hours of reflux showed 5-chloro-2-oxindole or N-bromosuccinimide ( $R_f$  0.8), product ( $R_f$  0.85) and a second product ( $R_f$  0.9) whose proportions did not change after another hour of reflux. The mixture was cooled to 10 °C, the precipitate was collected by vacuum filtration, washed with 25 mL of ethanol and sucked dry for 20 minutes in the funnel to give 14.1 g of wet product (56 % yield). The solid was suspended in 200 mL of denatured ethanol and slurry-washed by stirring and refluxing for 10 minutes. The mixture was cooled in an ice bath to 10 °C. The solid product was collected by vacuum filtration, washed with 25 mL of ethanol and dried under vacuum at 40 °C to give 12.7 g (51% yield) of 7-bromo-5-chloro-2-oxindole.

#### **5-Fluoro-2-oxindole**

5-Fluoroisatin (8.2 g) was dissolved in 50 mL of

hydrazine hydrate and refluxed for 1.0 hr. The reaction mixtures were then poured in ice water. The precipitate was then filtered, washed with water and dried in a vacuum oven to afford the title compound.

#### 5 **5-Nitro-2-oxindole**

2-Oxindole (6.5 g) was dissolved in 25 mL concentrated sulfuric acid and the mixture maintained at -10 to -15 °C while 2.1 mL of fuming nitric acid was added dropwise. After the addition of the nitric acid the reaction mixture was stirred at 0 °C for 0.5 hr and poured into ice-water. The precipitate was collected by filtration, washed with water and crystallized from 50% acetic acid. The crystalline product was then filtered, washed with water and dried under vacuum to give 6.3 g (70%) of 5-nitro-2-oxindole.

#### **5-Aminosulfonyl-2-oxindole**

To a 100 mL flask charged with 27 mL of chlorosulfonic acid was added slowly 13.3 g of 2-oxindole. The reaction temperature was maintained below 30 °C during the addition. After the addition, the reaction mixture was stirred at room temperature for 1.5 hr, heated to 68 °C for 1 hr, cooled, and poured into water. The precipitate was washed with water and dried in a vacuum oven to give 11.0 g of 5-chlorosulfonyl-2-oxindole (50% yield) which was used without further purification.

5-Chlorosulfonyl-2-oxindole (2.1 g) was added to 10 mL of ammonium hydroxide in 10 mL of ethanol and stirred at room temperature overnight. The mixture was concentrated and the solid collected by vacuum filtration to give 0.4 g (20% yield) of the title compound as an off-white solid.

#### 30 **5-Isopropylaminosulfonyl-2-oxindole**

To a 100 mL flask charged with 27 mL chlorosulfonic acid was slowly added 13.3 g 2-oxindole. The reaction temperature was maintained below 30° C during the addition. The reaction mixture was stirred at room temperature for 1.5 hour, heated to 68° C for 1 hour, cooled, and poured into

water. The precipitate which formed was filtered, washed with water and dried in a vacuum oven to give 11.0 g (50%) of 5-chlorosulfonyl-2-oxindole which was used without further purification.

5 A suspension of 3 g 5-chlorosulfonyl-2-oxindole, 1.15 g isopropylamine and 1.2 mL of pyridine in 50 mL of dichloromethane was stirred at room temperature for 4 hours during which time a white solid formed. The solid was collected by vacuum filtration, slurry-washed with hot  
10 ethanol, cooled, collected by vacuum filtration and dried under vacuum at 40° C overnight to give 1.5 g (45%) of 5-isopropylaminosulfonyl-2-oxindole.

<sup>1</sup>HNMR (360 MHz, DMSO-d<sub>6</sub>) δ 10.69 (s, br, 1H, NH), 7.63 (dd, J = 2 and 8 Hz, 1H), 7.59 (d, J = 2 Hz, 1H), 7.32 (d, J = 7 Hz, 1H, NH-SO<sub>2</sub>-), 6.93 (d, J = 8 Hz, 1H), 3.57 (s, 2H), 3.14-3.23 (m, 1H, CH-(CH<sub>3</sub>)<sub>2</sub>), 0.94 (d, J = 7 Hz, 6H, 2xCH<sub>3</sub>).

#### **5-Phenylaminosulfonyl-2-oxindole**

A suspension of 5-chlorosulfonyl-2-oxindole (1.62 g, 7 mmol), aniline (0.782 mL, 8.4 mmol) and pyridine (1 mL) in dichloromethane (20 mL) was stirred at room temperature for 4 hours. The reaction mixture was diluted with ethyl acetate (300 mL) and acidified with 1N hydrochloric acid (16 mL). The organic layer was washed with sodium bicarbonate and brine, dried and concentrated. The residue was washed with ethanol (3  
20 mL) and then chromatographed on silica gel eluting with methanol/ dichloromethane 1:9 to give of 5-phenylaminosulfonyl-2-oxindole.

<sup>1</sup>HNMR (360 MHz, DMSO-d<sub>6</sub>) δ 10.71 (s, br, 1H, NH), 10.10 (s, br, 1H, NH), 7.57-7.61 (m, 2H), 7.17-7.22 (m, 2H), 7.06-7.09 (m, 2H), 6.97-7.0 (m, 1H), 6.88 (d, J = 8.4 Hz, 1H), 3.52 (s, 2H).

#### **2-Oxo-2,3-dihydro-1H-indole-5-sulfonic acid pyridin-3-ylamide**

A solution of 5-chlorosulfonyl-2-oxindole (3 g) and 3-aminopyridine (1.46g) in pyridine (15 mL) was stirred at room  
35 temperature overnight at which time a brown solid was present. The solid was filtered, washed with ethanol and dried under

vacuum to yield 1.4 g (38%) of 2-oxo-2,3-dihydro-1H-indole-5-sulfonic acid pyridin-3-ylamide.

<sup>1</sup>H NMR (360 MHz, DMSO-d<sub>6</sub>) δ 10.74 (s, 1H, NH), 10.39 (s, 1H, SO<sub>2</sub>NH), 8.27-8.28 (d, 1H), 8.21-8.23 (m, 1H), 7.59-7.62 (m, 2H), 7.44-7.68 (m, 1H), 7.24-7.28 (m, 1H), 6.69-6.71 (d, 1H), 3.54 (s, 2H).

MS *m/z* (APCI+) 290.2.

### 5-Phenyloxindole

5-Bromo-2-oxindole (5 g, 23.5 mmol) was dissolved in 110 mL toluene and 110 mL ethanol with stirring and a little heat. Tetrakis(triphenylphosphine)palladium(0) (1.9 g, 1.6 mmol) was added followed by 40 mL (80 mmol) 2M aqueous sodium carbonate. To this mixture was added benzene boronic acid (3.7 g, 30.6 mmol) and the mixture was heated in a 100° C oil bath for 12 hours. The reaction was cooled, diluted with ethyl acetate (500 mL), washed with saturated sodium bicarbonate (200 mL), water (200 mL), 1N HCl (200 mL) and brine (200 mL). The organic layer was dried over magnesium sulfate and concentrated to afford a brown solid. Trituration with dichloromethane afforded 3.8 g (77%) of 5-phenyl-2-oxindole as a tan solid.

<sup>1</sup>H NMR (360 MHz, DMSO-d<sub>6</sub>) δ 10.4 (br s, 1H, NH), 7.57 (dd, *J* = 1.8 and 7.2 Hz, 1H), 7.5 to 7.35 (m, 5H), 7.29 (m, 1H), 6.89 (d, *J* = 8.2 Hz, 1H), 3.51 (s, 2H, CH<sub>2</sub>CO).

MS *m/z* 209 [M<sup>+</sup>].

In similar fashion, the following oxindoles can be prepared:

### 6-(3,5-Dichlorophenyl)-1,3-dihydroindol-2-one

<sup>1</sup>H NMR (360 MHz, DMSO-d<sub>6</sub>) δ 10.46 (br, 1H, NH), 7.64 (d, *J* = 1.8 Hz, 2H), 7.57 (m, 1H), 7.27 (m, 2H), 7.05 (d, *J* = 1.1 Hz, 1H), 3.5 (s, 2H).

MS-EI *m/z* 277/279 [M]<sup>+</sup>.

### 6-(4-Butylphenyl)-1,3-dihydroindol-2-one

<sup>1</sup>H NMR (360 MHz, DMSO-d<sub>6</sub>) δ 10.39 (s, 1H, NH), 7.49 (d, *J* = 8.0 Hz, 2H), 7.25 (d, *J* = 8 Hz, 3H), 7.17 (dd, *J* = 1.5 and

7.8 Hz, 1H), 6.99 (d,  $J = 1.5$  Hz, 1H), 3.48 (s, 2H,  $\text{CH}_2\text{CO}$ ), 2.60 (t,  $J = 7.5$  Hz, 2H,  $\text{CH}_2\text{CH}_3$ ), 1.57 (m, 2H,  $\text{CH}_2$ ), 1.32 (m, 2H,  $\text{CH}_2$ ), 0.9 (t,  $J = 7.5$  Hz, 3H,  $\text{CH}_3$ ).

**6-(5-Isopropyl-2-methoxyphenyl)-1,3-dihydroindol-2-one**

5  $^1\text{H}$  NMR (360 MHz, DMSO- $d_6$ )  $\delta$  10.29 (br s, 1H, NH), 7.16-7.21 (m, 2H), 7.08 (d,  $J = 2.4$  Hz, 1H), 6.97-7.01 (m, 2H), 6.89 (d,  $J = 0.8$  Hz, 1H), 3.71 (s, 3H,  $\text{OCH}_3$ ), 3.47 (s, 2H,  $\text{CH}_2\text{CO}$ ), 2.86 (m, 1H,  $\text{CH}(\text{CH}_3)_2$ ), 1.19 (d,  $J = 6.8$  Hz, 6H,  $\text{CH}(\text{CH}_3)_2$ ).

10 MS-EI  $m/z$  281  $[\text{M}]^+$ .

**6-(4-Ethylphenyl)-1,3-dihydroindol-2-one**

$^1\text{H}$  NMR (360 MHz, DMSO- $d_6$ )  $\delta$  10.39 (br s, 1H, NH), 7.50 (d,  $J = 8.2$  Hz, 2H), 7.28 (d,  $J = 8.2$  Hz, 2H), 7.25 (d,  $J = 7.5$  Hz, 1H), 7.17 (dd,  $J = 1.6$  & 7.5 Hz, 1H), 6.99 (d,  $J = 1.6$  Hz, 1H), 3.48 (s, 2H,  $\text{CH}_2\text{CO}$ ), 2.63 (q,  $J = 7.6$  Hz, 2H,  $\text{CH}_2\text{CH}_3$ ), 1.20 (t,  $J = 7.6$  Hz, 3H,  $\text{CH}_2\text{CH}_3$ ).

MS-EI  $m/z$  237  $[\text{M}]^+$ .

**6-(3-Isopropylphenyl)-1,3-dihydroindol-2-one**

$^1\text{H}$  NMR (360 MHz, DMSO- $d_6$ )  $\delta$  10.37 (br s, 1H, NH), 7.43 (m, 1H), 7.35-7.39 (m, 1H), 7.17-7.27 (m, 3H), 7.01 (d,  $J = 1.8$  Hz, 1H), 3.49 (s, 2H,  $\text{CH}_2\text{CO}$ ), 2.95 (m, 1H,  $\text{CH}(\text{CH}_3)_2$ ), 1.24 (d,  $J = 6.8$  Hz, 6H,  $\text{CH}(\text{CH}_3)_2$ ).

MS-EI  $m/z$  251  $[\text{M}]^+$ .

**6-(2,4-Dimethoxyphenyl)-1,3-dihydroindol-2-one**

25  $^1\text{H}$  NMR (360 MHz, DMSO- $d_6$ )  $\delta$  10.28 (br s, 1H, NH), 7.17 (m, 2H), 6.93 (dd,  $J = 1.6$  & 7.6 Hz, 1H), 6.86 (d,  $J = 1.6$  Hz, 1H), 6.63 (d,  $J = 2.4$  Hz, 1H), 6.58 (dd,  $J = 2.4$  & 8.5 Hz, 1H), 3.79 (s, 3H,  $\text{OCH}_3$ ), 3.74 (s, 3H,  $\text{OCH}_3$ ), 3.45 (s, 2H,  $\text{CH}_2\text{CO}$ ).

30 MS-EI  $m/z$  269  $[\text{M}]^+$ .

**6-Pyridin-3-yl-1,3-dihydroindol-2-one**

$^1\text{H}$  NMR (360 MHz, DMSO- $d_6$ )  $\delta$  10.51 (s, 1H, NH), 8.81 (d,  $J = 2.5$  Hz, 1H), 8.55 (dd,  $J = 1.8$  and 5.7 Hz, 1H), 8 (m, 1H), 7.45 (dd,  $J = 5.7$  and 9.3 Hz, 1H), 7.3 (m, 2H), 7.05 (s, 1H), 3.51 (s, 2H,  $\text{CH}_2\text{CO}$ ).

MS  $m/z$  210  $[M]^+$ .

**2-Oxo-2,3-dihydro-1H-indole-4-carboxylic acid (3-chloro-4-methoxyphenyl)-amide**

To a solution of 4-carboxy-2-oxindole (200 mg, 1.13 mmol) and 3-chloro-4-methoxyphenylamine (178 mg, 1.13 mmol) in dimethylformamide (15 mL) at room temperature was added benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (BOP reagent, 997 mg, 2.26 mmol) followed by 4-dimethylaminopyridine (206 mg, 1.69 mmol). The mixture was stirred at room temperature for 72 hours. The reaction was then diluted with ethyl acetate (300 mL), washed with saturated sodium bicarbonate (100 mL), water, 2N hydrochloric acid (100 mL), water (3x200 mL) and brine. It was then dried over magnesium sulfate and concentrated. The residue was triturated with ethyl acetate to give 2-oxo-2,3-dihydro-1H-indole-4-carboxylic acid (3-chloro-4-methoxyphenyl)-amide as a pink solid.

$^1\text{H}$ NMR (360 MHz, DMSO- $d_6$ )  $\delta$  10.50 (s, br, 1H, NH), 10.12 (s, br, 1H, NH), 7.9 (s,  $J$  = 2.5 Hz, 1H), 7.62 (dd,  $J$  = 2.5 & 9 Hz, 1H), 7.38 (d,  $J$  = 7.6 Hz, 1H), 7.32 (t,  $J$  = 7.6 Hz, 1H), 7.13 (d,  $J$  = 9 Hz, 1H), 6.98 (d,  $J$  = 7.6 Hz, 1H), 3.83 (s, 3H,  $\text{OCH}_3$ ), 3.69 (s, 2H,  $\text{CH}_2$ ).

MS-EI  $m/z$  316  $[M]^+$ .

**4-Carboxy-2-oxindole**

A solution of trimethylsilyldiazomethane in hexane (2 M) was added dropwise to a solution of 2.01 g 2-chloro-3-carboxynitrobenzene in 20 mL methanol at room temperature until no further gas evolution occurred. Acetic acid was then added to quench excess trimethylsilyldiazomethane. The reaction mixture was evaporated under vacuum and the residue was dried in an oven overnight. The 2-chloro-3-methoxycarbonylnitrobenzene obtained was pure enough for the following reaction.

Dimethyl malonate (6.0 mL) was added to an ice-cold suspension of 2.1 g sodium hydride in 15 mL DMSO. The reaction mixture was stirred at 100° C for 1 hour and then

cooled to room temperature. 2-Chloro-3-methoxycarbonylnitrobenzene (2.15 g) was added in one portion and the mixture was heated to 100° C for 1.5 hours. The reaction mixture was then cooled to room temperature, poured  
5 into ice water, acidified to pH 5 and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate and concentrated to give 3.0 g of the dimethyl 2-methoxycarbonyl-6-nitrophenyl- malonate.

Dimethyl 2-methoxycarbonyl-6-nitrophenylmalonate (3.0 g)  
10 was refluxed in 50 mL of 6 N hydrochloric acid overnight. The mixture was concentrated to dryness, 20 mL ethanol and 1.1 g of tin(II) chloride were added and the mixture was refluxed for 2 hours. The mixture was filtered through Celite, concentrated and chromatographed on silica gel using ethyl acetate:hexane:acetic acid as eluent to give 0.65 g (37%) of 4-carboxy-2-oxindole as a white solid.

<sup>1</sup>HNMR (360 MHz, DMSO-d<sub>6</sub>) δ 12.96 (s, br, 1H, COOH), 10.74 (s, br, 1H, NH), 7.53 (d, *J* = 8Hz, 1H), 7.39 (t, *J* = 8Hz, 1H), 7.12 (d, *J* = 8Hz, 1H), 3.67 (s, 2H).

#### **D. Synthesis of pyrrole substituted 2-indolinones.**

##### **Example 1**

4-Methyl-5-(2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-2-carboxylic acid

4-Methyl-2-pyrrolicarboxylic acid ethyl ester  
25 (commercially available) was formylated using method **A** to give (73%) of 5-formyl-4-methyl-2-pyrrolicarboxylic acid ethyl ester. It was then hydrolysed using method **B** to give 5-formyl-4-methyl-1H-pyrrole-2-carboxylic acid (58%).

Oxindole (133 mg, 1 mmol) was condensed with 5-formyl-4-methyl-1H-pyrrole-2-carboxylic acid (153 mg) using method **D** to  
30 give 268 mg (100%) of the title compound as an orange-red solid.

<sup>1</sup>HNMR (360 MHz, DMSO-d<sub>6</sub>) δ 13.84 (s, br, 1H, NH), 12.84 (s, br, 1H, COOH), 10.98 (s, br, 1H, NH), 7.82 (d, *J* = 7.5 Hz, 1H), 7.67 (s, 1H, H-vinyl), 7.18 (t, *J* = 7.5 Hz, 1H), 7.01 (t, *J* = 7.5 Hz, 1H), 6.88 (d, *J* = 7.5 Hz, 1H), 6.71 (d, *J* = 2.2

Hz, 1H), 2.32 (s, 3H, CH<sub>3</sub>).

MS (negative mode) 266.8 [M-1]<sup>+</sup>.

#### Example 2

4-Methyl-5-(1-methyl-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-2-carboxylic acid

1-Methyl-1,3-dihydroindol-2-one (147 mg, 1 mmol) was condensed with 5-formyl-4-methyl-1H-pyrrole-2-carboxylic acid (153 mg) using method **D** to give 250 mg (86%) of the title compound.

<sup>1</sup>HNMR (360 MHz, DMSO-d<sub>6</sub>) δ 13.82 (s, br, 1H, NH), 12.88 (s, br, 1H, NH), 7.83 (d, *J* = 7.5 Hz, 1H), 7.65 (s, 1H, H-vinyl), 7.26 (t, *J* = 7.5 Hz, 1H), 7.02-7.09 (m, 2H), 6.70 (d, *J* = 2.2 Hz, 1H), 2.32 (s, 3H, CH<sub>3</sub>).

MS *m/z* 283.0 [M+1]<sup>+</sup>.

#### Example 3

4-Methyl-5-(2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-2-carboxylic acid methyl ester

Oxindole (105 mg, 0.79 mmol) was condensed with 5-formyl-4-methyl-1H-pyrrole-2-carboxylic acid methyl ester (110 mg, 0.67 mmol) using method **E** to give 153.2 mg (81%) of the title compound.

<sup>1</sup>HNMR (360 MHz, DMSO-d<sub>6</sub>) δ 13.98 (s, br, 1H, NH), 10.97 (s, br, 1H, NH), 7.82 (d, *J* = 7.6 Hz, 1H), 7.67 (s, 1H, H-vinyl), 7.2 (dt, *J* = 1.2 & 7.7 Hz, 1H), 7.01 (dt, *J* = 1.2, 7.7 Hz, 1H), 6.90 (d, *J* = 7.6 Hz, 1H), 6.77 (d, *J* = 2 Hz, 1H).

MS (ES) *m/z* 283 [M<sup>+</sup>+1].

#### Example 4

5-(5-Chloro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-4-methyl-1H-pyrrole-2-carboxylic acid ethyl ester

5-Chloro-1,3-dihydroindol-2-one (2.22 g, 13.2 mmol) was condensed with 5-formyl-4-methyl-1H-pyrrole-2-carboxylic acid ethyl ester (2.43 g) using method **E** to give 4.1 g (94%) of the title compound as an orange solid.

<sup>1</sup>HNMR (360 MHz, DMSO-d<sub>6</sub>) δ 13.95 (s, br, 1H, NH), 7.98 (d, *J* = 2.2 Hz, 1H, H-4), 7.78 (s, 1H, H-vinyl), 7.18 (dd, *J* = 2.2



& 8.3 Hz, 1H, H-6), 6.87 (d,  $J = 8.3$  Hz, 1H, H-7), 7.34 (d,  $J = 1.8$  Hz, 1H, H-3'), 4.27 (q,  $J = 7.2$  Hz, 2H, OCH<sub>2</sub>CH<sub>3</sub>), 2.33 (s, 3H, CH<sub>3</sub>), 1.29 (t,  $J = 7.2$  Hz, 3H, OCH<sub>2</sub>CH<sub>3</sub>).

MS-EI  $m/z$  330 [ $M^+$ ].

#### 5 **Example 5**

##### 5-(5-Chloro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-4-methyl-1H-pyrrole-2-carboxylic acid

A mixture of 5-(5-chloro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-4-methyl-1H-pyrrole-2-carboxylic acid ethyl ester (1.3 g, 4 mmol) and potassium hydroxide in methanol (25 mL) and ethanol (25 mL) was heated to reflux for overnight. Insoluble materials were removed by filtration and the mixture was neutralized with 6N hydrochloric acid to give 0.876 g (70%) of the title compound.

<sup>1</sup>HNMR (360 MHz, DMSO-d<sub>6</sub>)  $\delta$  13.80 (s, br, 1H, NH), 12.90 (s, br, 1H, COOH), 11.06 (s, br, 1H, NH), 8.02 (d,  $J = 1.8$  Hz, 1H, H-4), 7.81 (s, 1H, H-vinyl), 7.20 (dd,  $J = 1.8$  & 8.3 Hz, 1H, H-6), 6.89 (d,  $J = 8.3$  Hz, 1H, H-7), 6.72 (d,  $J = 1.8$  Hz, 1H, H-3'), 2.35 (s, 3H, CH<sub>3</sub>).

MS-EI  $m/z$  302 [ $M^+$ ].

#### **Example 6**

##### 5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-4-methyl-1H-pyrrole-2-carboxylic acid (3-pyrrolidin-1-yl-propyl)amide

5-Bromo-1,3-dihydroindol-2-one (0.16 g, 0.76 mmol) was condensed with 5-formyl-4-methyl-1H-pyrrole-2-carboxylic acid (3-pyrrolidin-1-ylpropyl)amide (0.2 g, prepared by method C) to give 60 mg (17%) of the title compound as an orange solid.

<sup>1</sup>HNMR (300 MHz, DMSO-d<sub>6</sub>)  $\delta$  13.61 (s, br, 1H, NH), 11.02 (s, br, 1H, NH), 8.42 (t,  $J = 5.8$  Hz, 1H, CONHCH<sub>2</sub>), 8.12 (d,  $J = 1.8$  Hz, 1H, H-4), 7.78 (s, 1H, H-vinyl), 7.30 (dd,  $J = 1.8$  & 8.4 Hz, 1H, H-6), 6.82 (d,  $J = 8.4$  Hz, 1H, H-7), 6.77 (d,  $J = 2.4$  Hz, 1H, H-3'), 3.22-3.31 (m, 2H, CH<sub>2</sub>), 2.38-2.43 (m, 6H, 3xCH<sub>2</sub>), 2.35 (s, 3H, CH<sub>3</sub>), 1.62-1.71 (m, 6H, 3xCH<sub>2</sub>).

MS-EI  $m/z$  456 and 458 [ $M^+ - 1$  and  $M^+ + 2$ ].

### Example 7

5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-4-methyl-1H-pyrrole-2-carboxylic acid (3-diethylamino-propyl)amide

5-Bromo-1,3-dihydroindol-2-one (0.16 g, 0.75 mmol) was condensed with 5-formyl-4-methyl-1H-pyrrole-2-carboxylic acid (3-diethylaminopropyl)amide (0.2 g, prepared by method C) to give 30 mg (8%) of the title compound as an orange solid.

<sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 13.61 (s, br, 1H, NH), 11.02 (s, br, 1H, NH), 8.40 (m, 1H, CONHCH<sub>2</sub>), 8.12 (d, *J* = 1.5 Hz, 1H, H-4), 7.78 (s, 1H, H-vinyl), 7.30 (dd, *J* = 1.5 & 8.2 Hz, 1H, H-6), 6.82 (d, *J* = 8.2 Hz, 1H, H-7), 6.78 (d, *J* = 2.4 Hz, 1H, H-3'), 3.23 (m, 2H, CH<sub>2</sub>), 2.38-2.45 (m, 6H, CH<sub>2</sub> & N(CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>), 2.35 (s, 3H, CH<sub>3</sub>), 1.61 (m, 2H, CH<sub>2</sub>), 0.93 (t, *J* = 7.1 Hz, 6H, N(CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>).

MS-EI *m/z* 458 and 460 [*M*<sup>+</sup>-1 and *M*<sup>+</sup>+2].

### Example 8

5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-2-carboxylic acid (2-diethylaminoethyl)amide

5-Bromo-1,3-dihydroindol-2-one (212 mg, 1 mmol) was condensed with 5-formyl-1H-pyrrole-2-carboxylic acid (2-diethylaminoethyl)amide (prepared from ethyl pyrrole-2-carboxylate by method A, B and then C) to give 162 mg (38%) of the title compound.

<sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 13.53 (s, br, 1H, NH), 11.06 (s, br, 1H, NH), 8.37 (t, 1H, CONHCH<sub>2</sub>), 7.89 (m, 2H), 7.32 (dd, *J* = 2.0 Hz, 1H), 6.96 (s, 1H), 6.80-6.84 (m, 2H), 3.3 (m, 2H, CH<sub>2</sub>), 2.45-2.55 (m, 6H, N(CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub> & CH<sub>2</sub>), 0.95 (t, *J* = 7.2 Hz, 6H, N(CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>).

MS-EI *m/z* 430 and 432 [*M*<sup>+</sup>-1 and *M*<sup>+</sup>+ 1].

### Example 9

5-(2-Oxo-6-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-2-carboxylic acid (2-diethylaminoethyl)amide

6-Phenyl-1,3-dihydroindol-2-one (209 mg, 1mmol) was condensed with 5-formyl-1H-pyrrole-2-carboxylic acid (2-diethylaminoethyl)amide to give 182 mg (42%) of the title

compound.

<sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 13.56 (s, br, 1H, NH), 11.06 (s, br, 1H, NH), 8.36 (t, 1H, CONHCH<sub>2</sub>), 7.77 (s, 1H, H-vinyl), 7.73 (d, *J* = 7.8 Hz, 1H), 7.64 (d, *J* = 7.2 Hz, 2H), 7.46 (m, 2H), 7.32 (m, 2H), 7.11 (s, 1H), 6.96 (m, 1H), 6.80 (m, 1H), 3.31-3.32 (m, 2H, CH<sub>2</sub>), 2.46-2.53 (m, 6H, N(CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub> & CH<sub>2</sub>), 0.96 (t, *J* = 6.9 Hz, 6H, N(CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>).

MS-EI *m/z* 428 [M<sup>+</sup>].

#### Example 10

5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-2-carboxylic acid (2-diethylaminoethyl)-methyl-amide

5-Bromo-1,3-dihydroindol-2-one (212 mg, 1 mmol) was condensed with 5-formyl-1H-pyrrole-2-carboxylic acid (2-diethylaminoethyl)methylamide to give 246 mg (55%) of the title compound.

<sup>1</sup>H NMR (360 MHz, DMSO-d<sub>6</sub>) δ 13.54 (s, br, 1H, NH), 11.06 (s, br, 1H, NH), 7.90 (m, 2H), 7.33 (dd, *J* = 1.8 & 8.4 Hz, 1H), 6.82-6.85 (m, 3H), 3.55 (s, br, 2H, CH<sub>2</sub>), 3.25 (s, br, 3H, NCH<sub>3</sub>), 2.57 (t, *J* = 6.5 Hz, 2H, CH<sub>2</sub>), 2.45 (m, 4H, N(CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>), 0.91 (m, 6H, N(CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>).

MS-EI *m/z* 444 and 446 [M<sup>+</sup>-1 and M<sup>+</sup>+1].

#### Example 11

5-(2-Oxo-6-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-2-carboxylic acid (2-diethylaminoethyl)methylamide

6-Phenyl-1,3-dihydroindol-2-one (209 mg, 1 mmol) was condensed with 5-formyl-1H-pyrrole-2-carboxylic acid (2-diethylaminoethyl)methylamide to give 277 mg (63%) of the title compound.

<sup>1</sup>H NMR (360 MHz, DMSO-d<sub>6</sub>) δ 13.58 (s, br, 1H, NH), 11.04 (s, br, 1H, NH), 7.78 (s, 1H, H-vinyl), 7.73 (d, *J* = 7.8 Hz, 1H), 7.64 (d, *J* = 7.5 Hz, 2H), 7.46 (m, 2H), 7.33-7.36 (m, 2H), 7.11 (s, 1H), 6.84 (m, 1H), 6.78 (m, 1H), 3.55 (s, br, 2H, CH<sub>2</sub>), 3.25 (s, br, 3H, NCH<sub>3</sub>), 2.58 (t, 2H, CH<sub>2</sub>), 2.44 (m, 4H, N(CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>), 0.92 (m, 6H, N(CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>).

### Example 12

3-Methyl-5-(2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-2-carboxylic acid (3-diethylaminopropyl)amide

Oxindole (66.5 mg, 0.5 mmol) was condensed with 5-formyl-3-methyl-1H-pyrrole-2-carboxylic acid (3-diethylaminopropyl)amide (prepared from 3-formyl-3-methyl-1H-pyrrole-2-carboxylic acid ethyl ester by method **B** then **C**) to give 39 mg (21%) of the title compound.

<sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 13.34 (s, br, 1H, NH), 10.88 (s, br, 1H, NH), 7.62-7.67 (m, 3H), 7.17 (m, 1H), 6.99 (m, 1H), 6.87 (d, *J* = 7.6 Hz, 1H), 6.63 (d, *J* = 1 Hz, 1H), 3.26-3.32 (m, 2H, CH<sub>2</sub>), 2.41-2.48 (m, 6H, CH<sub>2</sub> & N(CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>), 2.29 (s, 3H, CH<sub>3</sub>), 1.63 (m, 2H, CH<sub>2</sub>), 0.93 (t, *J* = 7.2 Hz, 6H, N(CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>).

MS-EI *m/z* 380 [M<sup>+</sup>].

### Example 13

5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-3-methyl-1H-pyrrole-2-carboxylic acid (3-diethylamino-propyl)amide

5-Bromo-1,3-dihydroindol-2-one (106 mg, 0.5 mmol) was condensed with 5-formyl-3-methyl-1H-pyrrole-2-carboxylic acid (3-diethylaminopropyl)amide to give 35 mg (15%) of the title compound.

<sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 13.35 (s, br, 1H, NH), 11.00 (s, br, 1H, NH), 7.89 (d, *J* = 1.9 Hz, 1H, H-4), 7.80 (s, 1H, H-vinyl), 7.74 (t, *J* = 5.3 Hz, 1H, CONHCH<sub>2</sub>), 7.31 (dd, *J* = 1.9 & 8.4 Hz, 1H, H-6), 6.83 (d, *J* = 8.4 Hz, 1H, H-7), 6.63 (s, 1H, H-3'), 3.26 (m, 2H, CH<sub>2</sub>), 2.41-2.48 (m, 6H, CH<sub>2</sub> & N(CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>), 2.29 (s, 3H, CH<sub>3</sub>), 1.63 (m, 2H, CH<sub>2</sub>), 0.93 (t, *J* = 7.1 Hz, 6H, N(CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>).

MS-EI *m/z* 458 and 460 [M<sup>+</sup>-1 and M<sup>+</sup>+1].

### Example 14

3-Methyl-5-(2-oxo-6-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-2-carboxylic acid (3-diethylaminopropyl)amide

6-Phenyl-1,3-dihydroindol-2-one (105 mg, 0.5 mmol) was condensed with 5-formyl-3-methyl-1H-pyrrole-2-carboxylic acid

(3-diethylaminopropyl)amide to give 67.8 (30%) of the title compound.

<sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 13.37 (s, br, 1H, NH), 11.02 (s, br, 1H, NH), 7.23-7.73 (m, 11H), 3.29 (m, 2H, CH<sub>2</sub>), 2.41-2.48 (m, 6H, CH<sub>2</sub> & N(CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>), 2.29 (s, 3H, CH<sub>3</sub>), 1.64 (m, 2H, CH<sub>2</sub>), 0.94 (t, J = 7.0 Hz, 6H, N(CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>).

MS-EI m/z 456 [M<sup>+</sup>].

#### Example 15

5-(5-Methoxy-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-3-methyl-1H-pyrrole-2-carboxylic acid (3-diethylamino-propyl)amide

5-Methoxy-1,3-dihydroindol-2-one (82.5 mg, 0.5 mmol) was condensed with 5-formyl-3-methyl-1H-pyrrole-2-carboxylic acid (3-diethylaminopropyl)amide to give 80 mg (39%) of the title compound.

<sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 13.45 (s, br, 1H, NH), 10.70 (s, br, 1H, NH), 7.68-7.70 (m, 2H), 7.32 (d, J = 1.8 Hz, 1H), 6.72-6.79 (m, 2H), 6.60 (s, 1H), 3.73 (s, 3H, OCH<sub>3</sub>), 3.28 (m, 2H, CH<sub>2</sub>), 2.41-2.48 (m, 6H, CH<sub>2</sub> & N(CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>), 2.29 (s, 3H, CH<sub>3</sub>), 1.63 (m, 2H, CH<sub>2</sub>), 0.93 (t, J = 7.0 Hz, 6H, N(CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>).

MS m/z 410 [M<sup>+</sup>].

#### Example 16

5-(6-Methoxy-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-3-methyl-1H-pyrrole-2-carboxylic acid (3-diethylamino-propyl)amide

6-Methoxy-1,3-dihydroindol-2-one (82.5 mg, 0.5 mmol) was condensed with 5-formyl-3-methyl-1H-pyrrole-2-carboxylic acid (3-diethylaminopropyl)amide to give 63 mg (31%) of the title compound.

<sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 13.22 (s, br, 1H, NH), 10.86 (s, br, 1H, NH), 7.39-7.63 and 6.37-6.55 (m, 6H), 3.73 (s, 3H, OCH<sub>3</sub>), 3.3 (m, 2H, CH<sub>2</sub>), 2.45 (m, 6H, CH<sub>2</sub> & N(CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>), 2.28 (s, 3H, CH<sub>3</sub>), 1.63 (m, 2H, CH<sub>2</sub>), 0.93 (m, 6H, N(CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>).

MS m/z 410 [M<sup>+</sup>].

### Example 17

3-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-4,5,6,7-tetrahydro-2H-isoindole-1-carboxylic acid (2-diethylaminoethyl)amide

4,5,6,7-Tetrahydro-2H-isoindole-1-carboxylic acid ethyl ester (May, Donald A.; Lash, Timothy D.; J. Org. Chem., 1992, 57:18, 4820-4828) was formylated using method **A** then **B** to give 3-formyl-4,5,6,7-tetrahydro-2H-isoindole-1-carboxylic acid.

5-Bromo-1,3-dihydroindol-2-one (1.43 g, 6.8 mmol) was condensed with 3-formyl-4,5,6,7-tetrahydro-2H-isoindole-1-carboxylic acid (2-diethylaminoethyl)amide (1.97 g) to give 2.2 g (67%) of the title compound as a yellow-orange solid.

<sup>1</sup>H NMR (360 MHz, DMSO-d<sub>6</sub>) δ 13.47 (s, 1H, NH), 11.0 (s, 1H, NH), 8.0 (d, 1H, NH), 7.70 (s, 1H, CH), 7.28 (dd, *J* = 2.1 and 8.2 Hz, 1H, ArH), 7.16 (m, 1H, ArH), 6.8 (d, *J* = 8.3 Hz, 1H, ArH), 3.3 (s, 2H, CONH), 2.5 (m, 6H, 3xNCH<sub>2</sub>), 2.78 (br m, 2H, pyrrole CH<sub>2</sub>), 2.72 (br m, 2H, pyrrole CH<sub>2</sub>), 1.7 (br m, 4H, N(CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>), 1.74 (br s, 4H, CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>), 0.96 (t, *J* = 7.4 Hz, 6H, N(CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>).

MS-EI *m/z* 484 and 486 [*M*<sup>+</sup>-1 and *M*<sup>+</sup>+1].

### Example 18

3-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-4,5,6,7-tetrahydro-2H-isoindole-1-carboxylic acid (3-diethylaminopropyl)amide

5-Bromo-1,3-dihydroindol-2-one (20 mg, 0.1 mmol) was condensed with 3-formyl-4,5,6,7-tetrahydro-2H-isoindole-1-carboxylic acid (3-diethylaminopropyl)amide (30 mg) to give 33 mg (46%) of the title compound as an orange solid.

<sup>1</sup>H NMR (360 MHz, DMSO-d<sub>6</sub>) δ 10.9 (s, 1H, NH), 8.0 (m, 1H, NH), 7.68 (m, 1H, ArH), 7.4 (m, 1H, ArH), 7.29 (d, *J* = 1.9 and 8.5 Hz, 1H, ArH), 6.8 (d, *J* = 8 Hz, 1H, ArH), 2.7 (br m, 4H, 2xNCH<sub>2</sub>), 2.4 (m, 8H, 4xNCH<sub>2</sub>), 1.7 (br m, 4H, N(CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>), 1.6 (br m, 2H, CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>), 0.93 (t, *J* = 7.4 Hz, 6H, N(CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>).

MS-EI *m/z* 499 and 501 [*M*<sup>+</sup> and *M*<sup>+</sup>+2].

### Example 19

3-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-4,5,6,7-tetrahydro-2H-isoindole-1-carboxylic acid (3-pyrrolidin-1-ylpropyl)amide

5 5-Bromo-1,3-dihydroindol-2-one (80 mg, 0.4 mmol) was condensed with 3-formyl-4,5,6,7-tetrahydro-2H-isoindole-1-carboxylic acid (3-pyrrolidin-1-ylpropyl)amide (120 mg) to give 43 mg (22%) of the title compound as a tan-orange solid.

<sup>1</sup>H NMR (360 MHz, DMSO-d<sub>6</sub>) δ 13.4 (s, 1H, NH), 10.9 (s, 1H, NH), 8.0 (m, 1H, NH), 7.69 (m, 1H, ArH), 7.49 (m, 1H, ArH), 7.28 (d, J = 1.7 and 7.8 Hz, 1H, ArH), 6.8 (d, J = 8 Hz, 1H, ArH), 3.3 (br m, 2H, 2xNCH<sub>2</sub>), 2.8 (m, 4H, 2xpyrroleCH<sub>2</sub>), 2.5 (br m, 4H, N(CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>), 1.6 (br m, 8H, 2xpyrroleCH<sub>2</sub>CH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub> and CONHCH<sub>2</sub>).

MS-EI m/z 497 and 499 [M<sup>+</sup> and M<sup>+</sup>+2].

### Example 20

3-(2-Oxo-6-pyridin-3-yl-1,2-dihydroindol-3-ylidenemethyl)-4,5,6,7-tetrahydro-2H-isoindole-1-carboxylic acid (2-diethylaminoethyl)amide

6-Pyridin-3-yl-1,3-dihydroindol-2-one (60 mg, 0.4 mmol) was condensed with 3-formyl-4,5,6,7-tetrahydro-2H-isoindole-1-carboxylic acid (2-diethylaminoethyl)amide (80 mg) to give 50 mg (38%) of the title compound as a reddish solid.

<sup>1</sup>H NMR (360 MHz, DMSO-d<sub>6</sub>) δ 13.4 (s, 1H, NH), 11 (s, 1H, NH), 8.9 (d, 1H, NH), 8.7 (dd, 1H, ArH), 8.1 (dd, 1H, ArH), 7.9 (d, 1H, ArH), 7.6 (s, 1H, CH), 7.5 (dd, 1H, ArH), 7.3 (dd, 1H, ArH), 7.1 (m, 2H, ArH), 3.35 (m, 2H, CONHCH<sub>2</sub>), 2.8 (m, 4H, 2xpyrroleCH<sub>2</sub>), 2.5 (br m, 6H, N(CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub> and NCH<sub>2</sub>), 1.75 (br s, 4H, 2xpyrroleCH<sub>2</sub>CH<sub>2</sub>), 0.9 (t, 6H, N(CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>).

MS-EI m/z 484 [M<sup>+</sup>].

### Example 21

4-Benzoyl-5-(5-bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-3-methyl-1H-pyrrole-2-carboxylic acid (3-diethylaminopropyl)amide

To a mixture of benzoyl chloride (1 equiv.) and aluminum chloride (1 equiv.) in dichloroethane at 0°C was added ethyl

3,5-dimethyl-2-pyrrolicarboxylate (1 equiv.). The mixture was stirred at 80°C for 4 hr. The mixture was then extracted with ethyl acetate (EtOAc) and H<sub>2</sub>O. The combined organic extracts were washed with saturated sodium bicarbonate and brine, dried and concentrated to give (51%) of 4-benzoyl-3,5-dimethyl-1H-pyrrole-2-carboxylic acid.

A mixture of 4-benzoyl-3,5-dimethyl-1H-pyrrole-2-carboxylic acid ethyl ester (4.13 g, 15.2 mmol) and ceric ammonium nitrate (33 g, 4equiv.) in 50 mL of tetrahydrofuran (THF):acetic acid (HOAc):H<sub>2</sub>O 1:1:1 was refluxed overnight. The reaction mixture was then cooled, extracted with EtOAc and then basified to pH 9 with sodium carbonate. The organic layer was then washed with brine, dried (MgSO<sub>4</sub>) and concentrated followed by column chromatography to give 3.25 g (75%) of 4-benzoyl-5-formyl-3-methyl-1H-pyrrole-2-carboxylic acid ethyl ester as a yellow solid.

5-Bromo-1,3-dihydro-indol-2-one was condensed with 4-benzoyl-5-formyl-3-methyl-1H-pyrrole-2-carboxylic acid using method **D** to give 4-benzoyl-5-(5-bromo-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-3-methyl-1H-pyrrole-2-carboxylic acid.

The above carboxylic acid was then coupled with N,N-diethyl-1,3-propanediamine using method **C** to give the title compound.

<sup>1</sup>H NMR (360 MHz, DMSO-d<sub>6</sub>) δ 7.96 (m, 1H, CONHCH<sub>2</sub>), 7.76 (d, J = 7.0 Hz, 2H), 7.68 (t, 1H), 7.56 (m, 2H), 7.40 (s, 2H), 7.33 (dd, J = 1.6 & 8.3 Hz, 1H, H-6), 6.84 (d, J = 8.3 Hz, 1H, H-7), 3.33 (m, 2H, CH<sub>2</sub>), 2.42-2.46 (m, 6H, 3xCH<sub>2</sub>), 2.10 (s, 3H, CH<sub>3</sub>), 1.65 (m, 2H, CH<sub>2</sub>), 0.94 (t, J = 7.0 Hz, 6H, N(CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>).

MS Electron Impact m/z 564 [M<sup>+</sup>+1].

#### **Example 22**

4-Benzoyl-5-(5-bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-3-methyl-1H-pyrrole-2-carboxylic acid (3-morpholin-4-ylpropyl)amide

<sup>1</sup>H NMR (360 MHz, DMSO-d<sub>6</sub>) δ 14.10 (s, 1H, NH), 11.14 (br s, 1H, NH), 7.92 (m, 1H, CONHCH<sub>2</sub>), 7.75 (m, 2H), 7.69 (t, 1H), 7.56 (m, 2H), 7.42 (m, 2H), 7.33 (dd, J = 1.9 & 8.3 Hz, 1H, H-



6), 6.85 (d,  $J = 8.3$  Hz, 1H, H-7), 3.56 (m, 4H,  $2 \times \text{CH}_2$ ), 3.33 (m, 2H,  $\text{CH}_2$ ), 2.35 (m, 6H,  $3 \times \text{CH}_2$ ), 2.10 (s, 3H,  $\text{CH}_3$ ), 1.70 (m, 2H,  $\text{CH}_2$ ).

#### Example 23

5 4-Benzoyl-3-methyl-5-(2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-2-carboxylic acid (3-pyrrolidin-1-ylpropyl)amide

$^1\text{H}$  NMR (300 MHz, DMSO- $d_6$ )  $\delta$  14.18 (s, 1H, NH), 11.14 (br s, 1H, NH), 8.01 (m, 1H,  $\text{CONHCH}_2$ ), 7.74 (m, 1H), 7.67 (m, 1H), 7.55 (m, 1H), 7.32 (s, 1H, H-vinyl), 7.17 (m, 1H), 6.92 (m, 10 1H), 3.36 (m, 2H,  $\text{CH}_2$ ), 2.44 (m, 6 H,  $3 \times \text{CH}_2$ ), 2.11 (s, 3H,  $\text{CH}_3$ ), 1.65-1.75 (m, 6H,  $3 \times \text{CH}_2$ ).

MS Electron Impact  $m/z$  482 [ $\text{M}^+$ ].

#### Example 24

5 4-Benzoyl-5-(5-bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-3-methyl-1H-pyrrole-2-carboxylic acid (3-pyrrolidin-1-ylpropyl)amide

$^1\text{H}$  NMR (360 MHz, DMSO- $d_6$ )  $\delta$  14.01 (s, 1H, NH), 11.18 (br s, 1H, NH), 7.98 (m, 1H,  $\text{CONHCH}_2$ ), 7.75 (m, 2H), 7.68 (m, 1H), 7.55 (m, 2H), 7.40 (m, 2H), 7.33 (dd,  $J = 2.0$  & 8.2 Hz, 1H, H-6), 6.84 (d,  $J = 8.2$  Hz, 1H, H-7), 3.34 (m, 2H,  $\text{CH}_2$ ), 2.42-2.47 20 (m, 6 H,  $3 \times \text{CH}_2$ ), 2.09 (s, 3H,  $\text{CH}_3$ ), 1.70 (m, 2H,  $\text{CH}_2$ ), 1.64 (m, 4H,  $2 \times \text{CH}_2$ ).

#### Example 25

25 4-Benzoyl-3-methyl-5-(2-oxo-6-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-2-carboxylic acid (3-pyrrolidin-1-ylpropyl)amide

$^1\text{H}$  NMR (300 MHz, DMSO- $d_6$ )  $\delta$  14.15 (s, 1H, NH), 11.16 (br s, 1H, NH), 7.98 (m, 1H,  $\text{CONHCH}_2$ ), 7.77 (d,  $J = 7.7$  Hz, 2H), 7.69 (m, 1H), 7.53-7.63 (m, 4H), 7.44 (m, 2H), 7.33-7.37 (m, 2H), 7.24 (s, 2H), 7.12 (s, 1H), 3.36 (m, 2H,  $\text{CH}_2$ ), 2.43-2.48 30 (m, 6 H,  $3 \times \text{CH}_2$ ), 2.12 (s, 3H,  $\text{CH}_3$ ), 1.74 (m, 2H,  $\text{CH}_2$ ), 1.69 (m, 4H,  $2 \times \text{CH}_2$ ).

MS Electron Impact  $m/z$  558 [ $\text{M}^+$ ].

**Example 26**

4-Benzoyl-5-(6-methoxy-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-3-methyl-1H-pyrrole-2-carboxylic acid (3-pyrrolidin-1-ylpropyl)amide

5  $^1\text{H}$  NMR (300 MHz, DMSO- $d_6$ )  $\delta$  13.99 (s, 1H, NH), 11.05 (br s, 1H, NH), 7.93 (m, 1H, CONHCH<sub>2</sub>), 7.72 (m, 2H), 7.65 (m, 1H), 7.54 (m, 2H), 7.15 (s, 1H, H-vinyl), 7.04 (d,  $J$  = 8.4 Hz, 1H, H-4), 6.51 (dd,  $J$  = 2.3 & 8.4 Hz, 1H, H-5), 6.44 (d,  $J$  = 2.3 Hz, 1H, H-7), 3.74 (s, 3H, OCH<sub>3</sub>), 3.35 (m, 2H, CH<sub>2</sub>), 2.42-2.46  
10 (m, 6 H, 3xCH<sub>2</sub>), 2.10 (s, 3H, CH<sub>3</sub>), 1.72 (m, 2H, CH<sub>2</sub>), 1.65 (m, 4H, 2xCH<sub>2</sub>).

MS Electron Impact  $m/z$  512 [ $M^+$ ].

**Example 27**

4-Benzoyl-5-(5-methoxy-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-3-methyl-1H-pyrrole-2-carboxylic acid (3-pyrrolidin-1-ylpropyl)amide

5  $^1\text{H}$  NMR (360 MHz, DMSO- $d_6$ )  $\delta$  14.24 (s, 1H, NH), 10.90 (br s, 1H, NH), 7.97 (m, 1H, CONHCH<sub>2</sub>), 7.75 (d,  $J$  = 7.2 Hz, 2H), 7.69 (m, 1H), 7.56 (m, 2H), 7.24 (s, 1H, H-vinyl), 6.79 (m, 2H), 6.66 (m, 1H), 3.67 (s, 3H, OCH<sub>3</sub>), 3.34 (m, 2H, CH<sub>2</sub>), 2.43-  
20 2.48 (m, 6 H, 3xCH<sub>2</sub>), 2.14 (s, 3H, CH<sub>3</sub>), 1.71 (m, 2H, CH<sub>2</sub>), 1.66 (m, 4H, 2xCH<sub>2</sub>).

MS Electron Impact  $m/z$  512 [ $M^+$ ].

**Example 28**

25 4-Benzoyl-5-(5-fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-3-methyl-1H-pyrrole-2-carboxylic acid (3-pyrrolidin-1-ylpropyl)amide

$^1\text{H}$  NMR (300 MHz, DMSO- $d_6$ )  $\delta$  14.20 (s, 1H, NH), 11.14 (br s, 1H, NH), 8.03 (m, 1H, CONHCH<sub>2</sub>), 7.75 (m, 2H), 7.68 (m, 1H),  
30 7.55 (m, 2H), 7.38 (s, 1H, H-vinyl), 7.08 (m, 1H), 7.01 (m, 1H), 6.87 (m, 1H), 3.34 (m, 2H, CH<sub>2</sub>), 2.42-2.48 (m, 6 H, 3xCH<sub>2</sub>), 2.09 (s, 3H, CH<sub>3</sub>), 1.70 (m, 2H, CH<sub>2</sub>), 1.65 (m, 4H, 2xCH<sub>2</sub>).

MS Electron Impact  $m/z$  500 [ $M^+$ ].

**Example 29**

4-Acetyl-5-(5-bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-3-methyl-1H-pyrrole-2-carboxylic acid (3-diethylaminopropyl)amide

5 5-Bromo-1,3-dihydro-indol-2-one was condensed with 4-acetyl-5-formyl-3-methyl-1H-pyrrole-2-carboxylic acid (3-diethylaminopropyl)amide (prepared from 4-acetyl-5-formyl-3-methyl-1H-pyrrole-2-carboxylic acid ethyl ester by method **B** then **C**) to give the title compound.

10  $^1\text{H}$  NMR (300 MHz, DMSO- $d_6$ )  $\delta$  14.19 (s, 1H, NH), 11.19 (br s, 1H, NH), 8.15 (m, 1H, CONHCH<sub>2</sub>), 8.11 (s, 1H, H-vinyl), 7.72 (d,  $J$  = 1.8 Hz, 1H, H-4), 7.38 (dd,  $J$  = 1.8 & 8.2 Hz, 1H, H-6), 6.87 (d,  $J$  = 8.2 Hz, 1H, H-7), 3.27 (m, 2H, CH<sub>2</sub>), 2.57 (s, 3H, CH<sub>3</sub>CO), 2.46 (m, 9 H, CH<sub>3</sub> & 3xCH<sub>2</sub>), 1.64 (m, 2H, CH<sub>2</sub>), 0.93 (t,  $J$  = 7.1 Hz, 6H, N(CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>).

**Example 30**

4-Acetyl-5-(5-bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-3-methyl-1H-pyrrole-2-carboxylic acid (3-pyrrolidin-1-ylpropyl)amide

20  $^1\text{H}$  NMR (300 MHz, DMSO- $d_6$ )  $\delta$  8.14 (m, 1H, CONHCH<sub>2</sub>), 8.10 (s, 1H, H-vinyl), 7.70 (d, 1H, H-4), 7.36 (dd,  $J$  = 1.6 & 8.1 Hz, 1H, H-6), 6.85 (d,  $J$  = 8.1 Hz, 1H, H-7), 3.32 (m, 2H, CH<sub>2</sub>), 2.57 (s, 3H, CH<sub>3</sub>CO), 2.44 (s, 3H, CH<sub>3</sub>), 2.35-2.48 (m, 6H, 3xCH<sub>2</sub>), 1.65-1.71 (m, 6H, 3xCH<sub>2</sub>).

25 MS  $m/z$  499 & 501 [ $M^+$ ] & [ $M^+ + 2$ ].

**Example 31**

4-Acetyl-5-(5-bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-3-methyl-1H-pyrrole-2-carboxylic acid (3-morpholin-4-ylpropyl)amide

30  $^1\text{H}$  NMR (300 MHz, DMSO- $d_6$ )  $\delta$  14.20 (s, 1H, NH), 11.26 (br s, 1H, NH), 8.09 (m, 2H, H-vinyl & CONHCH<sub>2</sub>), 7.73 (d,  $J$  = 1.5 Hz, 1H, H-4), 7.38 (dd,  $J$  = 1.5 & 8.3 Hz, 1H, H-6), 6.87 (d,  $J$  = 8.3 Hz, 1H, H-7), 3.55 (m, 4H, 2xCH<sub>2</sub>), 3.26 (m, 2H, CH<sub>2</sub>), 2.57 (s, 3H, CH<sub>3</sub>CO), 2.44 (s, 3H, CH<sub>3</sub>), 2.35 (m, 6H, 3xCH<sub>2</sub>),  
35 1.68 (m, 2H, CH<sub>2</sub>).

MS-EI  $m/z$  514 & 516  $[M^+-1]$  &  $[M^++1]$ .

**Example 32**

4-Acetyl-5-(5-bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-3-methyl-1H-pyrrole-2-carboxylic acid (3-hydroxypropyl)amide

5  $^1\text{H}$  NMR (360 MHz, DMSO- $d_6$ )  $\delta$  14.17 (s, 1H, NH), 11.25 (br s, 1H, NH), 8.10 (s, 1H, H-vinyl), 8.03 (m, 1H, CONHCH<sub>2</sub>), 7.71 (br s, 1H, H-4), 7.37 (br d,  $J$  = 8.4 Hz, 1H, H-6), 6.87 (d,  $J$  = 8.4 Hz, 1H, H-7), 4.51 (br s, 1H, OH), 3.51 (br s, 2H, CH<sub>2</sub>), 3.36 (m, 2H, CH<sub>2</sub>), 2.57 (s, 3H, CH<sub>3</sub>CO), 2.43 (s, 3H, CH<sub>3</sub>), 1.70  
10 (m, 2H, CH<sub>2</sub>).

MS-EI  $m/z$  445 & 447  $[M^+-1]$  &  $[M^++1]$ .

**Example 34**

4-Acetyl-5-(5-bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-3-methyl-1H-pyrrole-2-carboxylic acid (2-morpholin-4-ylethyl)amide

5  $^1\text{H}$  NMR (360 MHz, DMSO- $d_6$ )  $\delta$  14.19 (s, 1H, NH), 11.14 (br s, 1H, NH), 8.10 (s, 1H, H-vinyl), 7.84 (m, 1H, CONHCH<sub>2</sub>), 7.71 (d,  $J$  = 1.8 Hz, 1H, H-4), 7.38 (dd,  $J$  = 1.8 & 8.2 Hz, 1H, H-6), 6.87 (d,  $J$  = 8.2 Hz, 1H, H-7), 3.58 (m, 4H, 2xCH<sub>2</sub>), 3.40  
20 (m, 2H, CH<sub>2</sub>), 2.57 (s, 3H, CH<sub>3</sub>CO), 2.49 (m, 4H, 2xCH<sub>2</sub>), 2.45 (m, CH<sub>3</sub> & CH<sub>2</sub>).

MS-EI  $m/z$  500 & 502  $[M^+-1]$  &  $[M^++1]$ .

**Example 35**

4-Acetyl-5-(5-bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-3-methyl-1H-pyrrole-2-carboxylic acid (2-pyrrolidin-1-ylethyl)amide

25  $^1\text{H}$  NMR (360 MHz, DMSO- $d_6$ )  $\delta$  14.17 (s, 1H, NH), 11.23 (s, 1H, NH), 8.11 (s, 1H, H-vinyl), 7.91 (m, 1H, CONHCH<sub>2</sub>), 7.73 (d,  $J$  = 1.9 Hz, 1H, H-4), 7.39 (dd,  $J$  = 1.9 & 8.3 Hz, 1H, H-6), 6.88 (d,  $J$  = 8.3 Hz, 1H, H-7), 3.40 (m, 2H, CH<sub>2</sub>), 2.62 (m, 2H, CH<sub>2</sub>), 2.57  
30 (s, 3H, CH<sub>3</sub>CO), 2.49 (m, 4H, 2xCH<sub>2</sub>), 2.44 (s, 3H, CH<sub>3</sub>), 1.69 (m, 4H, 2xCH<sub>2</sub>).

### Example 36

4-Acetyl-5-(5-bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-3-methyl-1H-pyrrole-2-carboxylic acid [2-(4-hydroxyphenyl)ethyl]amide

<sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 14.21 (s, 1H, NH), 11.18 (s, 1H, OH), 9.09 (s, 1H, NH), 8.06-8.10 (m, 2H), 7.73 (s, 1H), 7.38 (d, *J* = 7.8 Hz, 1H), 7.04 (d, *J* = 7.1 Hz, 2H), 6.88 (d, *J* = 7.8 Hz, 1H), 6.67 (d, *J* = 7.1 Hz, 2H), 3.42 (m, 2H, CH<sub>2</sub>), 2.72 (m, 2H, CH<sub>2</sub>), 2.56 (s, 3H, CH<sub>3</sub>CO), 2.37 (s, 3H, CH<sub>3</sub>).

MS-EI *m/z* 507 & 509 [M<sup>+</sup>-1] & [M<sup>+</sup>+1].

### Example 37

5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid (3-diethylaminopropyl)amide

A mixture of 2-aminoacetophenone hydrochloride (1 equiv.), ethyl isobutyrylacetate (1.2 equiv.) and sodium acetate (2.4 equiv.) in H<sub>2</sub>O was stirred at 100° C for 18 hours and then cooled to room temperature. The aqueous layer was decanted off and the oil was dissolved in ethyl acetate. It was then washed with water and brine and then dried to give (93%) of 2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid ethyl ester as a red brown oil.

<sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 11.21 (s, br, 1H, NH), 7.14-7.27 (m, 5H), 6.70 (d, *J* = 2.7 Hz, 1H), 4.02 (q, *J* = 7.1 Hz, 2H, OCH<sub>2</sub>CH<sub>3</sub>), 3.65 (m, 1H, CH(CH<sub>3</sub>)<sub>2</sub>), 1.22 (d, *J* = 7.5 Hz, 6H, CH(CH<sub>3</sub>)<sub>2</sub>), 1.04 (t, *J* = 7.1 Hz, 3H, OCH<sub>2</sub>CH<sub>3</sub>).

MS-EI *m/z* 257 [M<sup>+</sup>].

The above pyrrole was formylated using method **A** to give (41%) 5-formyl-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid ethyl ester as a reddish solid.

<sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 12.35 (s, br, 1H, NH), 9.14 (s, 1H, CHO), 7.36 (s, 5H), 3.96 (q, *J* = 7.1 Hz, 2H, OCH<sub>2</sub>CH<sub>3</sub>), 3.74 (m, 1H, CH(CH<sub>3</sub>)<sub>2</sub>), 1.29 (d, *J* = 6.9 Hz, 6H, CH(CH<sub>3</sub>)<sub>2</sub>), 0.90 (t, *J* = 7.1 Hz, 3H, OCH<sub>2</sub>CH<sub>3</sub>).

MS-EI *m/z* 285 [M<sup>+</sup>].

The pyrrolecarboxylic acid ester was hydrolysed using method **B** to give (57%) of 5-formyl-2-isopropyl-4-phenyl-1*H*-pyrrole-3-carboxylic acid as a beige solid.

<sup>1</sup>HNMR (300 MHz, DMSO-d<sub>6</sub>) δ 12.28 (s, br, 1H, COOH), 12.02 (s, br, 1H, NH), 9.10 (s, 1H, CHO), 7.35 (s, 5H), 3.81 (m, 1H, CH(CH<sub>3</sub>)<sub>2</sub>), 1.28 (d, *J* = 6.9 Hz, 6H, CH(CH<sub>3</sub>)<sub>2</sub>).

MS-EI *m/z* 257 [M<sup>+</sup>].

5-Bromo-1,3-dihydroindol-2-one (120 mg, 0.31 mmol) was condensed with 5-formyl-2-isopropyl-4-phenyl-1*H*-pyrrole-3-carboxylic acid (3-diethylaminopropyl)amide (prepared by method **C**) to give 120 mg (71%) of the title compound.

<sup>1</sup>HNMR (300 MHz, DMSO-d<sub>6</sub>) δ 14.23 (s, br, 1H, NH), 11.08 (s, br, 1H, NH), 7.38-7.55 (m, 7H, Ar-H & CONHCH<sub>2</sub>), 7.30 (s, 1H, H-vinyl), 7.26 (dd, *J* = 1.8 & 7.8 Hz, 1H), 6.85 (d, *J* = 8.7 Hz, 1H), 3.36 (m, 1H, CH(CH<sub>3</sub>)<sub>2</sub>), 3.07 (m, 2H, CH<sub>2</sub>), 2.34 (q, *J* = 7.1 Hz, 4H, N(CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>), 2.22 (t, *J* = 6.9 Hz, 2H, CH<sub>2</sub>), 1.40 (m, 2H, CH<sub>2</sub>), 1.31 (d, *J* = 6.9 Hz, 6H, CH(CH<sub>3</sub>)<sub>2</sub>), 0.86 (t, *J* = 7.1 Hz, 6H, N(CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>).

MS *m/z* 565.1 [M<sup>+</sup>+1].

### Example 38

5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2-isopropyl-4-phenyl-1*H*-pyrrole-3-carboxylic acid (3-pyrrolidin-1-ylpropyl)amide

5-(5-bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2-isopropyl-4-phenyl-1*H*-pyrrole-3-carboxylic acid (127 mg, 0.28 mmol) was condensed with 3-pyrrolidin-1-yl-propylamine (43 mg, 0.336 mmol) to give 140 mg (66%) of the title compound.

<sup>1</sup>HNMR (300 MHz, DMSO-d<sub>6</sub>) δ 14.40 (s, br, 1H, NH), 7.38-7.47 (m, 7H), 7.23-7.27 (m, 2H), 6.84 (d, *J* = 8.1 Hz, 1H), 3.36 (m, 1H, CH(CH<sub>3</sub>)<sub>2</sub>), 3.08 (m, 2H, CH<sub>2</sub>), 2.30 (m, 4H, 2xCH<sub>2</sub>), 2.20 (t, *J* = 7.0 Hz, 2H, CH<sub>2</sub>), 1.62 (m, 4H, 2xCH<sub>2</sub>), 1.42 (t, *J* = 7.0 Hz, 2H, CH<sub>2</sub>), 1.31 (d, *J* = 7.2 Hz, 6H, CH(CH<sub>3</sub>)<sub>2</sub>).

MS-EI *m/z* 560 and 562 [M<sup>+</sup> -1 and M<sup>+</sup>+1].

### Example 39

5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide

5-Bromo-1,3-dihydroindol-2-one (57 mg, 0.27 mmol) was condensed with 5-formyl-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide (120 mg) to give 78 mg (53%) of the title compound as a yellow solid.

<sup>1</sup>HNMR (300 MHz, DMSO-d<sub>6</sub>) δ 14.23 (s, br, 1H, NH), 11.09 (s, br, 1H, NH), 7.38-7.51 (m, 6H), 7.25-7.28 (m, 2H), 7.19 (t, 1H, CONHCH<sub>2</sub>), 6.85 (d, *J* = 7.8 Hz, 1H), 3.43 (m, 1H, CH(CH<sub>3</sub>)<sub>2</sub>), 3.11 (m, 2H, CH<sub>2</sub>), 2.28-2.39 (m, 6H, N(CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub> & CH<sub>2</sub>), 1.31 (d, *J* = 6.9 Hz, CH(CH<sub>3</sub>)<sub>2</sub>), 0.85 (t, *J* = 7.0 Hz, 6H, N(CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>).

MS-EI *m/z* 548 and 550 [*M*<sup>+</sup> -1 and *M*<sup>+</sup>+1].

### Example 40

5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid [3-(4-methylpiperazin-1-yl)propyl]amide

5-Bromo-1,3-dihydroindol-2-one (53 mg, 0.25 mmol) was condensed with 5-formyl-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid [3-(4-methylpiperazin-1-yl)propyl]amide (300 mg) to give 65 mg of the title compound.

<sup>1</sup>HNMR (300 MHz, DMSO-d<sub>6</sub>) δ 14.22 (s, br, 1H, NH), 11.08 (s, br, 1H, NH), 7.23-7.50 (m, 9H), 6.85 (d, *J* = 8.7 Hz, 1H), 3.37 (m, 1H, CH(CH<sub>3</sub>)<sub>2</sub>), 3.05 (m, 2H, CH<sub>2</sub>), 2.24 (m, 8H, 4xCH<sub>2</sub>), 2.11 (m, 5H, CH<sub>2</sub> & CH<sub>3</sub>), 1.42 (m, 2H, CH<sub>2</sub>), 1.31 (d, *J* = 7.2 Hz, 6H, CH(CH<sub>3</sub>)<sub>2</sub>).

MS-EI *m/z* 589 and 591 [*M*<sup>+</sup> -1 and *M*<sup>+</sup>+1].

### Example 41

5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid

5-Bromo-1,3-dihydroindol-2-one (170 mg, 0.8 mmol) was condensed with 5-formyl-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid (205 mg) using method **D** to give 210 mg (58%)

of the title compound as a yellow solid.

<sup>1</sup>HNMR (300 MHz, DMSO-d<sub>6</sub>) δ 14.31 (s, br, 1H, NH), 11.16 (s, br, 1H, NH), 7.26-7.44 (m, 7H), 7.11 (s, 1H, H-vinyl), 6.85 (d, *J* = 7.8 Hz, 1H), 3.78 (m, 1H, CH(CH<sub>3</sub>)<sub>2</sub>), 1.34 (d, *J* = 6.9 Hz, 6H, CH(CH<sub>3</sub>)<sub>2</sub>).

MS-EI *m/z* 452 [M<sup>+</sup>+1].

#### Example 42

5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2-methyl-4-phenyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-ylethyl)amide

5-Bromo-1,3-dihydroindol-2-one (44 mg, 0.21 mmol) was condensed with 5-formyl-2-methyl-4-phenyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-ylethyl)amide (70 mg, prepared in the same manner as the isopropyl analog, above) to give 0.03 g (27%) of the title compound as a yellow solid.

<sup>1</sup>HNMR (300 MHz, DMSO-d<sub>6</sub>) δ 13.87 (s, br, 1H, NH), 11.11 (s, br, 1H, NH), 7.36-7.51 (m, 6H), 7.26 (dd, *J* = 1.8 & 8.1 Hz, 1H), 7.2 (s, 1H, H-vinyl), 7.09 (m, 1H, CONHCH<sub>2</sub>), 6.83 (d, *J* = 8.1 Hz, 1H), 3.17 (m, 2H, NCH<sub>2</sub>), 2.48 (m, CH<sub>3</sub>), 2.29-2.35 (m, 6H, 3xNCH<sub>2</sub>), 1.59 (m, 4H, 2xCH<sub>2</sub>).

MS-EI *m/z* 518 and 520 [M<sup>+</sup>-1 and M<sup>+</sup>+1].

#### Example 43

5-[6-(2-Methoxyphenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2-methyl-4-phenyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-ylethyl)amide

6-(2-Methoxyphenyl)-1,3-dihydroindol-2-one (50 mg, 0.21 mmol) was condensed with 5-formyl-2-methyl-4-phenyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-ylethyl)amide (70 mg) to give 0.04 g (35%) of the title compound as a yellow-orange solid.

<sup>1</sup>HNMR (300 MHz, DMSO-d<sub>6</sub>) δ 13.82 (s, br, 1H, NH), 11.02 (s, br, 1H, NH), 7.48 (m, 2H), 7.43 (m, 1H), 7.38 (m, 2H), 7.32 (m, 1H), 7.24 (m, 2H), 7.16 (s, 1H, H-vinyl), 7.08 (m, 2H), 7.03 (m, 1H), 7.0 (m, 2H), 3.74 (s, 3H, OCH<sub>3</sub>), 3.19 (m, 2H, NCH<sub>2</sub>), 2.49 (m, CH<sub>3</sub>), 2.32-2.38 (m, 6H, 3xNCH<sub>2</sub>), 1.59 (m,



4H, 2xCH<sub>2</sub>).

MS-EI *m/z* 546 [M<sup>+</sup>].

#### Example 44

5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2-methyl-4-phenyl-1*H*-pyrrole-3-carboxylic acid (2-dimethylaminoethyl)amide

5-Bromo-1,3-dihydroindol-2-one (46 mg, 0.22 mmol) was condensed with 5-formyl-2-methyl-4-phenyl-1*H*-pyrrole-3-carboxylic acid (2-dimethylaminoethyl)amide (65 mg) to give 60 mg (55%) of the title compound as a yellow solid.

<sup>1</sup>HNMR (360 MHz, DMSO-d<sub>6</sub>) δ 13.86 (s, br, 1H, NH), 11.09 (s, br, 1H, NH), 7.47-7.49 (m, 2H), 7.38-7.41 (m, 4H), 7.26 (dd, *J* = 2.2 & 8.3 Hz, 1H), 7.21 (s, 1H, H-vinyl), 7.04 (m, 1H, CONHCH<sub>2</sub>), 6.77 (d, *J* = 8.3 Hz, 1H), 3.15 (m, 2H, NCH<sub>2</sub>), 2.48 (m, CH<sub>3</sub>), 2.16 (t, *J* = 6.8 Hz, 2H, 3xNCH<sub>2</sub>), 2.02 (s, 6H, 2xNCH<sub>3</sub>).

MS *m/z* 493 and 494.8 [M<sup>+</sup> and M<sup>+</sup>+2].

#### Example 45

5-[6-(2-Methoxyphenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2-methyl-4-phenyl-1*H*-pyrrole-3-carboxylic acid (2-dimethylaminoethyl)amide

6-(2-Methoxyphenyl)-1,3-dihydroindol-2-one (53 mg, 0.22 mmol) was condensed with 5-formyl-2-methyl-4-phenyl-1*H*-pyrrole-3-carboxylic acid (2-dimethylaminoethyl)amide (65 mg) to give 0.05 g (44%) of the title compound as an orange gum.

<sup>1</sup>HNMR (300 MHz, DMSO-d<sub>6</sub>) δ 13.82 (s, br, 1H, NH), 11.02 (s, br, 1H, NH), 7.37-7.52 (m, 5H), 7.32 (m, 1H), 7.22-7.27 (m, 2H), 7.16 (s, 1H), 7.08 (m, 2H), 7.03 (m, 1H), 7.0 (m, 2H), 3.74 (s, 3H, OCH<sub>3</sub>), 3.15 (m, 2H, NCH<sub>2</sub>), 2.49 (m, CH<sub>3</sub>), 2.16 (t, *J* = 6.5 Hz, 2H, NCH<sub>2</sub>), 2.02 (s, 6H, 2xNCH<sub>3</sub>).

MS *m/z* 521 [M<sup>+</sup>+1].

#### Example 46

5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2-methyl-4-phenyl-1H-pyrrole-3-carboxylic acid ethyl ester

5-Bromo-1,3-dihydroindol-2-one (60 mg, 0.29 mmol) was condensed with 5-formyl-2-methyl-4-phenyl-1H-pyrrole-3-carboxylic acid ethyl ester (75 mg) to give 78 mg (60%) of the title compound as an orange solid.

<sup>1</sup>HNMR (360 MHz, DMSO-d<sub>6</sub>) δ 14.01 (s, br, 1H, NH), 11.13 (s, br, 1H, NH), 7.42-7.46 (m, 3H), 7.27-7.34 (m, 4H), 7.12 (s, 1H), 6.84 (dd, *J* = 2.2 & 8.3 Hz, 1H), 3.99-4.03 (m, 2H, OCH<sub>2</sub>CH<sub>3</sub>), 2.61 (s, 3H, CH<sub>3</sub>), 0.98-1.03 (m, 3H, OCH<sub>2</sub>CH<sub>3</sub>).

MS-EI *m/z* 450 and 452 [*M*<sup>+</sup> -1 and *M*<sup>+</sup>+1].

#### Example 47

5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2-methyl-4-phenyl-1H-pyrrole-3-carboxylic acid (3-diethylaminopropyl)amide

5-bromo-1,3-dihydroindol-2-one (0.47 g, 2.2 mmol) was condensed with 5-formyl-2-methyl-4-phenyl-1H-pyrrole-3-carboxylic acid (3-diethylaminopropyl)amide (0.75 g) to give 0.11 g (42%) of the title compound as an orange solid.

<sup>1</sup>HNMR (300 MHz, DMSO-d<sub>6</sub>) δ 13.86 (s, br, 1H, NH), 7.42-7.46 (m, 3H), 7.37-7.50 (m, 7H), 7.24-7.28 (m, 2H), 6.83 (d, *J* = 8.1 Hz, 1H), 3.09 (m, 2H, NCH<sub>2</sub>), 2.45 (s, 3H, CH<sub>3</sub>), 2.38 (q, *J* = 7.1 Hz, 4H, 2xNCH<sub>2</sub>CH<sub>3</sub>), 2.26 (t, *J* = 6.9 Hz, 2H, NCH<sub>2</sub>), 1.42 (m, 2H, NCH<sub>2</sub>), 0.87 (t, *J* = 7.1 Hz, 6H, 2xNCH<sub>2</sub>CH<sub>3</sub>).

MS-EI *m/z* 535.0 and 537 [*M*<sup>+</sup> and *M*<sup>+</sup>+2].

#### Example 48

5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-dimethylaminoethyl)amide

A mixture of *tert*-butyl 3-oxobutyrate and sodium nitrite (1 equiv.) in acetic acid was stirred at room temperature to give *tert*-butyl-2-hydroximino-3-oxobutyrate.

Ethyl-3-oxobutyrate (1 equiv.), zinc dust (3.8 equiv.) and the crude *tert*-butyl-2-hydroximino-3-oxobutyrate in acetic acid was stirred at 60° C for 1 hr. The reaction

mixture was poured into H<sub>2</sub>O and the filtrate was collected to give (65%) 2-*tert*-butyloxycarbonyl-3,5-dimethyl-4-ethoxycarbonylpyrrole.

A mixture of 2-*tert*-butyloxycarbonyl-3,5-dimethyl-4-ethoxycarbonylpyrrole and triethyl orthoformate (1.5 equiv.) in trifluoroacetic acid was stirred at 15°C for 1 hour. The reaction was concentrated and the residue was purified to give (64%) 2,4-dimethyl-3-ethoxycarbonyl-5-formylpyrrole as yellow needles.

2,4-Dimethyl-3-ethoxycarbonyl-5-formylpyrrole was hydrolyzed using method B to give (90%) 5-formyl-2,4-dimethyl-1*H*-pyrrole-3-carboxylic acid.

<sup>1</sup>H NMR ( 360 MHz, DMSO-d<sub>6</sub> ) δ 12 (br s, 2H, NH and CO<sub>2</sub>H), 9.58 (s, 1H, CHO), 2.44 (s, 3H, CH<sub>3</sub>), 2.40 (s, 3H, CH<sub>3</sub>).

MS *m/z* 267 [M<sup>+</sup>].

5-Bromo-1,3-dihydroindol-2-one (0.17 g, 0.8 mmol) was condensed with 5-formyl-2,4-dimethyl-1*H*-pyrrole-3-carboxylic acid (2-dimethylaminoethyl)amide (0.2 g, prepared by method C) using method B to give 0.3 g (83%) of the title compound as a yellow solid.

<sup>1</sup>H NMR (360 MHz, DMSO-d<sub>6</sub>) δ 13.60 (s, br, 1H, NH), 10.94 (s, br, 1H, NH), 8.07 (d, *J* = 1.8 Hz, 1H, H-4), 7.75 (s, 1H, H-vinyl), 7.44 (t, *J* = 5.2 Hz, 1H, CONHCH<sub>2</sub>), 7.24 (dd, *J* = 1.8 & 8.4 Hz, 1H, H-6), 6.82 (d, *J* = 8.4 Hz, 1H, H-7), 3.26-3.33 (m, 2H, NCH<sub>2</sub>), 2.42 (s, 3H, CH<sub>3</sub>), 2.41 (s, 3H, CH<sub>3</sub>), 2.38 (t, *J* = 6.7 Hz, 2H, NCH<sub>2</sub>), 2.18 (s, 6H, N(CH<sub>3</sub>)<sub>2</sub>).

MS-EI *m/z* 430 and 432 [M<sup>+</sup>-1 and M<sup>+</sup>+1].

#### Example 49

2,4-Dimethyl-5-(2-oxo-6-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1*H*-pyrrole-3-carboxylic acid (2-dimethylaminoethyl)amide

6-Phenyl-1,3-dihydroindol-2-one (0.17 g, 0.8 mmol) was condensed with 5-formyl-2,4-dimethyl-1*H*-pyrrole-3-carboxylic acid (2-dimethylaminoethyl)amide (0.2 g) to give 0.13 g (36%) of the title compound as a yellow-orange solid.

<sup>1</sup>H NMR (360 MHz, DMSO-d<sub>6</sub>) δ 13.59 (s, br, 1H, NH), 10.93 (,

br, 1H, NH), 7.85 (d,  $J = 7.92$  Hz, 1H, H-4), 7.63-7.65 (m, 3H), 7.40-7.47 (m, 3H), 7.32-7.36 (m, 1H, Ar-H), 7.30 (dd,  $J = 1.6$  & 7.9 Hz, 1H, H-5), 7.11 (d,  $J = 1.6$  Hz, 1H, H-7), 3.28-3.34 (m, 2H, NCH<sub>2</sub>), 2.43 (s, 3H, CH<sub>3</sub>), 2.41 (s, 3H, CH<sub>3</sub>), 2.38 (t,  $J = 6.8$  Hz, 2H, NCH<sub>2</sub>), 2.18 (s, 6H, N(CH<sub>3</sub>)<sub>2</sub>).

MS-EI  $m/z$  428 [M<sup>+</sup>].

#### Example 50

5-(5-Chloro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-dimethylaminoethyl)amide

5-Chloro-1,3-dihydroindol-2-one (0.1 g, 0.6 mmol) was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-dimethylaminoethyl)amide (0.15 g) to give 0.22 g (90%) of the title compound as a yellow solid.

<sup>1</sup>HNMR (300 MHz, DMSO-d<sub>6</sub>)  $\delta$  13.61 (s, br, 1H, NH), 10.98 (, br, 1H, NH), 7.96 (d,  $J = 2.0$  Hz, 1H, H-4), 7.75 (s, 1H, H-vinyl), 7.50 (t,  $J = 5.5$  Hz, 1H, CONHCH<sub>2</sub>), 7.12 (dd,  $J = 2.0$  & 8.3 Hz, 1H, H-6), 6.86 (d,  $J = 8.3$  Hz, 1H, H-7), 3.26-3.31 (m, 2H, NCH<sub>2</sub>), 2.42 (s, 3H, CH<sub>3</sub>), 2.40 (s, 3H, CH<sub>3</sub>), 2.36 (t,  $J = 6.6$  Hz, 2H, NCH<sub>2</sub>), 2.17 (s, 6H, N(CH<sub>3</sub>)<sub>2</sub>).

MS-EI  $m/z$  386 [M<sup>+</sup>].

#### Example 51

5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide

5-Bromo-1,3-dihydroindol-2-one (0.17 g, 0.8 mmol) was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide (0.2 g) to give 0.09 g (26%) of the title compound as a yellow solid.

<sup>1</sup>HNMR (360 MHz, DMSO-d<sub>6</sub>)  $\delta$  13.61 (s, br, 1H, NH), 10.98 (, br, 1H, NH), 8.09 (d,  $J = 1.7$  Hz, 1H, H-4), 7.76 (s, 1H, H-vinyl), 7.42 (t,  $J = 5.5$  Hz, 1H, CONHCH<sub>2</sub>), 7.24 (dd,  $J = 1.7$  & 8.0 Hz, 1H, H-6), 6.82 (d,  $J = 8.0$  Hz, 1H, H-7), 3.23-3.32 (m, 2H, NCH<sub>2</sub>), 2.46-2.55 (m, 6H, 3xNCH<sub>2</sub>), 2.43 (s, 3H, CH<sub>3</sub>), 2.42 (s, 3H, CH<sub>3</sub>), 0.96 (t,  $J = 7.2$  Hz, 6H, 2xNCH<sub>2</sub>CH<sub>3</sub>).

MS-EI  $m/z$  458 and 460 [ $M^+-1$  and  $M^++1$ ].

**Example 52**

5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-  
dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-  
5 ethyl)amide

5-Bromo-1,3-dihydroindol-2-one (0.09 g, 0.4 mmol) was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-ylethyl)amide (0.1 g) to give 0.14 g (81%) of the title compound as a yellow-orange solid.

10  $^1\text{H}$ NMR (300 MHz, DMSO- $d_6$ )  $\delta$  13.61 (s, br, 1H, NH), 10.98 (, br, 1H, NH), 8.09 (d,  $J$  = 1.9 Hz, 1H, H-4), 7.76 (s, 1H, H-vinyl), 7.53 (t,  $J$  = 5.5 Hz, 1H, CONHCH<sub>2</sub>), 7.24 (dd,  $J$  = 1.9 & 8.5 Hz, 1H, H-6), 6.81 (d,  $J$  = 8.5 Hz, 1H, H-7), 3.29-3.35 (m, 2H, NCH<sub>2</sub>), 2.54 (t,  $J$  = 6.9 Hz, 2H, NCH<sub>2</sub>), 2.47 (m, under  
5 DMSO), 2.42 (s, 3H, CH<sub>3</sub>), 2.40 (s, 3H, CH<sub>3</sub>), 1.66-1.69 (m, 4H, 2xCH<sub>2</sub>).

MS-EI  $m/z$  456 and 458 [ $M^+-1$  and  $M^++1$ ].

### Example 53

5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (3-imidazol-1-ylpropyl)amide

5-Bromo-1,3-dihydroindol-2-one (0.09 g, 0.4 mmol) was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (3-imidazol-1-ylpropyl)amide (0.1 g) to give 0.1 g (59%) of the title compound as an orange solid.

<sup>1</sup>HNMR (300 MHz, DMSO-d<sub>6</sub>) δ 13.63 (s, br, 1H, NH), 10.99 (s, br, 1H, NH), 8.09 (d, *J* = 2.2 Hz, 1H, H-4), 7.77 (s, 1H, H-vinyl), 7.71 (t, *J* = 5.7 Hz, 1H, CONHCH<sub>2</sub>), 7.65 (s, 1H, Ar-H), 7.25 (dd, *J* = 2.2 & 8.4 Hz, 1H, H-6), 7.20 (s, 1H, Ar-H), 6.89 (s, 1H, Ar-H), 6.81 (d, *J* = 8.4 Hz, 1H, H-7), 4.02 (t, *J* = 6.7 Hz, 2H, NCH<sub>2</sub>), 3.18 (q, *J* = 6.7 Hz, 2H, NCH<sub>2</sub>), 2.43 (s, 3H, CH<sub>3</sub>), 2.41 (s, 3H, CH<sub>3</sub>), 1.93 (m, 2H, CH<sub>2</sub>).

MS-EI *m/z* 467 and 469 [*M*<sup>+</sup>-1 and *M*<sup>+</sup>+1].

### Example 54

5-[6-(2-Methoxyphenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-dimethylaminoethyl)amide

6-(2-Methoxyphenyl)-1,3-dihydroindol-2-one (30 mg, 0.13 mmol) was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-dimethylaminoethyl)amide (30 mg) to give 0.06 g (100%) of the title compound as a yellow-orange gum.

<sup>1</sup>HNMR (300 MHz, DMSO-d<sub>6</sub>) δ 13.60 (s, br, 1H, NH), 10.89 (s, br, 1H, NH), 7.79 (d, *J* = 8.4 Hz, 1H), 7.63 (s, 1H, H-vinyl), 7.46 (t, *J* = 5.5 Hz, 1H, CONHCH<sub>2</sub>), 7.28-7.35 (m, 2H), 6.99-7.11 (m, 4H), 3.76 (s, 3H, OCH<sub>3</sub>), 3.27-3.31 (m, 2H, NCH<sub>2</sub>), 2.43 (s, 3H, CH<sub>3</sub>), 2.39 (s, 3H, CH<sub>3</sub>), 2.37 (m, 2H, NCH<sub>2</sub>), 2.18 (s, 6H, N(CH<sub>3</sub>)<sub>2</sub>).

MS-EI *m/z* 458 [*M*<sup>+</sup>].

### Example 55

5-[6-(3-Methoxyphenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-dimethylaminoethyl)amide

5        6-(3-Methoxyphenyl)-1,3-dihydroindol-2-one (30 mg, 0.13 mmol) was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-dimethylaminoethyl)amide (30 mg) to give 8 mg (14%) of the title compound as a yellow-orange solid.

10        <sup>1</sup>HNMR (360 MHz, DMSO-d<sub>6</sub>) δ 13.59 (s, br, 1H, NH), 10.92 (s, br, 1H, NH), 7.84 (d, *J* = 7.6 Hz, 1H), 7.65 (s, 1H, H-vinyl), 7.42 (m, 1H, CONHCH<sub>2</sub>), 7.36 (d, *J* = 7.8 Hz, 1H), 7.29 (dd, *J* = 1.6 & 7.6 Hz, 1H), 7.20 (d, *J* = 7.8 Hz, 1H), 7.14 (d, *J* = 2.8 Hz, 1H), 7.11 (d, *J* = 1.6 Hz, 1H), 6.91 (dd, *J* = 2.8 & 7.8 Hz, 1H), 3.82 (s, 3H, OCH<sub>3</sub>), 3.21-3.33 (m, 2H, NCH<sub>2</sub>), 2.43 (s, 3H, CH<sub>3</sub>), 2.40 (s, 3H, CH<sub>3</sub>), 2.36-2.40 (m, 2H, NCH<sub>2</sub>), 2.18 (s, 6H, N(CH<sub>3</sub>)<sub>2</sub>).

MS-EI *m/z* 458 [M<sup>+</sup>].

### Example 56

20        2,4-Dimethyl-5-(2-oxo-5-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide

25        5-Phenyl-1,3-dihydroindol-2-one (80 mg, 0.4 mmol) was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide (0.1 g) using method B to give 79 mg (46%) of the title compound.

30        <sup>1</sup>HNMR (300 MHz, DMSO-d<sub>6</sub>) δ 13.66 (s, br, 1H, NH), 10.95 (s, br, 1H, NH), 8.15 (d, *J* = 1.2 Hz, 1H), 7.81 (s, 1H, H-vinyl), 7.71 (d, *J* = 7.5 Hz, 1H), 7.40-7.47 (m, 4H), 7.31 (m, 1H), 6.95 (d, *J* = 8.1 Hz, 1H), 3.2-3.31 (m, 2H, NCH<sub>2</sub>), 2.46-2.55 (m, 6H, 3xNCH<sub>2</sub>), 2.44 (s, 6H, 2xCH<sub>3</sub>), 0.96 (t, *J* = 7.4 Hz, 6H, 2xNCH<sub>2</sub>CH<sub>3</sub>).

MS-EI *m/z* 456 [M<sup>+</sup>].

### Example 57

2,4-Dimethyl-5-(2-oxo-5-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-ylethyl)amide

5-Phenyl-1,3-dihydroindol-2-one (0.04 g, 0.2 mmol) was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-ylethyl)amide (0.04 g) to give the title compound as a yellow-orange solid.

<sup>1</sup>HNMR (300 MHz, DMSO-d<sub>6</sub>) δ 13.65 (s, br, 1H, NH), 10.96 (, br, 1H, NH), 8.15 (d, *J* = 1.0 Hz, 1H), 7.80 (s, 1H, H-vinyl), 7.71 (d, *J* = 7.2 Hz, 2H), 7.49 (t, *J* = 6.3 Hz, 1H, CONHCH<sub>2</sub>), 7.41-7.46 (m, 3H), 7.31 (m, 1H), 6.95 (d, *J* = 7.8 Hz, 1H), 4.08 (m, 4H, 2x NCH<sub>2</sub>), 3.32 (m, 2H, NCH<sub>2</sub>), 2.55 (t, *J* = 7.1 Hz, 2H, NCH<sub>2</sub>), 2.47 (m, under DMSO), 2.43 (s, 6H, 2xCH<sub>3</sub>), 1.66 (m, 4H, 2xCH<sub>2</sub>).

MS-EI *m/z* 454 [M<sup>+</sup>].

### Example 58

2,4-Dimethyl-5-(2-oxo-5-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (3-imidazol-1-ylpropyl)amide

5-Phenyl-1,3-dihydroindol-2-one (8 mg, 0.04 mmol) was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (3-imidazol-1-ylpropyl)amide (10 mg) to give 10 mg (59%) of the title compound as an orange solid.

<sup>1</sup>HNMR (300 MHz, DMSO-d<sub>6</sub>) δ 13.67 (s, br, 1H, NH), 10.96 (, br, 1H, NH), 8.16 (d, *J* = 1.2 Hz, 1H), 7.81 (s, 1H, H-vinyl), 7.65-7.72 (m, 4H), 7.44 (m, 3H), 7.31 (m, 1H, CONHCH<sub>2</sub>), 7.21 (s, 1H, Ar-H), 4.02 (t, *J* = 6.5 Hz, 2H, NCH<sub>2</sub>), 3.19 (q, *J* = 6.5 Hz, 2H, CONHCH<sub>2</sub>), 2.44 (s, 6H, 2xCH<sub>3</sub>), 1.93 (m, 2H, CH<sub>2</sub>CH<sub>2</sub> CH<sub>2</sub>).

MS-EI *m/z* 465 [M<sup>+</sup>].



### Example 59

2,4-Dimethyl-5-(2-oxo-6-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide

5        6-Phenyl-1,3-dihydroindol-2-one (0.08 g, 0.4 mmol) was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide (0.1 g) to give 65 mg (38%) of the title compound as a yellow solid.

10        <sup>1</sup>HNMR (300 MHz, DMSO-d<sub>6</sub>) δ 13.61 (s, br, 1H, NH), 10.99 (, br, 1H, NH), 7.86 (d, *J* = 7.8 Hz, 1H), 7.62-7.66 (m, 3H), 7.40-7.47 (m, 3H), 7.28-7.36 (m, 2H), 7.10 (d, *J* = 1.2 Hz, 1H), 3.26 (m, 2H, NCH<sub>2</sub>), 2.46-2.55 (m, 6H, 3xNCH<sub>2</sub>), 2.44 (s, 3H, CH<sub>3</sub>), 2.41 (s, 3H, CH<sub>3</sub>), 0.97 (t, *J* = 7.2 Hz, 6H, 2xNCH<sub>2</sub>CH<sub>3</sub>).

15        MS-EI *m/z* 456 [M<sup>+</sup>].

### Example 60

2,4-Dimethyl-5-(2-oxo-6-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-ylethyl)amide

20        6-Phenyl-1,3-dihydroindol-2-one (30 mg, 0.15 mmol) was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-ylethyl)amide (40 mg) to give 5.9 mg (8.5%) of the title compound as a yellow-orange solid.

25        <sup>1</sup>HNMR (300 MHz, DMSO-d<sub>6</sub>) δ 13.60 (s, br, 1H, NH), 10.99 (, br, 1H, NH), 7.86 (d, *J* = 7.8 Hz, 1H), 7.63-7.66 (m, 3H), 7.51 (m, 1H, CONHCH<sub>2</sub>), 7.45 (m, 2H), 7.28-7.36 (m, 2H), 7.10 (d, *J* = 1.5 Hz, 1H), 3.31 (m, 6H, 3xNCH<sub>2</sub>), 2.55 (t, *J* = 6.6 Hz, 2H, NCH<sub>2</sub>), 2.43 (s, 3H, CH<sub>3</sub>), 2.40 (s, 3H, CH<sub>3</sub>), 1.67 (m, 4H, 2xCH<sub>2</sub>).

30        MS-EI *m/z* 454 [M<sup>+</sup>].

### Example 61

2,4-Dimethyl-5-(2-oxo-6-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (3-imidazol-1-ylpropyl)amide

6-Phenyl-1,3-dihydroindol-2-one (8 mg, 0.04 mmol) was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (3-imidazol-1-ylpropyl)amide (10 mg) to give 7.3 mg (43%) of the title compound as an orange solid.

<sup>1</sup>HNMR (300 MHz, DMSO-d<sub>6</sub>) δ 13.62 (s, br, 1H, NH), 10.99 (s, br, 1H, NH), 7.86 (d, *J* = 8.2 Hz, 1H), 7.62-7.70 (m, 5H), 7.45 (m, 2H), 7.35 (m, 1H), 7.30 (dd, *J* = 1.4 & 8.2 Hz, 1H), 7.21 (s, 1H), 7.10 (d, *J* = 1.4 Hz, 1H), 6.89 (s, 1H), 4.02 (t, *J* = 6.9 Hz, 2H, CH<sub>2</sub>), 3.19 (m, 2H, NCH<sub>2</sub> CH<sub>2</sub>), 2.43 (s, 3H, CH<sub>3</sub>), 2.41 (s, 3H, CH<sub>3</sub>), 1.93 (t, *J* = 6.9 Hz, 2H, NCH<sub>2</sub>).

MS-EI *m/z* 465 [M<sup>+</sup>].

### Example 62

5-[6-(3,5-Dichlorophenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide

6-(3,5-Dichlorophenyl)-1,3-dihydroindol-2-one (64 mg, 0.23 mmol) was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide (60 mg) to give 53 mg (44%) of the title compound as a light brown solid.

<sup>1</sup>HNMR (360 MHz, DMSO-d<sub>6</sub>) δ 13.62 (s, br, 1H, NH), 10.99 (s, 1H, NH), 7.89 (d, *J* = 7.9 Hz, 1H, H-4), 7.69-7.71 (m, 3H), 7.55 (m, 1H, CONHCH<sub>2</sub>), 7.37 (m, 2H), 7.14 (d, *J* = 1.4 Hz, 1H, H-7), 3.27 (m, 2H, NCH<sub>2</sub>), 2.48-2.58 (m, 6H, 3xNCH<sub>2</sub>), 2.45 (s, 3H, CH<sub>3</sub>), 2.42 (s, 3H, CH<sub>3</sub>), 0.97 (t, *J* = 6.8 Hz, 6H, 3xNCH<sub>2</sub>CH<sub>3</sub>).

MS *m/z* 526.9 [M<sup>+</sup>+1].

### Example 63

2,4-Dimethyl-5-(2-oxo-6-pyridin-3-yl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide

5        6-Pyridin-3-yl-1,3-dihydroindol-2-one (40 mg, 0.19 mmol) was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide (50 mg) give 29 mg (33%) of the title compound as a light orange solid.

<sup>1</sup>HNMR (300 MHz, DMSO-d<sub>6</sub>) δ 13.62 (s, br, 1H, NH), 11.05  
10 (s, br, 1H, NH), 8.86 (s, br, 1H), 8.53 (d, J = 5.8 Hz, 1H), 8.04 (m, 1H), 7.91 (d, J = 8.1 Hz, 1H), 7.70 (s, 1H, H-vinyl), 7.40-7.48 (m, 2H), 7.35 (d, J = 7.5 Hz, 1H), 7.14 (s, 1H), 3.26 (m, 2H, NCH<sub>2</sub>), 2.48-2.55 (m, 3xNCH<sub>2</sub>), 2.42 (s, 3H, CH<sub>3</sub>), 2.38 (s, 3H, CH<sub>3</sub>), 0.96 (t, J = 6.9 Hz, 6H, 2xNCH<sub>2</sub>CH<sub>3</sub>).

5        MS-EI m/z 457 [M<sup>+</sup>].

### Example 64

2,4-Dimethyl-5-(2-oxo-6-pyridin-3-yl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-ylethyl)amide

20        6-Pyridin-3-yl-1,3-dihydroindol-2-one (60 mg, 0.28 mmol) was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-ylethyl)amide (75 mg) to give 90 mg (71%) of the title compound as a light orange solid.

<sup>1</sup>HNMR (300 MHz, DMSO-d<sub>6</sub>) δ 13.61 (s, br, 1H, NH), 11.05  
25 (s, br, 1H, NH), 8.86 (d, J = 1.5 Hz, 1H), 8.54 (dd, J = 1.5 & 4.8 Hz, 1H), 8.05 (m, 1H), 7.91 (d, J = 7.8 Hz, 1H), 7.70 (s, 1H, H-vinyl), 7.44-7.53 (m, 2H), 7.36 (dd, J = 1.5 & 8.1 Hz, 1H), 7.15 (d, J = 1.2 Hz, 1H), 3.33 (m, 2H, NCH<sub>2</sub>), 2.47-2.57 (m, 6H, 3xNCH<sub>2</sub>), 2.43 (s, 3H, CH<sub>3</sub>), 2.41 (s, 3H, CH<sub>3</sub>), 1.67 (m,  
30 4H, 2xCH<sub>2</sub>).

MS-EI m/z 455 [M<sup>+</sup>].

### Example 65

2,4-Dimethyl-5-(2-oxo-6-pyridin-3-yl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (3-dimethylaminopropyl)amide

5 6-Pyridin-3-yl-1,3-dihydroindol-2-one (42 mg, 0.2 mmol) was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (3-dimethylaminopropyl)amide (50 mg) to give 67 mg (75%) of the title compound as yellow-brown solid.

<sup>1</sup>HNMR (360 MHz, DMSO-d<sub>6</sub>) δ 13.61 (s, br, 1H, NH), 11.00 (s, br, 1H, NH), 8.86 (s, br, 1H), 8.54 (s, br, 1H), 8.04 (m, 1H), 7.90 (d, J = 8.0 Hz, 1H), 7.69 (s, 1H, H-vinyl), 7.63 (m, 1H), 7.45-7.48 (m, 1H), 7.35 (dd, J = 1.7 & 8.0 Hz, 1H), 7.15 (d, J = 1.7 Hz, 1H), 3.21-3.27 (m, 2H, NCH<sub>2</sub>), 2.43 (s, 3H, CH<sub>3</sub>), 2.41 (s, 3H, CH<sub>3</sub>), 2.28 (m, 2H, NCH<sub>2</sub>), 2.14 (s, 6H, 2xNCH<sub>3</sub>), 1.64 (m, 2H, CH<sub>2</sub>).

MS-EI m/z 443 [M<sup>+</sup>].

### Example 66

2,4-Dimethyl-5-(2-oxo-5-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (3-dimethylaminopropyl)amide

5-Phenyl-1,3-dihydroindol-2-one (67 mg, 0.32 mmol) was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (3-dimethylaminopropyl)amide (81 mg) to give 40 mg (28%) of the title compound as an orange solid.

<sup>1</sup>HNMR (360 MHz, DMSO-d<sub>6</sub>) δ 13.66 (s, br, 1H, NH), 10.92 (s, br, 1H, NH), 8.14 (s, 1H), 7.79 (s, 1H), 7.71 (m, 2H), 7.62 (m, 1H), 7.44 (m, 3H), 7.32 (m, 1H), 6.95 (m, 1H), 3.33 (m, 2H, NCH<sub>2</sub>), 2.43 (s, 6H, 2xCH<sub>3</sub>), 2.27 (m, 2H, NCH<sub>2</sub>), 2.13 (s, 6H, 2xNCH<sub>3</sub>), 1.63 (m, 2H, CH<sub>2</sub>).

MS-EI m/z 442 [M<sup>+</sup>].

### Example 67

2,4-Dimethyl-5-(2-oxo-5-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (3-diethylaminopropyl)amide

5-Phenyl-1,3-dihydroindol-2-one (1.5 g, 7.16 mmol) was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (3-diethylaminopropyl)amide (2 g) to give 1.3 g (40%) of the title compound as a yellow-orange solid.

<sup>1</sup>HNMR (360 MHz, DMSO-d<sub>6</sub>) δ 13.64 (s, 1H, NH), 10.91 (s, 1H, NH), 8.14 (d, *J* = 1.4 Hz, 1H, ArH), 7.8 (s, 1H, ArH), 7.7 (dd, *J* = 1.2 and 8.5 Hz, 2H, ArH), 7.6 (t, *J* = 5.3 Hz, 1H, CONHCH<sub>2</sub>), 7.4 (m, 3H, ArH), 7.3 (t, *J* = 7.4 Hz, 1H, ArH), 6.9 (d, *J* = 8.0 Hz, 1H, ArH), 3.2 (m, 2H, CONHCH<sub>2</sub>), 2.5 (m, 12H, 3xNCH<sub>2</sub> and 2xCH<sub>3</sub>), 1.61 (m, 2H, CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>), 0.93 (t, *J* = 6.7 Hz, 6H, NCH<sub>2</sub>CH<sub>3</sub>).

MS-EI *m/z* 470 [M<sup>+</sup>].

### Example 68

2,4-Dimethyl-5-(2-oxo-6-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (3-diethylaminopropyl)amide

6-Phenyl-1,3-dihydroindol-2-one (1.5 g, 7.16 mmol) was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (3-diethylaminopropyl)amide (2 g) to give 1.9 g (57%) of the title compound as an orange solid.

<sup>1</sup>HNMR (360 MHz, DMSO-d<sub>6</sub>) δ 13.58 (s, 1H, NH), 10.94 (s, 1H, NH), 7.8 (d, *J* = 7.9 Hz, 1H, ArH), 7.6 (m, 4H, ArH), 7.4 (t, *J* = 7.5 Hz, 2H, ArH), 7.3 (m, 2H), 7.1 (d, *J* = 1.4 Hz, 1H, ArH), 3.2 (m, 2H, CONHCH<sub>2</sub>), 2.5 (m, 12H, 3xNCH<sub>2</sub> and 2xCH<sub>3</sub>), 1.61 (m, 2H, CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>), 0.93 (t, *J* = 6.7 Hz, 6H, NCH<sub>2</sub>CH<sub>3</sub>).

MS-EI *m/z* 470 [M<sup>+</sup>].

### Example 69

3-[4-(3-Diethylaminopropylcarbamoyl)-3,5-dimethyl-1H-pyrrol-2-ylmethylene]-2-oxo-2,3-dihydro-1H-indole-4-carboxylic acid (3-chloro-4-methoxyphenyl)amide

2-Oxo-2,3-dihydro-1H-indole-4-carboxylic acid (3-chloro-4-methoxyphenyl)amide (1 g, 3.16 mmol) was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (3-diethylaminopropyl)amide (1 g, 3.58 mmol) to give 1.7 g (85%) of the title compound as a yellow-orange solid.

MS-EI  $m/z$  578.2 [ $M^+$ ].

### Example 70

5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (3-diethylaminopropyl)amide

5-Bromo-1,3-dihydroindol-2-one (0.5 g, 2.36 mmol) was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (3-diethylaminopropyl)amide (0.51 g) to give 0.84 g of the title compound as a red-orange solid.

$^1\text{H}$ NMR (360 MHz, DMSO- $d_6$ )  $\delta$  13.61 (s, 1H, NH), 10.99 (s, 1H, NH), 8.09 (d,  $J$  = 1.8 Hz, 1H, ArH), 7.7 (m, 4H), 7.2 (dd,  $J$  = 1.8 and 8.3 Hz, 2H, ArH), 6.8 (d,  $J$  = 7.8 Hz, 1H, ArH), 3.3 (br s, 4H, 2xNCH<sub>2</sub>), 3.2 (m, 2H, CONHCH<sub>2</sub>), 2.6 (br s, 2H, NCH<sub>2</sub> and 2xCH<sub>3</sub>), 2.4 (s, 6H, 2xCH<sub>3</sub>), 1.66 (m, 2H, CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>), 0.98 (t,  $J$  = 7.1 Hz, 6H, NCH<sub>2</sub>CH<sub>3</sub>).

MS-EI  $m/z$  472 and 474 [ $M^+ - 1$  and  $M^+ + 1$ ].

### Example 71

5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-diisopropyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide

5-Bromo-1,3-dihydroindol-2-one (100 mg, 0.47 mmol) was condensed with 5-formyl-2,4-diisopropyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide (150 mg) to give 0.15 g (62%) of the title compound as a yellow-orange solid.

<sup>1</sup>HNMR (300 MHz, DMSO-d<sub>6</sub>) δ 13.97 (s, 1H, NH), 10.95 (s, 1H, NH), 8.09 (d, *J* = 1.3 Hz, 1H, ArH), 7.84 (m, 1H), 7.79 (s, 1H), 7.23 (dd, *J* = 1.3 and 8.1 Hz, 1H, ArH), 6.8 (d, *J* = 8.1 Hz, 1H, ArH), 3.5 (m, 1H, CH), 3.3 (m, 3H, CH and NHCH<sub>2</sub>), 2.5 (br m, 6H, 3xNCH<sub>2</sub>), 1.28 (d, *J* = 6.9 Hz, 6H, 2xCH<sub>3</sub>), 1.23 (d, *J* = 6.6 Hz, 6H, 2xCH<sub>3</sub>), 0.96 (m, 6H, 2xCH<sub>2</sub>CH<sub>3</sub>).

MS-EI *m/z* 514 and 516 [*M*<sup>+</sup>-1 and *M*<sup>+</sup>+1].

### Example 72

5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-diisopropyl-1H-pyrrole-3-carboxylic acid (3-diethylaminopropyl)amide

5-Bromo-1,3-dihydroindol-2-one (90 mg, 0.42 mmol) was condensed with 5-formyl-2,4-diisopropyl-1H-pyrrole-3-carboxylic acid (3-diethylaminopropyl)amide (140 mg) to give 54 mg (25%) of the title compound as red-brown solid.

<sup>1</sup>HNMR (300 MHz, DMSO-d<sub>6</sub>) δ 13.98 (s, 1H, NH), 10.96 (s, 1H, NH), 8.09 (d, *J* = 1.7 Hz, 2H), 7.78 (s, 1H, H-vinyl), 7.23 (dd, *J* = 1.7 and 8.1 Hz, 1H, ArH), 6.82 (d, *J* = 8.1 Hz, 1H, ArH), 3.5 (m, 1H, CH), 3.25 (m, 2H, NHCH<sub>2</sub>), 3.15 (m, 1H, CH), 2.7 (br s, 6H, 3xNCH<sub>2</sub>), 1.7 (br m, 2H, CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>), 1.28 (d, *J* = 6.9 Hz, 6H, 2xCH<sub>3</sub>), 1.24 (d, *J* = 5.9 Hz, 6H, 2xCH<sub>3</sub>), 1.06 (m, 6H, 2xCH<sub>2</sub>CH<sub>3</sub>).

MS-EI *m/z* 528 and 530 [*M*<sup>+</sup>-1 and *M*<sup>+</sup>+1].

### Example 73

5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-diisopropyl-1H-pyrrole-3-carboxylic acid (3-pyrrolidin-1-ylpropyl)amide

5-Bromo-1,3-dihydroindol-2-one (130 mg, 0.6 mmol) was condensed with 5-formyl-2,4-diisopropyl-1H-pyrrole-3-carboxylic acid (3-pyrrolidin-1-ylpropyl)amide (150 mg, 0.45 mmol) to give 36 mg (15%) of the title compound as a tan-orange solid.

<sup>1</sup>HNMR (300 MHz, DMSO-d<sub>6</sub>) δ 13.98 (s, 1H, NH), 10.97 (s, 1H, NH), 8.10 (d, *J* = 1.6 Hz, 2H), 7.78 (s, 1H, H-vinyl), 7.23 (dd, *J* = 1.6 and 7.6 Hz, 1H, ArH), 6.82 (d, *J* = 7.6 Hz, 1H, ArH), 3.5 (m, 1H, CH), 3.25 (m, 2H, NHCH<sub>2</sub>), 3.15 (m, 1H, CH), 2.7 (br s, 6H, 3xNCH<sub>2</sub>), 1.7 (br m, 6H, 3xNCH<sub>2</sub>CH<sub>2</sub>), 1.28 (d, *J* = 5.6 Hz, 6H, 2xCH<sub>3</sub>), 1.24 (d, *J* = 5.7 Hz, 6H, 2xCH<sub>3</sub>).

MS-EI *m/z* 526 and 528 [*M*<sup>+</sup>-1 and *M*<sup>+</sup>+1].

### Example 74

5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (pyridin-4-ylmethyl)-amide

5-Bromo-1,3-dihydroindol-2-one (170 mg, 0.8 mmol) was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (pyridin-4-ylmethyl)amide (200 mg) to give 14 mg (4%) of the title compound as a yellow solid.

<sup>1</sup>HNMR (300 MHz, DMSO-d<sub>6</sub>) δ 13.67 (s, 1H, NH), 11.01 (s, br, 1H, NH), 8.51 (dd, *J* = 1.6 & 4.3 Hz, 2H), 8.23 (t, *J* = 6.0 Hz, 1H, CONHCH<sub>2</sub>), 8.11 (d, *J* = 1.9 Hz, 1H), 7.78 (s, 1H, H-vinyl), 7.31 (d, *J* = 6.0 Hz, 2H), 7.25 (dd, *J* = 1.9 & 8.1 Hz, 1H), 6.82 (d, *J* = 8.1 Hz, 1H), 4.45 (d, *J* = 6.0 Hz, 2H, NCH<sub>2</sub>), 2.46 (s, 6H, 2xCH<sub>3</sub>).

MS-EI *m/z* 450 and 452 [*M*<sup>+</sup>-1 and *M*<sup>+</sup>+1].



### Example 75

5-[6-(4-Butylphenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-ylethyl)amide

5-[6-(4-Butylphenyl)]-1,3-dihydroindol-2-one (50 mg, 0.19 mmol) was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-ylethyl)amide (50 mg) to give 74 mg (76%) of the title compound as an orange solid.

<sup>1</sup>HNMR (360 MHz, DMSO-d<sub>6</sub>) δ 13.58 (s, 1H, NH), 10.93 (s, br, 1H, NH), 7.82 (d, *J* = 7.9 Hz, 1H), 7.63 (s, 1H, H-vinyl), 7.54 (d, *J* = 7.9 Hz, 2H), 7.46 (m, 1H, CONH), 7.26 (m, 3H), 7.09 (s, 1H), 3.30 (m, 2H, CH<sub>2</sub>), 2.52-2.63 (m, 4H, 2xCH<sub>2</sub>), 2.49 (m, 4H, 2xCH<sub>2</sub>), 2.43 (s, 3H, CH<sub>3</sub>), 2.40 (s, 3H, CH<sub>3</sub>), 1.68 (m, 4H, 2xCH<sub>2</sub>), 1.58 (m, 2H, CH<sub>2</sub>), 1.34 (m, 2H, CH<sub>2</sub>), 0.91 (t, *J* = 7.2 Hz, 3H, CH<sub>2</sub>CH<sub>3</sub>).

MS-EI *m/z* 510 [M<sup>+</sup>].

### Example 76

5-[6-(5-Isopropyl-2-methoxyphenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-ylethyl)amide

6-(5-Isopropyl-2-methoxyphenyl)-1,3-dihydroindol-2-one (50 mg, 0.17 mmol) was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)amide (45 mg) to give 67 mg (75%) of the title compound as an orange solid.

<sup>1</sup>HNMR (360 MHz, DMSO-d<sub>6</sub>) δ 13.60 (s, 1H, NH), 10.82 (s, br, 1H, NH), 7.77 (d, *J* = 7.9 Hz, 1H), 7.61 (s, 1H, H-vinyl), 7.45 (m, 1H, CONH), 7.0-7.19 (m, 5H), 3.73 (s, 3H, OCH<sub>3</sub>), 3.32 (m, 2H, CH<sub>2</sub>), 2.87 (m, 1H, CH(CH<sub>3</sub>)<sub>2</sub>), 2.56 (m, 2H, CH<sub>2</sub>), 2.48 (m, 4H, 2xCH<sub>2</sub>), 2.43 (s, 3H, CH<sub>3</sub>), 2.40 (s, 3H, CH<sub>3</sub>), 1.68 (m, 4H, 2xCH<sub>2</sub>), 1.21 (d, *J* = 6.8 Hz, 6H, CH(CH<sub>3</sub>)<sub>2</sub>).

MS *m/z* 527.2 [M<sup>+</sup>+1].

### Example 77

5-[6-(4-Ethylphenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-ylethyl)amide

5        6-(4-Ethylphenyl)-1,3-dihydroindol-2-one (45 mg, 0.19 mmol) was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-ylethyl)amide (50 mg) to give 60 mg (65%) of the title compound as a yellow-orange solid.

10        <sup>1</sup>HNMR (300 MHz, DMSO-d<sub>6</sub>) δ 13.59 (s, 1H, NH), 10.96 (s, br, 1H, NH), 7.83 (d, *J* = 8.4 Hz, 1H), 7.64 (s, 1H, H-vinyl), 7.51-7.56 (m, 3H), 7.25-7.30 (m, 3H), 7.08 (d, *J* = 1 Hz, 1H), 3.31 (m, 2H, CH<sub>2</sub>), 2.63 (m, 2H, CH<sub>2</sub>CH<sub>3</sub>), 2.55 (m, 2H, CH<sub>2</sub>), 2.49 (m, 4H, 2xCH<sub>2</sub>), 2.42 (s, 3H, CH<sub>3</sub>), 2.40 (s, 3H, CH<sub>3</sub>), 1.67 (m, 4H, 2xCH<sub>2</sub>), 1.20 (t, *J* = 7.5 Hz, 3H, CH<sub>2</sub>CH<sub>3</sub>).

5        MS-EI *m/z* 482 [M<sup>+</sup>].

### Example 78

5-[6-(2,4-Dimethoxyphenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-ylethyl)amide

10        6-(2,4-Dimethoxyphenyl)-1,3-dihydroindol-2-one (51 mg, 0.19 mmol) was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-ylethyl)amide (50 mg) to give 30 mg (31%) of the title compound as an orange solid.

25        <sup>1</sup>HNMR (300 MHz, DMSO-d<sub>6</sub>) δ 13.59 (s, 1H, NH), 10.86 (s, br, 1H, NH), 7.75 (d, *J* = 7.8 Hz, 1H), 7.60 (s, 1H, H-vinyl), 7.49 (m, 1H, CONH), 7.22 (d, *J* = 8.4 Hz, 1H), 7.03 (m, 1H), 6.97 (s, 1H), 6.58-6.65 (m, 2H), 3.79 (s, 3H, OCH<sub>3</sub>), 3.76 (s, 3H, OCH<sub>3</sub>), 3.33 (m, 2H, CH<sub>2</sub>), 2.55 (m, 2H, CH<sub>2</sub>), 2.50 (m, 4H, 2xCH<sub>2</sub>), 2.42 (s, 3H, CH<sub>3</sub>), 2.39 (s, 3H, CH<sub>3</sub>), 1.67 (m, 4H, 2xCH<sub>2</sub>).

30        MS-EI *m/z* 514 [M<sup>+</sup>].

### Example 79

5-[6-(3-Isopropylphenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-ylethyl)amide

6-(3-Isopropylphenyl)-1,3-dihydroindol-2-one (48 mg, 0.19 mmol) was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-ylethyl)amide (50 mg) to give 59 mg (63%) of the title compound as an orange solid.

<sup>1</sup>HNMR (300 MHz, DMSO-d<sub>6</sub>) δ 13.63 (s, 1H, NH), 10.97 (s, br, 1H, NH), 7.87 (d, *J* = 7.8 Hz, 1H), 7.68 (s, 1H, H-vinyl), 7.24-7.55 (m, 6H), 7.13 (s, 1H), 3.34 (m, 2H, CH<sub>2</sub>), 3.30 (m, 1H, CH(CH<sub>3</sub>)<sub>2</sub>), 2.60 (m, 2H, CH<sub>2</sub>), 2.50 (m, 4H, 2xCH<sub>2</sub>), 2.45 (s, 3H, CH<sub>3</sub>), 2.43 (s, 3H, CH<sub>3</sub>), 1.70 (m, 4H, 2xCH<sub>2</sub>), 1.27 (d, *J* = 6.9 Hz, 6H, CH(CH<sub>3</sub>)<sub>2</sub>).

MS-EI *m/z* 496 [M<sup>+</sup>].

### Example 80

5-(5-Fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide

5-Fluoro-1,3-dihydroindol-2-one (0.54 g, 3.8 mmol) was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide to give 0.83 g (55%) of the title compound as a yellow green solid.

<sup>1</sup>HNMR (360 MHz, DMSO-d<sub>6</sub>) δ 13.66 (s, 1H, NH), 10.83 (s, br, 1H, NH), 7.73 (dd, *J* = 2.5 & 9.4 Hz, 1H), 7.69 (s, 1H, H-vinyl), 7.37 (t, 1H, CONHCH<sub>2</sub>CH<sub>2</sub>), 6.91 (m, 1H), 6.81-6.85 (m, 1H), 3.27 (m, 2H, CH<sub>2</sub>), 2.51 (m, 6H, 3xCH<sub>2</sub>), 2.43 (s, 3H, CH<sub>3</sub>), 2.41 (s, 3H, CH<sub>3</sub>), 0.96 (t, *J* = 6.9 Hz, 6H, N(CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>).

MS-EI *m/z* 398 [M<sup>+</sup>].

### Example 80 (Alternative synthesis)

5-[5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide

Hydrazine hydrate (55 %, 3000 mL) and 5-fluoroisatin (300 g) were heated to 100 °C. An additional 5-fluoro-isatin (500 g) was added in portions (100 g) over 120 minutes with stirring. The mixture was heated to 110 °C and stirred for 4 hours. The mixture was cooled to room temperature and the solids collected by vacuum filtration to give crude (2-amino-5-fluoro-phenyl)-acetic acid hydrazide (748 g). The hydrazide was suspended in water (700 mL) and the pH of the mixture adjusted to < pH 3 with 12 N hydrochloric acid. The mixture was stirred for 12 hours at room temperature. The solids were collected by vacuum filtration and washed twice with water. The product was dried under vacuum to give 5-fluoro-1,3-dihydro-indol-2-one (600 g, 73 % yield) as a brown powder. <sup>1</sup>H-NMR (dimethylsulfoxide-d<sub>6</sub>) δ 3.46 (s, 2H, CH<sub>2</sub>), 6.75, 6.95, 7.05 (3 x m, 3H, aromatic), 10.35 (s, 1H, NH). MS m/z 152 [M+1].

3,5-Dimethyl-1H-pyrrole-2,4-dicarboxylic acid 2-tert-butyl ester 4-ethyl ester (2600 g) and ethanol (7800 mL) were stirred vigorously while 10 N hydrochloric acid (3650 mL) was slowly added. The temperature increased from 25 °C to 35 °C and gas evolution began. The mixture was warmed to 54 °C and stirred with further heating for one hour at which time the temperature was 67 °C. The mixture was cooled to 5 °C and 32 L of ice and water were slowly added with stirring. The solid was collected by vacuum filtration and washed three times with water. The solid was air dried to constant weight to give of 2,4-dimethyl-1H-pyrrole-3-carboxylic acid ethyl ester (1418 g, 87 % yield) as a pinkish solid. <sup>1</sup>H-NMR (dimethylsulfoxide-d<sub>6</sub>) δ 2.10, 2.35 (2xs, 2x3H, 2xCH<sub>3</sub>), 4.13 (q, 2H, CH<sub>2</sub>), 6.37 (s, 1H, CH), 10.85 (s, 1H, NH). MS m/z 167 [M+1].

Dimethylformamide (322 g) and dichloromethane (3700 mL) were cooled in an ice bath to 4 °C and phosphorus oxychloride (684 g) was added with stirring. Solid 2,4-dimethyl-1H-pyrrole-3-carboxylic acid ethyl ester (670 g) was slowly added in aliquots over 15 minutes. The maximum temperature reached was 18 °C. The mixture was heated to reflux for one hour, cooled to 10 °C in an ice bath and 1.6 L of ice water was rapidly added with vigorous stirring. The temperature increased to 15 °C. 10 N Hydrochloric acid (1.6 L) was added with vigorous stirring. The temperature increased to 22 °C. The mixture was allowed to stand for 30 minutes and the layers allowed to separate. The temperature reached a maximum of 40 °C. The aqueous layer was adjusted to pH 12-13 with 10 N potassium hydroxide (3.8 L) at a rate that allowed the temperature to reach and remain at 55 °C during the addition. After the addition was complete the mixture was cooled to 10 °C and stirred for 1 hour. The solid was collected by vacuum filtration and washed four times with water to give 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid ethyl ester (778 g, 100 % yield) as a yellow solid. <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>) δ 1.25 (t, 3H, CH<sub>3</sub>), 2.44, 2.48 (2xs, 2x3H, 2xCH<sub>3</sub>), 4.16 (q, 2H, CH<sub>2</sub>), 9.59 (s, 1H, CHO), 12.15 (br s, 1H, NH). MS m/z 195 [M+1].

5-Formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid ethyl ester (806 g), potassium hydroxide (548 g), water (2400 mL) and methanol (300 mL) were refluxed for two hours with stirring and then cooled to 8 °C. The mixture was extracted twice with dichloromethane. The aqueous layer was adjusted to pH 4 with 1000 mL of 10 N hydrochloric acid keeping the temperature under 15 °C. Water was added to facilitate stirring. The solid was collected by vacuum filtration, washed three times with water and dried under vacuum at 50 °C to give 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic (645 g, 93.5 % yield) acid as a yellow solid. NMR (DMSO-d<sub>6</sub>) δ 2.40, 2.43 (2xs, 2x3H, 2xCH<sub>3</sub>), 9.57 (s, 1H, CHO), 12.07 (br s, 2H, NH+COOH). MS m/z 168 [M+1].

5-Formyl-2,4-dimethyl-1*H*-pyrrole-3-carboxylic acid (1204 g) and 6020 mL of dimethylformamide were stirred at room temperature while 1-(3-dimethyl-aminopropyl-3-ethylcarbodiimide hydrochloride (2071 g), hydroxybenzotriazole (1460 g), triethylamine (2016 mL) and diethylethylenediamine (1215 mL) were added. The mixture was stirred for 20 hours at room temperature. The mixture was diluted with 3000 mL of water, 2000 mL of brine and 3000 mL of saturated sodium bicarbonate solution and the pH adjusted to greater than 10 with 10 N sodium hydroxide. The mixture was extracted twice with 5000 mL each time of 10 % methanol in dichloromethane and the extracts combined, dried over anhydrous magnesium sulfate and rotary evaporated to dryness. The mixture was with diluted with 1950 mL of toluene and rotary evaporated again to dryness. The residue was triturated with 3:1 hexane:diethyl ether (4000 mL). The solids were collected by vacuum filtration, washed twice with 400 mL of ethyl acetate and dried under vacuum at 34 °C for 21 hours to give 5-formyl-2,4-dimethyl-1*H*-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide (819 g, 43 % yield) as a light brown solid. <sup>1</sup>H-NMR (dimethylsulfoxide-d<sub>6</sub>) δ 0.96 (t, 6H, 2xCH<sub>3</sub>), 2.31, 2.38 (2xs, 2 x CH<sub>3</sub>), 2.51 (m, 6H 3xCH<sub>2</sub>), 3.28 (m, 2H, CH<sub>2</sub>), 7.34 (m, 1H, amide NH), 9.56 (s, 1H, CHO), 11.86 (s, 1H, pyrrole NH). MS *m/z* 266 [M+1].

5-Formyl-2,4-dimethyl-1*H*-pyrrole-3-carboxylic acid (2-diethylaminoethyl)-amide (809 g), 5-fluoro-1,3-dihydro-indol-2-one (438 g), ethanol (8000 mL) and pyrrolidine (13 mL) were heated at 78 °C for 3 hours. The mixture was cooled to room temperature and the solids collected by vacuum filtration and washed with ethanol. The solids were stirred with ethanol (5900 mL) at 72 °C for 30 minutes. The mixture was cooled to room temperature. The solids were collected by vacuum filtration, washed with ethanol and dried under vacuum at 54 °C for 130 hours to give 5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3*Z*)-ylidenemethyl]-2,4-dimethyl-1*H*-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide (1013 g, 88 % yield) as an orange solid. <sup>1</sup>H-NMR (dimethylsulfoxide-*d*<sub>6</sub>) δ 0.98 (t, 6H, 2xCH<sub>3</sub>), 2.43, 2.44 (2xs, 6H, 2xCH<sub>3</sub>), 2.50 (m, 6H, 3xCH<sub>2</sub>), 3.28 (q, 2H, CH<sub>2</sub>), 6.84, 6.92, 7.42, 7.71, 7.50 (5xm, 5H, aromatic, vinyl, CONH), 10.88 (s, 1H, CONH), 13.68 (s, 1H, pyrrole NH). MS *m/z* 397 [M-1].

#### Example 81

3-[4-(2-Diethylaminoethylcarbamoyl)-3,5-dimethyl-1*H*-pyrrol-2-ylmethylene]-2-oxo-2,3-dihydro-1*H*-indole-6-carboxylic acid

2-Oxo-2,3-dihydro-1*H*-indole-6-carboxylic acid (80 mg, 0.45 mmol) was condensed with 5-formyl-2,4-dimethyl-1*H*-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide to give 210 mg (92%) of the title compound as a yellow orange solid.

<sup>1</sup>HNMR (360 MHz, DMSO-*d*<sub>6</sub>) δ 13.6 (s, 1H, NH), 7.76 (d, *J* = 8.0 Hz, 1H), 7.66 (s, 1H, H-vinyl), 7.57 (dd, *J* = 1.5 & 8.0 Hz, 1H), 7.40-7.42 (m, 2H), 3.28 (m, 2H, CH<sub>2</sub>), 2.88 (m, H-piperidine), 2.54 (m, 6H, 3xCH<sub>2</sub>), 2.44 (s, 3H, CH<sub>3</sub>), 2.40 (s, 3H, CH<sub>3</sub>), 1.56 (m, H-piperidine), 0.97 (t, *J* = 6.98 Hz, 6H, N(CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>).

MS *m/z* 424 [M<sup>+</sup>].

### Example 82

5-(5-Dimethylsulfamoyl-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-ylethyl)amide

2-Oxo-2,3-dihydro-1H-indole-5-sulfonic acid dimethylamide (90 mg, 0.38 mmol) was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-ylethyl)amide (100 mg) to give 100 mg (54%) of the title compound as a yellow solid.

<sup>1</sup>HNMR (360 MHz, DMSO-d<sub>6</sub>) δ 13.65 (s, 1H, NH), 11.30 (s, br, 1H, NH), 8.25 (d, 1H), 7.92 (s, 1H, H-vinyl), 7.48-7.53 (m, 2H), 7.07 (d, *J* = 8.2 Hz, 1H), 3.33 (m, 2H, CH<sub>2</sub>), 2.61 (s, 6H, N(CH<sub>3</sub>)<sub>2</sub>), 2.56 (t, 2H, CH<sub>2</sub>), 2.49 (m, 4H, 2xCH<sub>2</sub>), 2.45 (s, 3H, CH<sub>3</sub>), 2.44 (s, 3H, CH<sub>3</sub>), 1.67 (m, 4H, 2xCH<sub>2</sub>).

MS-EI *m/z* 485 [M<sup>+</sup>].

### Example 83

5-[5-(3-Chlorophenylsulfamoyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-ylethyl)amide

2-Oxo-2,3-dihydro-1H-indole-5-sulfonic acid (3-chlorophenyl)amide (120 mg, 0.38 mmol) was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-ylethyl)amide (100 mg) to give 150 mg (69%) of the title compound as a yellow orange solid.

<sup>1</sup>HNMR (360 MHz, DMSO-d<sub>6</sub>) δ 13.55 (s, 1H, NH), 11.26 (br s, 1H, NH), 10.30 (br s, 1H, NH), 8.26 (d, 1H), 7.79 (s, 1H, H-vinyl), 7.51-7.57 (m, 2H), 7.22 (t, *J* = 8.1 Hz, 1H), 7.15 (m, 1H), 7.07 (m, 1H), 7.0 (m, 2H), 3.44 (m, 2H, CH<sub>2</sub>), 2.57 (t, *J* = 7.0 Hz, 2H, CH<sub>2</sub>), 2.49 (m, 4H, 2xCH<sub>2</sub>), 2.44 (s, 3H, CH<sub>3</sub>), 2.43 (s, 3H, CH<sub>3</sub>), 1.68 (m, 4H, 2xCH<sub>2</sub>).

MS *m/z* 568 [M<sup>+</sup>].



#### Example 84

2,4-Dimethyl-5-[2-oxo-5-(pyridin-3-ylsulfamoyl)-1,2-dihydroindol-3-ylidenemethyl]-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-ylethyl)amide

2-Oxo-2,3-dihydro-1H-indole-5-sulfonic acid pyridin-3-ylamide (110 mg, 0.38 mmol) was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-ylethyl)amide (100 mg) to give 150 mg (74%) of the title compound as an orange solid.

<sup>1</sup>HNMR (360 MHz, DMSO-d<sub>6</sub>) δ 13.58 (s, 1H, NH), 8.21 (d, J = 2.0 Hz, 2H), 8.04 (m, 1H), 7.76 (s, 1H, H-vinyl), 7.49-7.54 (m, 2H), 7.41 (m, 1H), 7.14 (m, 1H), 6.94 (d, J = 8.5 Hz, 1H), 3.33 (m, 2H, CH<sub>2</sub>), 2.56 (t, J = 7.06 Hz, 2H, CH<sub>2</sub>), 2.49 (m, 4H, 2xCH<sub>2</sub>), 2.43 (s, 6H, 2xCH<sub>3</sub>), 1.68 (m, 4H, 2xCH<sub>2</sub>).

MS m/z 535 [M<sup>+</sup>].

#### Example 85

3-[3,5-Dimethyl-4-(4-methylpiperazine-1-carbonyl)-1H-pyrrol-2-ylmethylene]-4-(2-hydroxyethyl)-1,3-dihydroindol-2-one

4-(2-Hydroxyethyl)-1,3-dihydroindol-2-one (71 mg, 0.4 mmol) was condensed with 3,5-dimethyl-4-(4-methyl-piperazine-1-carbonyl)-1H-pyrrole-2-carbaldehyde to give 90 mg (55%) of the title compound as an orange solid.

<sup>1</sup>HNMR (300 MHz, DMSO-d<sub>6</sub>) δ 14.25 (s, 1H, NH), 10.88 (s, 1H, NH), 7.57 (s, 1H, H-vinyl), 7.03 (m, 1H), 6.75-6.82 (m, 2H), 4.86 (m, 1H, OH), 3.70 (m, 2H, CH<sub>2</sub>), 3.04 (m, 2H, CH<sub>2</sub>), 2.48 (m, 4H, 2xCH<sub>2</sub>), 2.28 (br s, 7H), 2.19 (s, 3H, CH<sub>3</sub>), 2.18 (s, 3H, CH<sub>3</sub>).

MS m/z (+ve) 409.3 [M<sup>+</sup>].

#### Example 86

3-[3,5-Dimethyl-4-(4-methylpiperazine-1-carbonyl)-1H-pyrrol-2-ylmethylene]-2-oxo-2,3-dihydro-1H-indole-5-sulfonic acid phenylamide

2-Oxo-2,3-dihydro-1H-indole-5-sulfonic acid phenylamide (110 mg, 0.4 mmol) was condensed with 3,5-dimethyl-4-(4-methylpiperazine-1-carbonyl)-1H-pyrrole-2-carbaldehyde (100 mg) to give 50 mg (24%) of the title compound as a yellow

solid.

<sup>1</sup>HNMR (300 MHz, DMSO-d<sub>6</sub>) δ 13.52 (s, 1H, NH), 11.26 (s, 1H, NH), 10.08 (s, 1H, NH), 8.21 (d, *J* = 1.6 Hz, 1H), 7.75 (s, 1H, H-vinyl), 7.50 (dd, *J* = 1.6 & 8.3 Hz, 1H), 7.19 (m, 2H), 7.10 (m, 2H), 6.97 (m, 2H), 2.49 (m, 4H, 2xCH<sub>2</sub>), 2.28 (m, 10H, 2xCH<sub>3</sub> & 2xCH<sub>2</sub>), 2.18 (s, 3H, CH<sub>3</sub>).

MS-EI *m/z* 519 [M<sup>+</sup>].

#### Example 87

5-(5-Dimethylsulfamoyl-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide

2-Oxo-2,3-dihydro-1H-indole-5-sulfonic acid dimethylamide (90 mg, 0.38 mmol) was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide (100 mg) to give 80 mg (43%) of the title compound as a yellow solid.

<sup>1</sup>HNMR (300 MHz, DMSO-d<sub>6</sub>) δ 11.30 (s, 1H, NH), 8.27 (d, *J* = 1.7 Hz, 1H), 7.94 (s, 1H, H-vinyl), 7.49 (dd, *J* = 1.7 & 8.0 Hz, 1H), 7.44 (m, 1H, CONHCH<sub>2</sub>CH<sub>2</sub>), 7.07 (d, *J* = 8.0 Hz, 1H), 3.26 (m, 2H, CH<sub>2</sub>), 2.60 (s, 6H, N(CH<sub>3</sub>)<sub>2</sub>), 2.53 (m, 2H, CH<sub>2</sub>), 2.45-2.50 (m, 10H, 2xCH<sub>3</sub> & N(CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>), 0.96 (t, *J* = 7.2 Hz, 6H, N(CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>).

MS-EI *m/z* 487 [M<sup>+</sup>].

#### Example 88

5-[5-(3-Chlorophenylsulfamoyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide

2-Oxo-2,3-dihydro-1H-indole-5-sulfonic acid (3-chlorophenyl)amide (120 mg, 3.8 mmol) was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide (100 mg) to give 80 mg (37%) of the title compound as a yellow solid.

<sup>1</sup>HNMR (360 MHz, DMSO-d<sub>6</sub>) δ 13.55 (s, 1H, NH), 11.24 (s, 1H, NH), 10.29 (s, 1H, NH), 8.25 (d, *J* = 1.87 Hz, 1H), 7.79 (s, 1H, H-vinyl), 7.52 (dd, *J* = 1.87 & 8.3 Hz, 1H), 7.42 (m,

1H, CONHCH<sub>2</sub>CH<sub>2</sub>), 7.22 (t, *J* = 8.02 Hz, 1H), 7.15 (t, *J* = 2 Hz, 1H), 7.08 (m, 1H), 7.0 (m, 2H), 3.27 (m, 2H, CH<sub>2</sub>), 2.48-2.57 (m, 6H, 3xCH<sub>2</sub>), 2.45 (s, 3H, CH<sub>3</sub>), 2.44 (s, 3H, CH<sub>3</sub>), 0.97 (t, *J* = 7.0 Hz, 6H, N(CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>).

MS *m/z* 570.1 [M<sup>+</sup>].

#### Example 95

3-(2-Oxo-5-phenyl-1,2-dihydroindol-3-ylidenemethyl)-4,5,6,7-tetrahydro-2H-isoindole-1-carboxylic acid ethyl ester

<sup>1</sup>HNMR (360 MHz, DMSO-d<sub>6</sub>) δ 13.74 (s, 1H, NH), 11.00 (s, 1H, NH), 8.13 (d, *J* = 1.7 Hz, 1H), 7.74 (s, 1H, H-vinyl), 7.70 (d, *J* = 7.7 Hz, 2H), 7.49 (dd, *J* = 1.7 & 8.0 Hz, 1H), 7.44 (t, *J* = 7.7 Hz, 2H), 7.32 (m, 1H), 6.96 (d, *J* = 8.0 Hz, 1H), 4.26 (q, *J* = 7.0 Hz, 2H, OCH<sub>2</sub>CH<sub>3</sub>), 2.79 (m, 2H, CH<sub>2</sub>), 2.72 (m, 2H, CH<sub>2</sub>), 1.73 (m, 4H, 2xCH<sub>2</sub>), 1.30 (t, *J* = 7.0 Hz, 3H, OCH<sub>2</sub>CH<sub>3</sub>).

MS-EI *m/z* 412 [M<sup>+</sup>].

#### Example 99

3-(2-Oxo-5-phenylsulfamoyl-1,2-dihydroindol-3-ylidenemethyl)-4,5,6,7-tetrahydro-2H-isoindole-1-carboxylic acid ethyl ester

<sup>1</sup>HNMR (360 MHz, DMSO-d<sub>6</sub>) δ 13.64 (s, 1H, NH), 11.33 (s, 1H, NH), 10.07 (s, 1H, NH), 8.24 (d, *J* = 1.8 Hz, 1H), 7.74 (s, 1H, H-vinyl), 7.57 (dd, *J* = 1.8 & 8.0 Hz, 1H), 7.21 (t, *J* = 7.6 Hz, 2H), 7.11 (d, *J* = 7.6 Hz, 2H), 6.99 (d, *J* = 8.0 Hz, 1H), 6.98 (d, *J* = 7.6 Hz, 1H), 4.27 (q, *J* = 7.0 Hz, 2H, OCH<sub>2</sub>CH<sub>3</sub>), 2.80 (m, 2H, CH<sub>2</sub>), 2.73 (m, 2H, CH<sub>2</sub>), 1.73 (m, 4H, 2xCH<sub>2</sub>), 1.30 (t, *J* = 7.0 Hz, 3H, OCH<sub>2</sub>CH<sub>3</sub>).

MS-EI *m/z* 491 [M<sup>+</sup>].

#### Example 109

3-[3-(Morpholine-4-carbonyl)-4,5,6,7-tetrahydro-2H-isoindol-1-ylmethylene]-2-oxo-2,3-dihydro-1H-indole-6-carboxylic acid

<sup>1</sup>HNMR (360 MHz, DMSO-d<sub>6</sub>) δ 13.60 (s, 1H, NH), 12.75 (br s, 1H, COOH), 11.08 (s, 1H, NH), 7.85 (d, *J* = 7.8 Hz, 1H), 7.71 (s, 1H, H-vinyl), 7.62 (dd, *J* = 1.4 & 7.8 Hz, 1H), 7.41 (d, *J* = 1.4 Hz, 1H), 3.65 (m, 4H, 2xCH<sub>2</sub>), 3.55 (m, 4H, 2xCH<sub>2</sub>), 2.81 (m, 2H, CH<sub>2</sub>), 2.54 (m, 2H, CH<sub>2</sub>), 1.73 (m, 4H, 2xCH<sub>2</sub>).

MS-EI *m/z* 421 [M<sup>+</sup>].

**Example 112**

5-Bromo-3-[3-(pyrrolidine-1-carbonyl)-4,5,6,7-tetrahydro-2H-isoindol-1-ylmethylene]-1,3-dihydro-indol-2-one

<sup>1</sup>HNMR (360 MHz, DMSO-d<sub>6</sub>) δ 13.56 (s, 1H, NH), 11.00 (s, 1H, NH), 8.05 (d, *J* = 1.8 Hz, 1H), 7.74 (s, 1H, H-vinyl), 7.28 (dd, *J* = 1.3 & 8.3 Hz, 1H), 6.83 (d, *J* = 8.3 Hz, 1H), 3.57 (m, 4H, 2×CH<sub>2</sub>), 2.79 (m, 2H, CH<sub>2</sub>), 2.65 (m, 2H, CH<sub>2</sub>), 1.88 (m, 4H, 2×CH<sub>2</sub>), 1.71 (m, 4H, 2×CH<sub>2</sub>).

MS-EI *m/z* 439 & 441 [M<sup>+</sup>-1] & [M<sup>+</sup>+1].

**Example 114**

3-(3-Dimethylcarbamoyl-4,5,6,7-tetrahydro-2H-isoindol-1-ylmethylene)-2-oxo-2,3-dihydro-1H-indole-6-carboxylic acid

<sup>1</sup>HNMR (360 MHz, DMSO-d<sub>6</sub>) δ 13.60 (s, 1H, NH), 12.72 (br s, 1H, COOH), 11.05 (s, 1H, NH), 7.85 (d, *J* = 7.9 Hz, 1H), 7.72 (s, 1H, H-vinyl), 7.62 (dd, *J* = 1.3 & 7.9 Hz, 1H), 7.42 (d, *J* = 1.3 Hz, 1H), 3.03 (s, 6H, N(CH<sub>3</sub>)<sub>2</sub>), 2.81 (m, 2H, CH<sub>2</sub>), 2.55 (m, 2H, CH<sub>2</sub>), 1.73 (m, 4H, 2×CH<sub>2</sub>).

MS-EI *m/z* 379 [M<sup>+</sup>].

**Example 115**

4-Methyl-5-(5-methylsulfamoyl-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid

<sup>1</sup>HNMR (300 MHz, DMSO-d<sub>6</sub>) δ 13.56 (br s, 1H, NH), 8.24 (d, *J* = 1.5 Hz, 1H), 7.86 (s, 1H, H-vinyl), 7.74 (d, *J* = 2.96 Hz, 1H), 7.56 (dd, *J* = 1.5 & 8.1 Hz, 1H), 7.20 (br m, 1H, NHCH<sub>3</sub>), 7.03 (d, *J* = 8.1 Hz, 1H), 2.57 (s, 3H, CH<sub>3</sub>), 2.41 (s, 3H, CH<sub>3</sub>).

MS-EI *m/z* 361 [M<sup>+</sup>].

**Example 116**

{[4-Methyl-5-(4-methyl-5-methylsulfamoyl-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-1H-pyrrole-3-carbonyl]-amino}-acetic acid ethyl ester

4-Methyl-1H-pyrrole-3-carboxylic acid ethyl ester (lit. ref. D.O. Cheng, T. L. Bowman and E. LeGoff; J. Heterocyclic Chem.; 1976; 13; 1145-1147) was formylated using method A, hydrolysed using method B followed by amidation (method C) to give [(5-formyl-4-methyl-1H-pyrrole-3-carbonyl)-amino]-acetic acid ethyl ester.

4-Methyl-5-methylaminosulfonyl-2-oxindole (50 mg, 0.21

mmol) was condensed with [(5-formyl-4-methyl-1H-pyrrole-3-carbonyl)-amino]-acetic acid ethyl ester (100 mg, 0.42 mmol) and piperidine (0.1 mL) in ethanol (2 mL) to give 50 mg (52%) of the title compound.

5  $^1\text{H}$ NMR (360 MHz, DMSO- $d_6$ )  $\delta$  13.59 (s, 1H, NH), 11.29 (v.br. s, 1H, NH-CO), 8.33 (t,  $J$  = 5.8 Hz, 1H, CONHCH<sub>2</sub>), 7.83 (d,  $J$  = 3.11 Hz, 1H), 7.80 (s, 1H, H-vinyl), 7.71 (d,  $J$  = 8.5 Hz, 1H), 7.34 (br m, 1H, NHCH<sub>3</sub>), 6.89 (d,  $J$  = 8.5 Hz, 1H), 4.11 (q,  $J$  = 7.1 Hz, 2H, OCH<sub>2</sub>CH<sub>3</sub>), 3.92 (d,  $J$  = 5.8 Hz, 2H, GlyCH<sub>2</sub>), 2.86 (s, 3H, CH<sub>3</sub>), 2.48 (s, 3H, CH<sub>3</sub>), 2.42 (d,  $J$  = 4.71 Hz, 3H, HNCH<sub>3</sub>), 1.20 (t,  $J$  = 7.1 Hz, 3H, OCH<sub>2</sub>CH<sub>3</sub>).

MS-EI  $m/z$  460 [ $M^+$ ].

#### Example 117

{[4-Methyl-5-(5-methylsulfamoyl-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-1H-pyrrole-3-carbonyl]-amino}-acetic acid ethyl ester

A mixture of 5-methylaminosulfonyl-2-oxindole (0.06 g, 0.22 mmol), [(5-formyl-4-methyl-1H-pyrrole-3-carbonyl)-amino]-acetic acid ethyl ester (0.075 g, 0.27 mmol) and piperidine (2 drops) in ethanol (5 mL) was heated in a sealed tube at 90°C for 12 hrs. After cooling, the precipitate was collected by vacuum filtration, washed with ethanol, triturated with dichloromethane/ether and dried to give 0.035 g (36%) of the title compound as a yellowish brown solid.

25  $^1\text{H}$  NMR ( 360 MHz, DMSO- $d_6$  )  $\delta$  13.6 (s, 1H, NH), 11 (v.br. s, 1H, NH-CO), 8.30 (t,  $J$  = 5.7 Hz, 1H, CONHCH<sub>2</sub>), 8.25 (d,  $J$  = 1.2 Hz, 1H), 7.88 (s, 1H, H-vinyl), 7.84 (d,  $J$  = 3.3 Hz, 1H), 7.57 (dd,  $J$  = 1.9 & 8.5 Hz, 1H), 7.14 (br m, 1H, NHCH<sub>3</sub>), 7.04 (d,  $J$  = 8.5 Hz, 1H), 4.11 (q,  $J$  = 6.7 Hz, 2H, OCH<sub>2</sub>CH<sub>3</sub>), 3.92 (d,  $J$  = 5.7 Hz, 2H, GlyCH<sub>2</sub>), 2.55 (s, 3H, CH<sub>3</sub>), 2.41 (m, 3H, NCH<sub>3</sub>), 1.20 (t,  $J$  = 6.7 Hz, 3H, OCH<sub>2</sub>CH<sub>3</sub>).

MS  $m/z$  446 [ $M^+$ ].

#### Example 118

35 {[4-Methyl-5-(5-methylsulfamoyl-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-1H-pyrrole-3-carbonyl]-amino}-acetic acid

A mixture of [(5-formyl-4-methyl-1H-pyrrole-3-carbonyl)-

amino]-acetic acid ethyl ester (0.142 g, 0.59 mmol) and 1N NaOH (1.2 mL) in methanol (10 mL) was stirred at room temperature for 1 hr. The reaction was concentrated and the residue was condensed with 5-methylaminosulfonyl-2-oxindole (0.13 g, 0.48 mmol) and piperidine (0.12 mL) in ethanol (12 mL) to give 0.11 g (52%) of the title compound.

<sup>1</sup>HNMR (300 MHz, DMSO-d<sub>6</sub>) δ 13.98 (br s, 1H, NH), 8.17 (s, 1H), 7.80 (s, 1H), 7.75 (d, *J* = 3.1 Hz, 1H), 7.51 (dd, *J* = 2 & 8.2 Hz, 1H), 7.21 (m on br s, 2H), 6.97 (d, *J* = 8.1 Hz, 1H), 3.41 (d, *J* = 4.2 Hz, 2H, CH<sub>2</sub>NH), 2.54 (s, 3H, pyrrole-CH<sub>3</sub>), 2.39 (s, 3H, ArCH<sub>3</sub>).

MS *m/z* 417 [M-1]<sup>+</sup>.

#### Example 120

5-Methyl-2-(2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid

<sup>1</sup>HNMR (300 MHz, DMSO-d<sub>6</sub>) δ 13.77 (br s, 1H, NH), 12.49 (s, 1H, COOH), 11.07 (s, 1H, NH), 8.39 (s, 1H, H-vinyl), 7.43 (d, *J* = 7.47 Hz, 1H), 7.20 (t, *J* = 7.47 Hz, 1H), 7.03 (t, *J* = 7.47 Hz, 1H), 6.91 (d, *J* = 7.47 Hz, 1H), 6.49 (d, *J* = 1.53 Hz, 1H), 2.34 (s, 3H, CH<sub>3</sub>).

MS *m/z* 269 [M+H]<sup>+</sup>.

#### Example 121

5-Methyl-2-(2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid ethyl ester

<sup>1</sup>HNMR (300 MHz, DMSO-d<sub>6</sub>) δ 13.79 (s, 1H, NH), 11.08 (s, 1H, NH), 8.31 (s, 1H, H-vinyl), 7.45 (d, *J* = 7.52 Hz, 1H), 7.20 (t, *J* = 7.52 Hz, 1H), 7.03 (t, *J* = 7.52 Hz, 1H), 6.91 (d, *J* = 7.52 Hz, 1H), 6.50 (d, *J* = 2.1 Hz, 1H), 4.26 (q, *J* = 7.2 Hz, 2H, OCH<sub>2</sub>CH<sub>3</sub>), 2.33 (s, 3H, CH<sub>3</sub>), 1.32 (t, *J* = 7.2 Hz, 3H, OCH<sub>2</sub>CH<sub>3</sub>).

MS *m/z* 297.1 [M+H]<sup>+</sup>.

#### Example 122

2-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-5-methyl-1H-pyrrole-3-carboxylic acid ethyl ester

<sup>1</sup>HNMR (360 MHz, DMSO-d<sub>6</sub>) δ 13.72 (s, 1H, NH), 11.16 (s, 1H, NH), 8.29 (s, 1H, H-vinyl), 7.53 (d, *J* = 2.0 Hz, 1H), 7.35

(dd,  $J = 2.0$  &  $8.05$  Hz, 1H), 6.87 (t,  $J = 8.05$  Hz, 1H), 6.53 (d,  $J = 2.4$  Hz, 1H), 4.28 (q,  $J = 7.03$  Hz, 2H,  $\text{OCH}_2\text{CH}_3$ ), 2.35 (s, 3H,  $\text{CH}_3$ ), 1.33 (t,  $J = 7.03$  Hz, 3H,  $\text{OCH}_2\text{CH}_3$ ).

MS  $m/z$  375 & 377  $[\text{M}+\text{H}]^+$ .

5 **Example 123**

2-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-5-methyl-1H-pyrrole-3-carboxylic acid

$^1\text{H}$ NMR (300 MHz,  $\text{DMSO}-d_6$ )  $\delta$  13.72 (s, 1H, NH), 12.57 (s, 1H, COOH), 11.19 (s, 1H, NH), 8.36 (s, 1H, H-vinyl), 7.51 (d,  $J = 1.4$  Hz, 1H), 7.34 (dd,  $J = 1.4$  &  $8.17$  Hz, 1H), 6.87 (t,  $J = 8.17$  Hz, 1H), 6.52 (d,  $J = 2.5$  Hz, 1H), 2.35 (s, 3H,  $\text{CH}_3$ ).

MS  $m/z$  347 & 349  $[\text{M}+\text{H}]^+$ .

**Example 124**

2-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-5-methyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-ylethyl)-amide

To a solution of 2-formyl-5-methyl-1H-pyrrole-3-carboxylic acid (250 mg, 1.63 mmol) in dimethylformamide (3 mL) was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (376 mg, 1.2 equiv.), 1-hydroxybenzotriazole (265 mg, 1.2 equiv.), triethylamine (0.45 mL, 2 equiv.) and 1-(2-aminoethyl)pyrrolidine (0.23 mL, 1.1 equiv.). After stirring at room temperature overnight, the reaction was diluted with saturated sodium bicarbonate and brine (with extra salt) and extracted with 10% methanol in dichloromethane. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate and concentrated to give 130 mg of 2-formyl-5-methyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide.

A mixture of 5-bromo-2-oxindole (106 mg, 0.5 mmol), 2-formyl-5-methyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide (125 mg, 1 equiv.) and piperidine (0.2 mL) in ethanol (2 mL) was heated in a sealed tube at  $80^\circ\text{C}$  for 1 hr and then cooled. The precipitate which formed was collected by vacuum filtration, washed with ethanol and ethyl acetate and dried to give the title compound as an orange solid.

$^1\text{H}$ NMR (300 MHz,  $\text{DMSO}-d_6$ )  $\delta$  13.62 (s, 1H, NH), 11.06 (br s,

1H, NH), 8.56 (s, 1H, H-vinyl), 8.15 (m, 1H, CONHCH<sub>2</sub>), 7.48 (d, J = 1.8 Hz, 1H), 7.31 (dd, J = 1.8 & 7.9 Hz, 1H), 6.86 (d, J = 7.9 Hz, 1H), 6.60 (d, J = 2.3 Hz, 1H), 3.35 (m, 2H, HNCH<sub>2</sub>CH<sub>2</sub>), 2.56 (t, J = 6.91 Hz, 2H, HNCH<sub>2</sub>CH<sub>2</sub>), 2.35 (s, 3H, CH<sub>3</sub>), 1.67 (m, 4H, 2xCH<sub>2</sub>).

MS m/z 443/ 445 [M<sup>+</sup> and M<sup>+</sup>+2].

#### Example 125

#### 2-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-5-methyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)-amide

To a solution of 2-formyl-5-methyl-1H-pyrrole-3-carboxylic acid (320 mg, 2.1 mmol) in dimethylformamide (3 mL) was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (483 mg, 1.2 equiv.), 1-hydroxybenzotriazole (340 mg, 1.2 equiv.), triethylamine (0.59 mL, 2 equiv.) and N,N-diethylethylenediamine (0.32 mL, 1.1 equiv.). After stirring at room temperature overnight, the reaction was diluted with saturated sodium bicarbonate and brine (with extra salt) and extracted with 10% methanol in dichloromethane. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate and concentrated to give 2-formyl-5-methyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)-amide.

A mixture of 5-bromo-2-oxindole (106 mg, 0.5 mmol), 2-formyl-5-methyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)-amide (126 mg, 1 equiv.) and piperidine (0.2 mL) in ethanol (2 mL) was heated in a sealed tube at 80°C for 1 hr and then cooled. The precipitate was collected by vacuum filtration, washed with ethanol and ethyl acetate and dried to give the title compound as an orange solid.

<sup>1</sup>HNMR (360 MHz, DMSO-d<sub>6</sub>) δ 13.62 (s, 1H, NH), 11.11 (br s, 1H, NH), 8.54 (s, 1H, H-vinyl), 8.1 (m, 1H, CONHCH<sub>2</sub>), 7.49 (d, J = 2.2 Hz, 1H), 7.31 (dd, J = 2.2 & 8.3 Hz, 1H), 6.86 (d, J = 8.3 Hz, 1H), 6.58 (d, J = 2.24 Hz, 1H), 3.31 (m, 2H, HNCH<sub>2</sub>CH<sub>2</sub>), 2.59 (m, 6H, 3xCH<sub>2</sub>), 2.36 (s, 3H, CH<sub>3</sub>), 0.99 (t, J = 6.8 Hz, 6H, N(CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>).

MS m/z 445/ 447 [M<sup>+</sup> and M<sup>+</sup>+2].



**Example 126**

2,4-Dimethyl-5-(2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide

A mixture of 1,3-dihydro-indol-2-one (266 mg, 2 mmol), 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide (530 mg, 2 mmol) and piperidine (1 drop) in ethanol was heated at 90°C for 2 hours. The reaction was cooled to room temperature, the resulting precipitate was collected by vacuum filtration, washed with ethanol and dried to give 422 mg (55%) of the title compound as a light yellow solid.

<sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ 13.7 (s, 1H, NH), 10.9 (s, 1H, NH), 7.88 (d, *J* = 7.6 Hz, 1H), 7.64 (s, 1H, H-vinyl), 7.41 (t, *J* = 5.4 Hz, 1H, NH), 7.13 (dt, *J* = 1.2 & 7.6 Hz, 1H), 6.99 (dt, *J* = 1.2 & 7.6 Hz, 1H), 6.88 (d, *J* = 7.6 Hz, 1H), 3.28 (m, 2H), 2.48-2.55 (m, 6H), 2.44 (s, 3H, CH<sub>3</sub>), 2.41 (s, 3H, CH<sub>3</sub>), 0.97 (t, *J* = 7.2 Hz, 6H, N(CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>).  
MS + ve APCI 381 [M<sup>+</sup> + 1].

**Example 127**

5-(5-Chloro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide

A mixture of 5-Chloro-1,3-dihydro-indol-2-one (335 mg, 2 mmol), 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide (530 mg, 2 mmol) and piperidine (1 drop) in ethanol was heated at 90°C for 2 hours. The reaction was cooled to room temperature, the resulting precipitate was collected by vacuum filtration, washed with ethanol and dried to give 565 mg (68%) of the title compound as an orange solid.

<sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ 13.65 (s, 1H, NH), 11.0 (s, 1H, NH), 7.98 (d, *J* = 2.1 Hz, 1H), 7.77 (s, 1H, H-vinyl), 7.44 (t, NH), 7.13 (dd, *J* = 2.1 & 8.4 Hz, 1H), 6.87 (d, *J* = 8.4 Hz, 1H), 3.28 (g, 2H), 2.48-2.53 (m, 6H), 2.44 (s, 3H, CH<sub>3</sub>), 2.43 (s, 3H, CH<sub>3</sub>), 0.97 (t, *J* = 7.0 Hz, 6H, N(CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>).  
MS + ve APCI 415 [M<sup>+</sup> + 1].

**Example 128**

2,4-Dimethyl-5-(2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-ethyl)-amide

1,3-Dihydro-indol-2-one was condensed with 5-formyl-2,4-

dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide to give the title compound.

MS + ve APCI 379 [M<sup>+</sup> + 1].

5 **Example 129**

5-(5-Fluoro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide

10 5-Fluoro-1,3-dihydro-indol-2-one was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide to give the title compound.

MS + ve APCI 397 [M<sup>+</sup> + 1].

15 **Scale-up procedure:**

5-Formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (61 g), 5-fluoro-1,3-dihydro-indol-2-one (79 g), ethanol (300 mL) and pyrrolidine (32 mL) were refluxed for 4.5 hours. Acetic acid (24 mL) was added to the mixture and refluxing was continued for 30 minutes. The mixture was cooled to room temperature and the solids collected by vacuum filtration and washed twice with ethanol. The solids were stirred for 130 minutes in 40 % acetone in water (400 mL) containing 12 N hydrochloric acid (6.5 mL). The solids were collected by vacuum filtration and washed twice with 40 % acetone in water. The solids were dried under vacuum to give 5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (86 g, 79 % yield) as an orange solid. <sup>1</sup>H-NMR (dimethylsulfoxide-d<sub>6</sub>) δ 2.48, 2.50 (2xs, 6H, 2xCH<sub>3</sub>), 6.80, 6.88, 7.68, 7.72 (4xm, 4H, aromatic and vinyl), 10.88 (s, 1H, CONH), 12.12 (s, 1H, COOH), 13.82 (s, 1H, pyrrole NH). MS m/z 299 [M-1].

35 5-[5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (100 g) and dimethylformamide (500 mL) were stirred and benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (221 g), 1-(2-aminoethyl)pyrrolidine (45.6 g) and triethylamine (93 mL) were added. The mixture was stirred for 2 hours at ambient temperature. The solid product was collected by vacuum

filtration and washed with ethanol. The solids were slurry-washed by stirring in ethanol (500 mL) for one hour at 64 °C and cooled to room temperature. The solids were collected by vacuum filtration, washed with ethanol, and dried under vacuum to give 5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide (101.5 g, 77 % yield). <sup>1</sup>H-NMR (dimethylsulfoxide-d<sub>6</sub>) δ 1.60 (m, 4H, 2xCH<sub>2</sub>), 2.40, 2.44 (2xs, 6H, 2xCH<sub>3</sub>), 2.50 (m, 4H, 2xCH<sub>2</sub>), 2.57, 3.35 (2xm, 4H, 2XCH<sub>2</sub>), 7.53, 7.70, 7.73, 7.76 (4xm, 4H, aromatic and vinyl), 10.88 (s, 1H, CONH), 13.67 (s, 1H, pyrrole NH). MS m/z 396 [M+1].

#### Example 130

5-(5-Chloro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide

5-Chloro-1,3-dihydro-indol-2-one was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide to give the title compound. MS + ve APCI 413 [M<sup>+</sup> + 1].

#### Example 131

2,4-Dimethyl-5-(2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (2-dimethylaminoethyl)-amide

1,3-Dihydro-indol-2-one was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-dimethylaminoethyl)amide to give the title compound.

<sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ 13.63 (s, 1H, NH), 10.90 (s, 1H, NH), 7.78 (d, J = 7.8 Hz, 1H), 7.63 (s, 1H H-vinyl), 7.48 (t, 1H, NH), 7.13 (dt, 1H), 6.98 (dt, 1H), 6.88 (d, J=7.7 Hz, 1H), 3.31 (q, J=6.6 Hz, 2H), 2.43 (s, 3H, CH<sub>3</sub>), 2.40 (s, 3H, CH<sub>3</sub>), 2.38 (t, J=6.6 Hz, 2H), 2.19 (s, 6H, N(CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>) MS + ve APCI 353 [M<sup>+</sup> + 1].

#### Example 132

5-(5-Fluoro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-dimethylaminoethyl)-amide

5-Fluoro-1,3-dihydro-indol-2-one was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-

dimethylaminoethyl)amide to give the title compound.

<sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ 13.68 (s, 1H, NH), 10.90 (s, 1H, NH), 7.76 (dd, *J* = 2.4 & 9.4 Hz, 1H), 7.71 (s, 1H H-vinyl), 7.51 (t, 1H, NH), 6.93 (m, 1H), 6.84 (dd, *J*=4.6 & 8.4 Hz, 1H), 3.31 (q, *J*=6.6 Hz, 2H), 2.43 (s, 3H, CH<sub>3</sub>), 2.41 (s, 3H, CH<sub>3</sub>), 2.38 (t, *J*=6.6 Hz, 2H), 2.19 (s, 6H, N(CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>)  
MS + ve APCI 371 [M<sup>+</sup> + 1].

### Example 193

5-[5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-ethylamino-ethyl)-amide

5-Formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-ethylamino-ethyl)-amide (99 g), ethanol (400 mL), 5-fluoro-2-oxindole (32 g) and pyrrolidine (1.5 g) were refluxed for 3 hours with stirring. The mixture was cooled to room temperature and the solids collected by vacuum filtration. The solids were stirred in ethanol at 60 °C, cooled to room temperature and collected by vacuum filtration. The product was dried under vacuum to give 5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-ethylamino-ethyl)-amide (75 g, 95 % yield). <sup>1</sup>H-NMR (dimethylsulfoxide-d<sub>6</sub>) δ 1.03 (t, 3H, CH<sub>3</sub>), 2.42, 2.44 (2xs, 6H, 2xCH<sub>3</sub>), 2.56 (q, 2H, CH<sub>2</sub>), 2.70, 3.30 (2xt, 4H, 2xCH<sub>2</sub>), 6.85, 6.92, 7.58, 7.72, 7.76 (5xm, 5H, aromatic, vinyl and CONH), 10.90 (br s, 1H, CONH), 13.65 (br s, 1H, pyrrole NH). MS *m/z* 369 [M-1].

### Example 195

5-[5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethyl-N-oxoamino-ethyl)-amide

#### Method A:

5-[5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide (598 mg) and dichloromethane (60 mL) in an ice bath were treated with 3-chloroperbenzoic acid (336 mg) and the mixture stirred at room temperature overnight. The solvent was rotary evaporated and the residue suspended in methanol

(20 mL). Water (20 mL) containing sodium hydroxide (240 mg) was added and the mixture stirred for one hour. The precipitate was collected by vacuum filtration, washed with 5 mL of water and dried under a vacuum to give 5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethyl-N-oxoamino-ethyl)-amide (510 mg, 82 % yield) as an orange solid. <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>) δ 13.72 (br s, 1H, NH), 11.02 (br s, 1H, CONH), 9.81 (br s, 1H, CONH), 7.75 (dd, 1H, aromatic), 7.70 (s, 1H, aromatic), 6.93 (td, 1H, aromatic), 6.84 (m, 1H, aromatic), 3.63 (m, 2H, CH<sub>2</sub>), 3.29 (m, 2H, CH<sub>2</sub>), 3.14 (m, 4H, 2xCH<sub>2</sub>), 2.47 (s, 1H, CH<sub>3</sub>), 2.45 (s, 3H, CH<sub>3</sub>), 1.64 (t, 6H, 2xCH<sub>3</sub>). MS m/z 415 [M+1].

#### Method B:

5-Formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide (10 g) was suspended in dichloromethane (100 mL) and cooled in an ice bath. 3-Chloroperoxybenzoic acid (13.1 g) was added with stirring and the mixture allowed to warm to room temperature and then stirred overnight. The mixture was rotary evaporated to dryness and chromatographed on a column of silica gel eluting with 20 % methanol in dichloromethane. Fractions containing product were combined and rotary evaporated to dryness to give 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethyl-N-oxoamino-ethyl)-amide (9 g, 83 % yield).

5-Formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethyl-N-oxoamino-ethyl)-amide (9 g), 5-fluoro-1,3-dihydro-indol-2-one ((9 g, 83 % yield)), and pyrrolidine ((9 g, 83 % yield (0.1 g) were refluxed in ethanol (30 mL) for 4 hours. The mixture was cooled in an ice bath and the precipitate collected by vacuum filtration and washed with ethanol. The solids were stirred in ethyl acetate (30 mL), collected by vacuum filtration, washed with ethyl acetate and dried under vacuum to give 5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethyl-N-oxoamino-ethyl)-amide (10.3 g 80 % yield) as an orange solid. <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>) δ 13.72 (br s, 1H, NH), 11.02